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ABSTRACT 
The seven human cytidine deaminases in the APOBEC3 (A3) family deaminate cytosine 
in single-stranded DNA to form uracil. The enzymes recognize specific di- and tri-nucleotide 
sequences and deaminate cytosines within them. The A3 proteins are potent antiviral restriction 
factors capable of inhibiting retrotransposons and both exogenous and endogenous retroviruses.  
The overall goal of my Ph.D. research was to biochemically characterize the A3 enzymes, 
APOBEC3F (A3F) and APOBEC3G (A3G) and identify the biochemical determinants of their 
anti-HIV-1 function. I characterized these enzymes alone and how they may act in concert to 
restrict HIV-1 replication. In order to inhibit HIV-1, A3 enzymes must become encapsidated into 
budding virions and upon infection of the next target cell, the enzymes can deaminate cytosines in 
HIV-1 single-stranded DNA generated during reverse transcription. The promutagenic uracils 
formed act as a template for second strand synthesis and result in numerous transition mutations 
in the double-stranded proviral DNA. These mutations inactivate the virus. 
To understand how these deaminations take place, I characterized A3F and A3G 
biochemically. I found that like A3G, A3F is a processive enzyme that can deaminate at least two 
cytosines in a single enzyme-substrate encounter. Processivity is achieved through diffusional 
mechanisms termed sliding, jumping, and intersegmental transfer. Unlike A3G, which scans 
ssDNA using both sliding and jumping movements, A3F solely relies on jumping movements. 
Further, A3F jumping movements are distinct from A3G. We discovered that a 190NPM192 motif 
in A3F prevents its sliding movement since insertion of 195NPM197 into A3G decreased its sliding 
movements. Our data demonstrated that A3G is a more potent inhibitor of HIV-1 owing primarily 
to its unique DNA scanning mechanism and secondly to its deamination motif specificity. The 
data support a model in which the processive DNA scanning mechanism of an A3 enzyme can 
predict its mutagenic potential. 
Since A3F and A3G are coexpressed in the CD4+ T cells that HIV-1 infects, we undertook 
a study to determine if A3F and A3G were coencapsidated and could be concurrently deaminating 
viral DNA. First, we found that an A3F/A3G hetero-oligomer can form in cells and in vitro, in the 
absence of RNA. This hetero-oligomer has unique biochemical properties and more efficiently 
deaminates cytosines compared to each A3 alone. Namely, the A3F in the A3F/A3G hetero-
oligomer enhances A3G-mediated deamination. Moreover, A3F and A3F/A3G caused the 
accumulation of shorter reverse transcripts due to decreasing the reverse transcriptase efficiency, 
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which would leave single-stranded (-)DNA exposed for longer periods of time enabling more 
deamination events to occur.  
Overall my thesis research identified and characterized the mechanisms by which A3F, 
A3G, and A3F/A3G hetero-oligomer act as inhibitors of HIV-1.  Future studies on whether hetero-
oligomers of other A3s involving A3D, A3F, A3G, and A3H will be very interesting. 
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CHAPTER 1. INTRODUCTION AND LITERATURE REVIEW 
1.1. Introduction 
The unifying function of the APOBEC enzyme family is that they are single-stranded 
polynucleotide cytidine deaminases and use this activity to either form uracil in mRNA to edit and 
modify function or uracil in single-stranded (ss) DNA as a promutagenic lesion to enable gene 
evolution or inactivation. In RNA, uracil has a coding function and as a result cytosine deamination 
is referred to as editing. In contrast, in ssDNA, uracil is a promutagenic lesion since if left 
unrepaired, it will template addition of adenine at a site that should have incorporated a guanine, 
thus creating C/G→T/A transition mutations. APOBEC1 (A1), an mRNA editing enzyme, is the 
namesake of the enzyme family, has anti-retroelement activity, but primarily acts in lipid 
metabolism by editing the mRNA of apolipoprotein B in gastrointestinal cells to create a smaller 
protein than the apolipoprotein B expressed in the liver (1-3). APOBEC2 (A2), whose expression 
is restricted to heart and skeletal muscles, is important for normal muscle development and 
function (4). Deamination by an APOBEC protein called activation-induced cytidine deaminase 
(AID), a lymphoid-specific ssDNA deaminase, is responsible for B cell maturation and 
immunoglobulin-gene diversification (5).  The discovery of A3G in 2002 (6) and other cytidine 
deaminases (APOBEC3A-H, excluding E) shortly thereafter opened-up the field of intrinsic 
immunity by host encoded viral “restriction factors” (7-10).  
Humans defend themselves against invading pathogens using innate and adaptive immune 
systems. The innate immune system is the first line of defense that protects the host from invading 
pathogens and is comprised of soluble factors like cytokines, complement proteins and various 
cellular factors, such as mast cells, granulocytes, natural killer cells, macrophages, and dendritic 
cells (11). A subcategory of innate immunity, called intrinsic immunity, produces specific anti-
viral proteins called “restriction factors” to counteract viral replication. The members of the 
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cytidine deaminase family, apolipoprotein B mRNA-editing, catalytic enzymes (APOBEC), are 
restriction factors that provide overlapping protection against exogenous and endogenous 
pathogens with a single-stranded DNA intermediate, such as retroviruses and retrotransposons (12, 
13). The APOBEC field came into the limelight after a discovery that implicated one of the family 
member, APOBEC3G (A3G) as a host restriction factor against Human Immunodeficiency Virus 
1 (HIV-1) that causes AIDS (Acquired Immunodeficiency Syndrome) (6).  
Out of seven A3 enzymes only four A3D, A3F, A3G and A3H, suppress HIV-1 replication. 
These four enzymes function by packaging into newly synthesized viral particles, which enables 
them to deaminate cytosines to form promutagenic uracils on nascent cDNA and directly interfere 
with the reverse transcription step of viral replication (12, 13). The end result is a hypermutated 
and nonfunctional virus. To counteract the deleterious effects of these enzymes, HIV encodes a 
protein called viral infectivity factor (Vif) that induces their polyubiquitination and proteasomal 
degradation (14-16). A3D, A3F, A3G and A3H are coexpressed in CD4+ T cells. Each are 
independently able to inhibit HIV-1 infection (17-20).  A3G has been the most widely studied and 
appears to be the most effective restrictor of HIV-1 replication as measured by cell-based assays 
(21-24) and indicated from clinical studies (25-30). Clinical subjects found to have an inherent 
ability to express a high level of A3G are less likely to become infected with HIV-1 or convert 
from HIV-1 to AIDS (25-32). The proviruses recovered from HIV-1 patients often carry 
C/G→T/A mutations in an A3G preferred sequence (CCC) context, which supports the notion that 
cytosine deaminations in the HIV-1 genome by A3G occur most frequently (25-27). At a 
population level, these actions of A3G are sufficiently repressed by Vif so that the virus continues 
to replicate, although the defective viruses that build up in a person during an HIV-1 infection are 
in part due to A3-induced mutations (33). 
1.2. Endogenous retroelements, endogenous retroviruses and exogenous retroviruses 
Retroelements are transposable genetic elements that have integrated into mammalian 
genomes over millions of years (34). Retroelements replicate via RNA intermediates. Depending 
on the presence or absence of long terminal repeats (LTRs), they are divided into two groups, LTR 
retrotransposons (also known as endogenous retroviruses) and non-LTR retrotransposons (35).  
Non-LTR retrotransposons comprise the majority of transposable elements in the human 
genome. About one third of the human genome is comprised of non-LTR retrotransposons. Non-
LTR retrotransposons have been further grouped into three types; long interspersed elements 
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(LINEs), short interspersed elements (SINEs) and the composite hominid-specific 
retrotransposons. There are three types of non LTR transposable elements currently active in 
human genome. These are LINE-1, Alu and SINE-VNTR-Alu (SVA) (36, 37). 
LTR retrotransposons (endogenous retroviruses) constitute about 10% of human and mice 
genomes. Owing to the accumulation of mutations, endogenous retroviruses have become largely 
inactive in humans (38, 39). Reconstruction of endogenous retroviruses has led to the hypothesis 
that they were inactivated by A3 enzyme activity (40). When active, endogenous retroviruses could 
fully bud and reinfect other cells within the same host. In particular, if endogenous retroviruses 
infect germ cells, virus could be vertically transferred to the offspring.  
Exogenous retroviruses have a similar lifecycle to endogenous retroviruses except that they 
are transferred through horizontal, rather than vertical transmission. Exogenous retroviruses were 
originally identified as RNA tumor viruses, causing tumors in mice, birds and sheep (41-44). 
However, after discovery of reverse transcriptase, “they” were called retroviruses (44). 
Retroviruses are a family of single-strand (+) RNA viruses that reverse transcribe the genome (7-
12 kb in length) into a double-stranded (ds) DNA which can then integrate into the genome of the 
host cell. All retroviruses contain two copies of genomic RNA (gRNA) that become non-
covalently linked with their 5’ ends in the mature virion (44, 45). Retroviruses were classified into 
the family Retroviridae. The Retroviridae family is divided into three main groups, (i) Oncoviridae 
or oncoviruses (tumour causing virus), (ii) Spumaviridae or spuma- or foamy viruses and (iii) 
Lentiviridae or lentiviruses. The most complex and widely studied retroviruses (Lentiviridae) are, 
HIV-1 and HIV-2 in humans and simian immunodeficiency virus (SIV) in simian species. The 
name lentivirus was derived from the Latin word “lentus” meaning slow, based on the slow 
progressive nature of the infection (46).  
1.3. History of HIV 
The retrovirus HIV, was identified in 1983 as the causative agent of Acquired Immune 
Deficiency Syndrome (AIDS), which was recognized as a new disease in 1981 when many 
homosexual men became susceptible to unusual rare malignancies and opportunistic infections 
(47-49). The reasons for HIV-1 emergence, spread, and unique pathogenicity have been a subject 
of intense investigation. A first clue regarding the origin came in 1986 when a morphologically 
related but antigenically different virus, now termed HIV-2, was found to be closely related to a 
simian virus causing immunodeficiency in captive macaques (50, 51). HIV-2 was found to cause 
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AIDS in patients in western Africa (52). Other, simian viruses were discovered in primates from 
sub-Saharan Africa, including, e.g, sooty mangabeys, African green monkeys, mandrills, and 
chimpanzees. These viruses were collectively termed simian immunodeficiency viruses (SIVs) 
with a suffix to denote their species of origin (47). Interestingly, it was found that SIVs in 
chimpanzees were more closely related to HIV-1 (53), whereas close simian relatives of HIV-2 
were found in sooty mangabeys (54). These findings provided the first proof for the cross-species 
lentivirus infections in primate species that led to the emergence of AIDS in both humans and 
macaques (Figure 1.1) (47). Indeed, subsequent studies confirmed that HIV-1 and HIV-2 
originated in Africa as result of zoonotic transfers of viruses infecting primates (55). 
HIV-1 strains have been classified into four highly divergent groups based on the 
sequences of full-length viral genomes. HIV-1 strains are M (main), O (outlier), N (non M or O) 
and P (putative) (56, 57). Out of 4 groups, Group M represents the major group, which is 
responsible for more than 95% of HIV-1 infections in the world (58). The prevalence of other 
groups is extremely low and mostly restricted to West Central Africa (59-61).  Group M is 
relatively evenly distributed worldwide and has been further divided into nine phylogenetic 
subtypes or clades, named A, B, C, D, F, G, H, J, and K. Different clades within several infected 
patients can create circulating recombinant forms (CRFs) by genetic recombination (62, 63). In 
the Americas and Europe, clade B is predominant, but it is rarely found in Africa (64). The clade 
C is the most prevalent HIV-1 subtype causing 50% of the infections worldwide, followed by clade 
A (12%), clade B (10%), CRF02-AG (5%) and CRF01-AE (4.8%) (63, 65). 
HIV-2 is also very divergent and is classified into eight different groups (A to H). Unlike 
HIV-1, HIV-2 is largely geographically restricted to West Africa, but recently has been identified 
in Europe and India (66, 67). HIV-2 shares 50-60% nucleotide sequence identity with HIV-1 (51), 
but is genetically most closely related to the SIVsmm from sooty mangabey, whereas HIV-1 is 
most closely related to the SIVcpz from chimpanzee (67). Compared to HIV-1 infected patients, 
AIDS develops more slowly after HIV-2 infection, and the patients survive longer (68, 69). 
Furthermore, the transmissibility of HIV-2 is significantly lower than that of HIV-1 (70, 71). Since 
my research did not involve HIV-2, this literature review will mainly discuss HIV-1 henceforward. 
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Figure 1.1. Origins of HIV viruses . More than 40 different lentiviruses termed as simian 
immunodeficiency viruses (SIVs) naturally infect Old World monkeys. The suffix listed denotes 
their primate species of origin (e.g., SIVsmm from sooty mangabeys). Humans were infected with 
SIV through the cross-species transmission. Zoonotic transfers of SIVs from Sooty mangabeys, 
Chimpanzees, and the Western gorilla has resulted in the generation of HIV-2 (A-H), HIV-1 (M 
& N) and HIV-1 (P) types, respectively. Reprinted with permission from (47). 
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1.4. Genome organization of HIV-1 
The HIV-1 genome is a 9.2 kb positive-stranded RNA molecule. It contains nine genes that 
encode fifteen viral proteins (Figure 1.2). Three of the ORFs encode Gag, Pol and Env 
polyproteins, which are proteolytically processed into individual proteins. Gag, which is also 
referred to as p55, is cleaved by protease (PR) to generate structural proteins Matrix (p17), Capsid 
(p24), Nucleocapsid (p7), and p6 protein. The Gag-pol precursor is proteolytically processed into 
three enzymes PR, RT and integrase (IN). The Env precursor gp160 is cleaved by the host 
endoprotease furin into gp120 and gp41 (72). There are also two regulatory protein genes, 
transactivator (Tat) and regulator of expression of virion protein (Rev) and accessory proteins 
which are virion infectivity factor (Vif), viral proteins R (Vpr), viral proteins U (Vpu) and negative 
factor (Nef). These accessory proteins can exhibit multiple functions and interact with various 
human proteins during the viral life cycle (73). In addition, the HIV-1 RNA genome forms several 
secondary structures, including the, packaging signal (Ψ), pseudoknots, transfer RNA mimics, 
ribosomal frameshift motifs, cis-regulatory elements, Tat-acting region (TAR), primer binding site 
(PBS), dimer initiation site (DIS), polypurine tract (PPT), and an internal ribosome entry site 
(IRES) (74). Although HIV-1 has an IRES, the cap dependent translation is thought to be the main 
translation mechanism used (75). These RNA structures regulate viral replication, from reverse 
transcription initiation and reading frames manipulation to RNA nuclear export and viral RNA 
packaging. 
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Figure 1.2. Schematic model of the HIV-1 full-length genome . HIV-1 genome contains 9 ORFs 
flanked by the long terminal repeats (LTRs) and several structural landmarks (italic characters). 
Gag and Gag-pol polyproteins are processed by viral protease. Gag is processed into matrix (MA), 
capsid (CA), nucleocapsid (NC), and p6. Gag-pol is processed into protease (PR), reverse 
transcriptase (RT), and integrase (IN). the envelope (Env) is cleaved by cellular proteases into 
gp120 and gp41. Landmarks include Tat-acting region (TAR), primer binding site (PBS), dimer 
initiation site (DIS), splice donor (SD) and central polypurine tract (cPPT), rev response element 
(RRE) and PPT. Modified from Guangdi et al. (76). 
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1.5. HIV-1 virion structure 
The HIV-1 virion is approximately 100 to 120 nm in diameter with a roughly spherical 
shape as shown in Figure 1.3. The capsid is coated with a lipid envelope, which contains cell-
derived lipid bilayers and viral envelope glycoproteins (Envs) (77). On the surface of the mature 
virion, Envs are displayed in knobbed spike structures, formed from surface protein gp120 and 
transmembrane protein gp 41. These two glycoproteins noncovalently bind to each other and form 
heterodimers (78). The central core of the virion consists of the Gag structural proteins: p17, p24, 
and p7. The matrix (MA) protein p17 forms the inner surface of the viral envelope; the capsid 
(CA) protein p24 forms the cone-shaped core; and the nucleocapsid (NC) protein p7 is located 
within the core, as a binding partner of viral RNA (79). Inside the core, there are two copies of the 
single-stranded RNA genome, which is associated with viral enzymes and accessory proteins (80). 
In addition, cellular molecules such as tRNAs, annexins, actin, and A3’s from the infected cells 
are incorporated into virions as bystanders or through interacting with viral proteins or viral RNA 
(6, 81-86). 
1.6. Viral proteins 
1.6.1. Viral structural proteins 
Gag is a 55 kDa precursor protein that is cleaved to produce the mature proteins: MA (P17), 
CA (P24), p2, NC (P7), p1 and p6 protein. The p2 and p1 proteins are spacer peptides and do not 
have any known function (87) 
 MA is a 17 kDa structural protein that is post-translationally myristoylated at the N-
terminus (88). During viral assembly, MA, which is at the N-terminal domain of Gag, regulates 
the Gag intracellular location, and directs Gag to the plasma membrane (88). It also interacts with 
the gp41 cytoplasmic tail and promotes incorporation of Env into the virion (89, 90). Additionally, 
it contributes to nuclear migration, nuclear import and integration as a part of the reverse 
transcription complex (RTC) and pre-integration complex (PIC) (91-93). 
NC is a 7 kDa nucleic acid chaperone protein that is able to promote nucleic acid 
rearrangement during viral assembly and replication, by binding to genomic RNA. NC enables 
selection, dimerization and encapsidation of genomic RNA into virions (94-96). NC also facilitates 
nucleic acid structural reorganization, primer annealing, and strand transfers which are required 
for efficient reverse transcription (97, 98). 
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Figure 1.3. Morphologic structure of HIV-1.  Lipoprotein membrane enveloped HIV-1 virus. Env 
glycoprotein complexes composed of gp120 and gp41 are integrated into this lipid membrane. The 
inner surface of viral envelope remains anchored with the matrix protein. Capsid makes the cone-
shaped core. Inside the viral core, nucleocapsid is associated with two copies of HIV-1 RNA 
genome. Other viral enzymes like reverse transcriptase, integrase, and protease are also present in 
virus particles. 
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P6 Gag is located at the C terminal domain of Gag and regulates the final step of virus 
budding. It promotes separation of assembled virions from the plasma membrane through 
interaction with the endosomal sorting complex required for transport (ESCRT) (99). It is also 
required for the incorporation of Vpr into virions (100, 101). 
Env encodes the polyprotein precursor gp160 that is cleaved by the cellular endoprotease 
furin into two subunits gp120 or SU (surface unit) and gp41 or TM (transmembrane). These two 
subunits non-covalently bind to each other and form the gp120/gp41 complex. HIV-1 Env 
mediates viral entry into target cells, in which the gp120 subunit is responsible for cell receptor 
(CD4) and coreceptor (CCR5 or CXCR4) binding, and gp41 embeds in the viral envelope to 
facilities the virus to attach to and fuse with target cell membranes (77, 102). 
1.6.2. Viral enzymes 
The Pol protein of HIV-1 is composed of three viral enzymes vital for viral replication; 
PR, RT, and IN (103). Pol is expressed as a 160 kDa protein, and the ORF partially overlaps with 
Gag resulting in the formation of Gag-Pol polyprotein through -1 ribosomal frameshifting (104). 
After viral release, viral PR auto-activates and cleaves the Gag-Pol polyprotein generating MA, 
CA, spacer peptide p2, NC, PR (p10), RT (p66/p51) and IN (p32) (105).  
HIV-1 PR functions as a homodimer. PR is classified as an aspartic protease, since it has 
the sequence Asp-Thr-Gly, which is conserved in several cellular aspartic proteases (106). PR is 
known for cleaving viral precursor proteins, however HIV-1 PR also cleaves host cell proteins, 
such as anti-apoptotic protein Bcl-2, cytoskeletal proteins, and thereby contributes to necrotic or 
apoptotic cell-death (107, 108). 
HIV-1 RT is a DNA- and RNA-dependent DNA polymerase with an RNaseH domain. The 
RT is capable of strand displacement synthesis and template switching (109, 110). RT is a 
heterodimer consisting of two polypeptides p66 (66 kDa) and p51 (51 kDa). RT requires hetero-
dimerization for its activity. The larger subunit p66 exhibits both DNA polymerase and RNase H 
activities. The smaller subunit p51 is catalytically inactive and plays a primarily structural role 
(111). The p51 subunit is produced by the removal of the C-terminal RNase H domain from p66 
by PR cleavage (112).  
HIV-1 integrase (IN) functions in a tetrameric form and facilitates the integration of viral 
DNA into the host genome. IN is a 32 kDa protein encoded by the end of the pol gene. Integrase 
facilitates 3′ processing and strand transfer leading to the integration of processed viral DNA ends 
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into the host genomic DNA (113). Besides an enzymatic function during the integration, HIV-1 
IN has additional non-enzymatic roles at steps prior to viral integration such as reverse 
transcription, nuclear import, polyprotein processing, assembly, and maturation (114-116).  
1.6.3. Viral regulatory proteins  
HIV-1 Rev is a 19 kDa phosphoprotein localized predominantly in the nucleolus/nucleus 
(117). Rev is a functionally conserved regulatory protein of lentiviruses and frequently cycles 
between the nucleus and cytoplasm. During the late stages of viral replication, Rev promotes the 
nuclear export of singly spliced or unspliced viral mRNAs by binding to their RRE (118). Stability, 
translation, and encapsidation of Rev-bound viral transcripts is also affected by Rev (119). HIV-1 
Rev also regulates viral integration frequency by binding to integrase and LEDGF/p75 (120).  
HIV-1 Tat, a 12 kDa protein, is the transactivator of HIV gene expression. Tat is localized 
primarily in the nucleus. Tat is one of the two viral regulatory factors essential for HIV-1 
transcription from the viral 5'LTR promoter. Tat binds to a trans-activation response (TAR) RNA 
element, and activates transcription initiation and elongation from the 5'LTR promoter, preventing 
transcription termination by the 5'LTR polyadenylation signal (121). Tat is secreted by infected 
cells and acts as an extra-cellular toxin (122). Exogenous Tat can induce certain cytokines, 
neurotoxicity in the central nervous system and programmed cell-death in uninfected bystander 
CD4+ T cells (73, 123). 
1.6.4. Viral accessory proteins  
HIV-1 Vif is a 23 kDa protein that promotes the viral infectivity. During the assembly of 
viral particles, Vif binds to viral genomic RNA and the NC domain of Pr55-Gag, and functions as 
a temporal regulator of viral assembly (124). Vif counteracts the antiviral activity of A3 proteins 
of the infected cells by inducing their proteasomal degradation in the cytoplasm. This will be 
discussed further in section 1.10. 
HIV-1 Nef is a 27 kDa myristoylated protein, which is expressed at the early stage of viral 
replication (125). Nef induces down-regulation of cell surface receptors (CD4, CXCR4 and CCR5) 
that promote viral entry into the cells, thus suppressing superinfection (126, 127). Nef-mediates 
down-regulation of major histocompatibility complex class I (MHC-I) on infected cells to facilitate 
viral evasion from cytotoxic T lymphocyte mediated apoptosis (128). Moreover, Nef modulates 
cytoskeletal remodeling, vesicular transport, and cellular signal transduction pathways for 
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promoting viral replication (73). Recent studies identified that host transmembrane proteins serine 
incorporator 3 (SERINC3) and SERINC5 incorporate into budding HIV-1 virions and impair 
subsequent virion penetration of the susceptible target cells but this restriction is counteracted by 
Nef (129, 130). The evidence for an essential role of Nef in viral pathogenesis also comes from 
the observation that patients infected with Nef-deleted HIV-1 become long-term nonprogressors 
(131), who remain asymptomatic for prolonged length of time even without anti-viral therapy 
(132). 
HIV-1 Vpu is a 9 kDa type 1 integral membrane protein. Vpu has at least two main 
biological functions. First, it degrades newly synthesized CD4 in the endoplasmic reticulum (133-
135); second, Vpu enhances virion release from the plasma membrane of HIV-1 infected cells 
(136). Vpu counters host restriction factor tetherin (BST-2) mediated inhibition of viral release 
through β-TrCP and endo-lysosomal trafficking (137). 
HIV-1 Vpr is a 14 kDa nuclear protein. Vpr participates in the nuclear import of pre-
integration complexes (PIC) (138). It was suggested that the first α helix structure on Vpr mediates 
the docking of the PIC to the nuclear pore complex (139, 140). Interaction of Vpr with importin α, 
is essential for nuclear import (141, 142). In addition, two non-classical nuclear localizing signals 
(NLS) of Vpr may also help in the nuclear import of PIC (143). Vpr induces G2 cell cycle arrest 
in infected cells (144). Vpr also induces T-cell apoptosis through mitochondria-dependent pathway 
(145-147), transactivates cellular genes, and acts as coactivator to induce translational activation 
of the HIV-1 5'LTR (147, 148).  
1.7. HIV-1 life cycle 
HIV-1 replication is a complex process regulated by both viral and cellular proteins. 
1.7.1. Receptor binding and entry 
The first step of the HIV-1 life-cycle begins with the binding and entry into the host cells. 
HIV-1 attaches to the host cell by binding to the cell surface receptor CD4 via gp120 of Env. CD4 
binding prompts a conformational change in gp120 protein, resulting in exposure of sites that 
enables coreceptor binding (CCR5 or CXCR4). Binding of both CD4 and the coreceptor induces 
gp41 rearrangement that exposes hydrophobic gp41 fusion peptide, which promotes virus-cell 
membrane fusion by inserting into the host cell membrane (149, 150). 
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1.7.2. Viral uncoating  
Following the insertion of HIV-1 core into the target cell, host deoxynucleotide 
triphosphates begin to diffuse into the capsid and reverse transcription of the viral RNA begins 
(151). The uncoating process is believed to be regulated by viral and host cellular factors through 
modulating capsid stability, however the precise location and timing of uncoating remain poorly 
defined (152, 153). Previous studies suggested that viral uncoating takes about 4-8 h to complete 
(154). However, a recent study using multicolored virus and single-particle imaging demonstrated 
that HIV-1 viral disassembly process takes place mostly in the middle-cytoplasm region and is 
complete between 60-120 min post-infection (155).  
1.7.3. Reverse transcription 
Figure 1.4 represents a schematic of HIV-1 reverse transcription. HIV-1 uses the cellular 
tRNAlys3, which is hybridized to the genome encoded primer-binding site at the 5’ terminus 
through NC chaperone activity, as the primer for negative-strand DNA synthesis. Extension of the 
tRNAlys3 primer creates the negative strong-stop DNA (156). After this is synthesized, NC 
facilitates a (-) strand transfer which moves the DNA/ tRNAlys3 to the 3’ end of the genome where 
it anneals to the complementary R region and enables DNA synthesis to continue. As RNA/DNA 
hybrid regions are formed the RNaseH activity of RT degrades the genomic RNA, except the two 
PPT regions at the 3’ end and center of the RNA genome. The PPTs are more resistant to RNase 
H degradation and remain bound to the minus-strand DNA for longer times. This enables them to 
act as primers for the initiation of plus-strand DNA synthesis (157). The synthesis from the PPTs 
extends through the U3-R-U5 long terminal just formed, and on through the 18 nucleotides of the 
tRNA that were initially hybridized to the primer binding site on genomic RNA. The short DNA 
intermediate made is designated as the “plus-strand strong-stop DNA.” RNase H activity removes 
the tRNA from the minus-strand DNA copy and exposes the primer binding site on the plus-strand 
strong stop DNA. Then the “second strand transfer” takes place. It could involve a circular 
intermediate, with the plus-strand strong-stop DNA acting as a bridge between the two ends of the 
minus-strand DNA. Both the minus and plus DNA strands are then extended by reverse 
transcriptase to the ends of their respective template strands. This results in a linear, double-
stranded DNA with long terminal repeats at both ends. This DNA is called proviral DNA (98, 
157). Reverse transcription critically relies on the nucleic acid chaperone activity of NC, which 
remodels nucleic acid structures to the most thermodynamically stable conformation (79, 98, 158). 
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NC plays a crucial role in almost all steps of reverse transcription such as tRNAlys3 primer 
annealing and DNA synthesis initiation, minus- and plus-strand transfers, and RT-catalyzed DNA 
elongation (79, 98, 158).  
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Figure 1.4. HIV Reverse Transcription.  For starting reverse transcription, the HIV RNA genome 
absolutely requires a human tRNALys3 as a primer to bind to the Primer Binding Site (PBS). HIV 
reverse transcriptase (RT) starts to reverse transcribe the RNA to form DNA at the 5’ end of the 
RNA genome. The RNase H domain degrades the genomic RNA. Upon reaching the 5’ end of the 
RNA genome, the nucleocapsid (NC) protein mediates a strand transfer of the (-) DNA strand. 
During (-) DNA elongation, RT degrades the RNA genome except for distinct PPT regions that 
are resistant to RT-mediated degradation. The (+) DNA strand is synthesized by RT from the 
RNA-DNA duplexes remaining at the PPT sequences. A circular intermediate is then formed, with 
the plus-strand strong-stop DNA acting as a bridge between the two ends of the (-) DNA strand. 
Finally, double-stranded DNA with long terminal repeats at both ends is formed. Reprinted with 
permission from (156). 
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1.7.4. Nuclear entry and integration 
Following the synthesis of double stranded viral DNA, newly synthesized DNA is 
transported into the nucleus as part of the PIC. With the help of nuclear membrane transport 
machinery PICs cross the nuclear envelope (159). After nuclear entry, the viral DNA integrates 
into the chromosomal DNA with the help of virus-encoded IN protein. To facilitate viral DNA 
integration, IN initiates strand transfer by performing 3′ processing, wherein IN recognizes and 
removes a pGT dinucleotide from each 3′ end of LTR. This process generates a 3′-hydroxyl group 
at the viral DNA ends, which can then be covalently ligated to the 5′-phosphates of a staggered cut 
made by IN in chromosomal DNA (160-162). Then, cellular DNA repair enzymes repair the DNA 
gaps created between unpaired viral 5′ ends and chromosomal DNA (163, 164). Hence, complete 
integration of viral DNA into host genome creates a provirus that acts as the precursor for new 
virion synthesis (165). 
1.7.5. Transcription 
 Following the HIV-1 provirus formation, viral mRNA synthesis starts by hijacking 
cellular RNA polymerase II (166). In the beginning, completely spliced mRNAs encoding Tat, 
Rev and Nef are synthesized. Then, endogenous cellular pathways export newly synthesized 
mRNA to the cytoplasm. Transcription is actively up-regulated after accumulation of Tat, resulting 
in the synthesis of incompletely spliced mRNAs encoding Env, Vpu, Vif and Vpr. Then, full-
length unspliced transcripts for the Gag-Pol polyprotein is generated (167, 168). Rev dependent 
export pathways transport unspliced and incompletely spliced mRNAs through the nuclear pore to 
the cytoplasm (167). 
1.7.6. Virion assembly 
After the synthesis of gp160 in the endoplasmic reticulum (ER), gp160 is transported to 
the cell membrane for virus assembly using the vesicular transport pathway. Gag and Gag-Pol 
precursor are synthesized on free polyribosomes. HIV-1 virion assembly takes place on the plasma 
membrane. Gag acts as the “assembly machine” for virion assembly. Gag multimerization drives 
a number of essential events in virion assembly (169, 170), including recruitment of viral genomic 
RNA, recruitment of protein components, and self-assembly into spherical virion particles. 
However, post-translationally modified Env glycoproteins traffic independently to the assembly 
site (171). 
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1.7.7. Virion maturation 
In order to promote virion release from the plasma membrane of the infected cells, HIV-1 
Gag recruits the ESCRT (endosomal sorting complex required for transport) pathway through a 
late-assembly domain in p6 Gag. The virion release from the plasma membrane is facilitated by 
the ESCRT complex mediated membrane fission (99). After virion budding, immature virions 
undergo maturation via viral PR-mediated cleavage of Gag and Gag-Pol polyproteins. Then, the 
rearrangement of cleaved products creates a fully mature and infectious virion. 
1.8. Retroviral restriction factors and their roles in HIV-1 infection 
Restriction factors are germline encoded, involved in innate immunity, and can inhibit 
replication of specific viruses in host cells (6, 172). These factors target viral replication by 
different mechanisms and are important in determining viral host range and cross-species 
transmission. So far, four types of HIV-1 restriction factors have been identified (Figure 1.5 & 
Table 1.1). These are APOBEC3 enzymes, tripartite motif (TRIM) 5α, bone marrow stromal cell 
antigen 2 (BST-2, also known as tetherin) and sterile alpha motif and histidine-aspartic domain 1 
(SAMHD1).  
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Figure 1.5. The host restriction factors and the retroviral accessory proteins. Overview of 
restriction factors that target HIV and their viral antagonists. The figure depicts the key 
mechanisms that restriction factors employ to prevent the retroviral replication and their 
counteraction by viral accessory proteins. The process of viral genome hypermutation by 
APOBEC3 is indicated in the inset panel. Reprinted with permission from (173). 
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Table 1.1. Characteristics of host restriction factors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Restriction 
Factor 
IFN 
Induced 
Life cycle stage 
inhibited 
Viral 
antagonists  
Antagonistic 
mechanism 
Under 
positive 
selection 
References 
TRIM5α Yes Capsid uncoating None known 
(escape through 
capsid mutations) 
variation in 
retroviral capsid 
Yes  (174, 175) 
SAMHD1 Yes Reverse Transcription Vpx (some SIVs) 
Vpr (some SIVs) 
proteasomal 
degradation 
Yes  (176, 177) 
Tetherin Yes Budding Nef (Some SIVs) 
Vpu (HIV-1) 
Env (HIV-2) 
prevent viral 
detachment from 
host cell 
Yes (175) 
In CD4+ T-cells: 
APOBEC3D, 
APOBEC3F, 
APOBEC3G, 
APOBEC3H 
No Reverse Transcription, 
integration, infectivity 
Vif polyubiquitination 
and 
degradation 
Yes (18, 31, 175, 
178, 179) 
In monocytes: 
APOBEC3A 
Yes Reverse Transcription None None Yes    (18, 31, 175, 
178, 180, 181) 
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1.8.1. Hallmarks of restriction factors  
Restriction factors have at least four defining characteristics (Figure 1.6) 
i. Immune induction: Restriction factor expression is often induced by interferon, but some 
restriction factors are also expressed constitutively due to having a role in restricting 
endogenous retroelement events which do not lead to IFN responses (172). 
ii. Virus restriction: A restriction factor must cause a significant decrease in virus infectivity 
and impair viral infectivity by at least 10-fold (173). 
iii. Counteraction: Restriction factors should be evolving with potent counter restriction 
mechanisms. These viral antagonist proteins are often encoded by ‘accessory genes’ that are 
not needed for virus replication except in the presence of restriction factors (182). Although 
viral antagonists overcome antiviral effects through diverse mechanisms, antagonism is 
exclusively triggered by direct protein-protein interactions between the viral antagonist and 
corresponding restriction factor and often recruits cellular degradation or transport pathways 
(154). 
iv. Positive selection: Positive selection results when two genetic entities such as hosts and 
viruses evolve in conflict with one another. In general, if mutations are advantageous it will 
be maintained in a population. If a host species constantly experiences pathogenic pressure, it 
selects for altered variants of host restriction factors that are not susceptible to the pathogen’s 
counteraction mechanism. During virus-host interactions both the host and virus evolve to 
increase their fitness and this results in the host restriction factor gene having a high number 
of non-synonymous mutations compared with synonymous mutations, a process called 
positive selection. Because antagonism is exclusively triggered by direct protein-protein 
interactions between viral antagonist and corresponding restriction factors, the restriction 
factor contains a signature of positive selection primarily in the nucleotides that code for the 
amino acids that directly interact with the virus protein. These positive selection signatures 
become apparent by comparing restriction factor gene sequences between the host and related 
evolutionary species (172).   
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Figure 1.6. Hallmarks of a restriction factor.  The four hallmarks that define an HIV restriction 
factor include a virus-encoded counter mechanism (fist sign), dominant restriction of viral growth 
(palm sign; clockwise from top left), interferon-inducible (arrow sign), and signatures of positive 
selection (plus sign). Modified from (154). 
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1.8.2. TRIM5 
TRIM5α (57.3 kDa,) is a member of TRIpartite Motif family of proteins that share a 
common architecture but have distinct functions. TRIM5α was originally discovered as an 
important determinant of the resistance of monkey cells to HIV-1 infection (183). TRIM family 
members  bind to incoming viral capsids in the cytoplasm and lead to capsid disruption and/or 
degradation (184). TRIM5α promotes rapid and premature disassembly of the viral capsid (184) 
and promotes downstream innate immune responses (Figure 1.5 & Table 1.1) (185). TRIM5α 
contains an N-terminal domain comprising RING, B-box, and coiled-coil domains. RING is a zinc-
binding domain that confers E3 ubiquitin ligase activity. B box and coiled-coil domains mediate 
formation of TRIM5α multimers, which is required for antiviral activity. The C-terminal domain 
(CTD) of TRIM5α, called B30.2 or SPRY domain, recognizes the lattice of viral CA in a species-
specific manner, and determines the specificity of restriction (173, 186). TRIM5α activity is not 
antagonized by an accessory gene like other restriction factors. Instead, the HIV-1 capsid has 
evolved point mutations to avoid recognition by human TRIM5α, but HIV-1 capsid is still 
susceptible to the Rhesus Monkey version of TRIM5α (187). Generally, TRIM5α is ineffective 
against retroviruses that naturally infect the same host species, but actively blocks replication of 
retroviruses that are found in other species. 
1.8.3. SAMHD1  
SAMHD1 is 72 kDa protein, which is IFN-γ-inducible and highly expressed in myeloid 
cells and resting CD4+ T cells.  SAMHD1 depletes deoxynucleotide triphosphate (dNTP) pools in 
the cell to block HIV-1 reverse transcription (Figure 1.7) (176). Such interference obstructs the 
completion of viral cDNA synthesis before the capsid dissociates, and this subsequently leads to 
cellular protease- and nuclease- mediated virus degradation (154). SAMHD1 is composed of an 
N-terminal nuclear localization domain, SAM domain, HD domain and C-terminal variable 
domain (188). The SAM domain mediates protein-protein interactions. The HD domain contains 
conserved histidine and aspartate residues and is involved in nucleic acid metabolism and RNA 
binding (189). 
SAMHD1 depletes the intracellular dNTP pool through dNTPase activity. After activation 
by dGTP, SAMHD1 hydrolyzes dNTPs substrates to deoxynucleosides and inorganic triphosphate 
(176, 190). SAMHD1 mediated restriction can be relieved by addition of exogenous dNTPs to the 
level required for the synthesis of viral cDNA. Moreover, HIV-2 and SIV Vpx proteins counteract 
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viral restriction by triggering the degradation of SAMHD1 (191, 192). However, HIV-1 lacks an 
antagonistic protein against SAMHD1 because it does not have a Vpx protein and its Vpr protein 
is not capable of interacting with SAMHD1. This makes myeloid cells more resistant to HIV-1 
infection. Due to this reason, SAMHD1 does not show all the four hallmarks (not antagonized by 
the HIV-1 virus) of a restriction factor in regards HIV-1.  
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Figure 1.7. HIV restriction by SAMHDI.  In myeloid cells, SAMHD1 prevents HIV-1 reverse 
transcriptase (RT)-mediated polymerization by depletion of cellular dNTPs. HIV-2/SIV Vpx and 
some Vpr variants can overcome the SAMHD1 restriction block by acting as an adaptor to an E3 
ubiquitin (Ub) ligase complex that polyubiquitinates SAMHD1 and targets them for proteasomal 
degradation by 26 S proteasome. Reprinted with permission from (154). 
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1.8.4. BST-2 (tetherin) 
BST-2 is a 19.7 kDa (180 amino acids) IFN-induced type 2 transmembrane protein that 
that acts as an inhibitor against the release of Vpu-deficient HIV-1 and other enveloped viruses 
(Figure 1.8). It blocks the release of virus by trapping nascent but mature virions at the cell surface 
(193, 194) from where they may be endocytosed. This defect in release of virus particles from the 
cell surface was due to tetherin, which can simultaneously associate with both viral and cellular 
membranes. At the time of virus budding from the cell, tetherin becomes incorporated into the 
viral envelope and physically bridges nascent virions to the cell (195). However, viruses have also 
adapted diverse strategies to antagonize BST-2. More than one antagonist has been employed by 
primate lentiviruses, including Vpu, Nef, and Env. HIV-1 Vpu directly interacts with BST-2 via 
their transmembrane domains and transports BST-2 to the trans-Golgi network/early endosomes 
where BST-2 undergoes proteasomal and/or lysosomal degradation (196). Instead of Vpu, some 
SIVs use Nef to antagonize BST-2. Nef recruits adaptor Protein-2 clathrin adaptor complex to 
target BST-2 and induces its endocytosis (197). Additionally, Env gp41 cytoplasmic tail of HIV-
2 and SIVMAC physically interacts with BST-2 and promotes the internalization and sequestration 
of BST-2 from sites of viral assembly on the cell surface (154, 198). Thus, BST-2 is a potent 
restriction factor that different immunodeficiency viruses have found a way to counteract, even in 
the absence of Vpu. 
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Figure 1.8. HIV restriction by BST-2/Tetherin.  Tetherin blocks the release of budding virions by 
trapping them at the cell surface of infected cells. HIV-1 Vpu or HIV-2 Env overcomes tetherin 
restriction by promoting the internalization and sequestration of tetherin in compartments away 
from sites of viral budding. HIV-1 Vpu can also restrict tetherin by recruiting an E3 ubiquitin 
ligase complex that ubiquitinates tetherin and targets it for degradation in lysosomes. Reprinted 
with permission from (154). 
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1.8.5. APOBEC3s 
The antiviral function of A3G was discovered when it was found that Vif was absolutely 
required for HIV-1 replication in some cell lines (non-permissive cells), but not others (permissive 
cells) (6, 199, 200). Using subtractive hybridization between a permissive and non-permissive cell 
lines from the same origin (CEM cell line), Sheehy et al., identified that the gene that encoded 
A3G was the non-permissive factor. Earlier research used hybrid cells constructed by fusing 
permissive and non-permissive cell lines to show that the non-permissive phenotype was due to a 
dominant-acting factor that restricted Vif-deficient HIV-1 infectivity (6). Subsequent genetic 
analysis of chromosome 22 by an unrelated research group revealed that A3G is the part of a larger 
subfamily of seven APOBEC3 proteins that included A3A, A3B, A3C, A3D, A3F and A3H (201). 
Each have the capacity to catalyze deamination of cytosine to uracil in ssDNA (C→U) (202). In 
the CD4+ T cells that HIV-1 infects, the restriction factors A3G, A3D, A3F and A3H are expressed. 
For A3 enzymes to restrict HIV-1 in CD4+ T cells, their encapsidation into the budding virion is a 
prerequisite (Figure 1.9) (203). It is also reported that in the absence of Vif, there is encapsidation 
of 7 ± 4 A3G molecules into the viral particle and this is sufficient to block viral replication (204, 
205). Although A3A has been shown to restrict HIV-1 replication in myeloid cells, the mechanism 
is different since target cell A3A, not encapsidated A3A, restricts the virus (180, 206).  
Each A3 gene encodes a protein with one or two conserved zinc (Z)-coordinating motifs 
(Z1, Z2 or Z3) (207). The defining feature of A3 family is a conserved His-X-Glu-X25-31-Pro-
Cys-X2-4-Cys zinc-coordinating motif within the active site where a water molecule binds Zn+2 
and the metal ion is coordinated by one histidine and two cysteines (208). The Zinc coordination 
motif is strictly required for deaminase activity (209, 210). The A3 Z domain was grouped into 
one of three distinct phylogenetic clusters – Z1, Z2 or Z3. In the Z-based classification system, Z1 
and Z2 proteins have a Ser-Trp-Ser/Thr-Cys-X2–4-Cys motif, whereas the corresponding motif in 
Z3 proteins is a Thr-Trp-Ser-Cys-X2-Cys (TW-S-C-x2-C) motif.  Z1 and Z2 proteins can be 
further distinguished by His-X1-Glu-X5- X-Val/Iso and His-X1-Glu-X5-Trp-Phe motifs, 
respectively (207). Genes for A3A (Z1), A3C (Z2), and A3H (Z3) contain a single Zn+2 binding 
domain whereas genes for A3B (Z1-Z2), A3D (Z2-Z2), A3F (Z2-Z2) and A3G (Z1-Z2) have 
resulted from duplications of the primordial gene (201, 210) and contain two putative zinc-binding 
motifs (Figure 1.10). However, only the C-terminal Z-domain is catalytically active (210-212). 
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Figure 1.9. APOBEC3 (A3) mediated inhibition of HIV-1. HIV-1 Vif counteracts the A3-
mediated restriction in the producer cells by binding CBFβ and recruiting an E3 ubiquitin (Ub) 
ligase complex to polyubiquitinate the A3 proteins and target them for degradation by the 26 S 
proteasome. A3s (A3D, A3F, A3G, and A3H) that avoid Vif-induced proteasomal degradation 
encapsidate into HIV-1 virions. In target cells, encapsidated A3s catalyze the deamination of 
cytosines to uracils in viral cDNA during RT-mediated polymerization. RT uses uracil as a 
template during positive-strand synthesis, resulting in G→A mutations. These proviral cDNAs are 
subsequently degraded or integrated into host genome. Reprinted with permission from (154).  
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Figure 1.10. Zinc (Z) coordinating-type domains of human A3 enzymes. A3 enzymes coordinate 
zinc by using the motif H-X-E-X23-28-P-C-X2-4-C. Zinc-hydroxide-mediated nucleophilic attack 
to complete the deamination reaction is enabled by the glutamate by activating a water molecule. 
All A3 enzymes have deamination activity. A legend depicts known biochemical functions of each 
Z-type domain of the A3 enzymes. The segregation of functions in the N-terminal domain (NTD) 
and C-terminal domain (CTD) is common feature of A3 enzymes with two Z-type domains. The 
NTD and the CTD are responsible for encapsidation and deamination activity, respectively.  Both 
domains can bind nucleic acids. The Vif binding site is in the CTD for A3D and A3F and the NTD 
for A3G. Reprinted with permission from (213).   
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Due to different amino acids on structural loop 7 surrounding the active site, different A3 
proteins deaminate cytosines in different preferred sequence contexts (214, 215). A3G 
preferentially deaminates the 3′C in 5′CC motifs. The deaminations of cytosine on the minus-
strand DNA result in a GGGA mutation signature on the plus-strand DNA (216, 217). A3D, 
A3F, and A3H each deaminate at 5′TC motifs, resulting in a GAAA mutation signature (2, 218, 
219). More detailed analysis of the signature mutations revealed that A3G is most active at  5′CCC 
motifs and A3D can be differentiated from A3F and A3H by examining a larger surrounding 
sequence 3′ of the cytosine (220). In the absence of HIV-1 Vif, A3G, A3F, A3D, and A3H 
molecules can package into progeny virion by binding RNA (HIV genome or cellular RNA such 
as 7SL or Y) that also interact with the HIV-1 nucleocapsid (NCp7) region of Gag polyprotein 
(186, 221, 222). Despite being present in the cytoplasm of the CD4+ T cells that HIV-1 infects, the 
A3s have to encapsidate into the virion to restrict HIV-1 replication (223). This is a requirement 
because the capsid structure does not allow A3 enzymes to diffuse into the capsid and A3 enzymes 
are compartmentalized in regions of RNA processing, e.g., stress granules or P-bodies (224, 225). 
However, the capsid does allow for dNTPs from the host to diffuse inside so that after viral 
maturation and entry to the next target cell, reverse transcription can begin (151) 
When the reverse transcription starts in virions that have encapsidated A3s, the A3 cytidine 
deaminase activity acts upon the nascent minus-strand viral cDNAs to deaminate cytosines to 
uracils (Figure 1.9). The reverse transcription stage is a very competitive environment where A3 
enzymes have to compete with RT for single-stranded (-)DNA before it is copied to form dsDNA 
and compete to bind RNA or DNA also bound by NC. As a result A3 enzymes must search within 
the HIV-1 (-) DNA for their specific recognition sequence efficiently in order to deaminate the 
most cytosines in the short window of time that the (-)DNA is exposed as single-stranded. A3 
enzymes that restrict HIV-1 have been characterized to use specific DNA scanning mechanisms 
to search for cytosines on ssDNA and can catalyze multiple cytosines in a single enzyme–DNA 
substrate encounter, meaning that they are processive enzymes (213, 226, 227).  
The A3 cytosine deaminase activity  results in the misincorporation of adenines, instead of 
guanines, in the (+)DNA due to using uracil as a template (216). It is known that many proviral 
genomes undergo successful integration with these hypermutations (228), but other proviral 
genomes may not fully complete reverse transcription due to A3 interference (229-231). 
Additionally, some preintegration complexes containing U are degraded by host DNA repair 
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mechanisms, although there is no consensus regarding the extent to which this occurs in cells (230, 
232). The uracils commonly cause missense and nonsense mutations that are lethal for viral 
replication. A3G may also hinder functional viral protein expression and progeny virus production 
(233). It was also reported that the introduction of C→U mutations in the trans-activation response 
(TAR) element, a key regulation factor of HIV-1 transcription elongation, can lead to an early 
block of viral gene expression (234). Previously it was proposed that A3 sublethal mutagenesis of 
proviral genomes has the potential to accelerate the development of drug resistance (235-244). 
However, recent studies contradict the previous hypothesis and provide some evidence for minimal 
contribution of A3-induced G→A hypermutation to HIV-1 evolution and emergence of drug 
resistance (215, 235, 245).  
1.9. Restriction of HIV-1 by A3G, A3F, A3D, and A3H 
1.9.1. Deamination-dependent restriction of HIV-1 
1.9.1.1. A3G mediated restriction 
A3G (46.4 kDa) was the first A3 enzyme discovered and was found to restrict HIV-1 and 
be responsible for the non-permissive phenotype (6). A3G exist in the cells as a high molecular 
mass ribonucleoprotein complex. Evidence suggests that only newly synthesized low molecular 
mass A3G is encapsidated into the virion (246). The amino terminal domain (NTD) of A3G is 
solely responsible for its virion encapsidation because the RNA binding and oligomerization of 
A3G is primarily mediated by the NTD of A3G (247). Work largely conducted by our lab has 
established that A3G is highly effective at restricting HIV-1, after successful virion encapsidation, 
because of its ability to efficiently scan ssDNA in search of its deamination target motif (226). 
Enzymes that do not use an energy source for movement on DNA use a mechanism termed 
facilitated diffusion to speed up the target site search (248, 249). These mechanisms include sliding 
along DNA, microscopic dissociation-reassociation events, and intersegmental transfer (Figure 
1.11) (248). Sliding is a 1-dimensional DNA scanning mechanism by which the enzyme 
undertakes an in-depth search of local areas of a substrate to find their specific motif. Enzymes 
may also undergo a 3-dimensional DNA scanning path by jumping or intersegmental transfer to 
search for its motifs. An enzyme jump is a micro-dissociation from the DNA and subsequent 
reassociation of the enzyme with the DNA without entering the bulk solution. The enzyme stays 
in the negatively charged domain of the DNA and thus has a higher likelihood of reassociating 
with the same DNA substrate than if it had diffused into the bulk solution. Jumping helps in larger 
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translocations on DNA substrates, but lacks a local search mechanism. Intersegmental transfer is 
when a DNA-binding enzyme binds two areas of DNA simultaneously before dissociating from 
one area to move to another (226, 250). Intersegmental transfer enables even larger translocations 
on DNA substrates than jumping, but also lacks a local search process and requires that the enzyme 
have at least two DNA binding domains (226, 251). A combination of 1-D and 3-D movements 
results in a more efficient search of the DNA substrate (226). A3G is efficient in deamination of 
HIV-1 genome because it uses a balanced combination of 1-D sliding and 3-D jumping motions 
(250). 
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Figure 1.11. APOBEC3-mediated ssDNA scanning mechanisms.  Illustration of DNA scanning 
by facilitated diffusion. (A) Sketch of DNA surrounded with negatively charged region that 
facilitates diffusion of A3 enzymes. (B–D) sketches of A3 enzyme is shown as a dimer, although 
the oligomerization state may vary with different A3 enzymes. (B) Sketch depicting 1- 
dimensional sliding movement. Path of enzyme is denoted by dotted line (orange). (C) Sketch 
depicting jumping motion of A3 enzyme that includes micro-dissociations and re-association of 
the enzyme from the DNA without diffusion into the bulk solution. The jumping motion entails a 
3-dimensional DNA scanning path and enables larger translocations on DNA substrates. (D) 
Sketch depicting a 3-dimensional DNA scanning path by intersegmental transfer. Intersegmental 
transfer is a doubly bound state of an enzyme where the enzyme leaves the charged domain of the 
DNA and enters into the bulk solution to bind another DNA segment before releasing the first 
bound DNA. Reprinted with permission from (213).  
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Mechanisms of DNA scanning that support processive enzyme activity allow enzymes to 
catalyze multiple events in a single enzyme-DNA substrate encounter. In contrast, if an enzyme 
undergoes macroscopic dissociation from DNA and becomes part of the bulk solution after one 
turnover, it will not be able to catalyze multiple events per DNA contact and is considered to be 
non-processive or distributive. Most studies suggest that A3G is processive and scans ssDNA by 
1-D sliding motions and 3-D jumping motions (227, 252, 253). A3G is a positively charged 
enzyme (charge of +6.5 at pH 7) that scans ssDNA by facilitated diffusion because it is retained 
in the negatively charged domain of the DNA and moves via electrostatic interactions (205, 227). 
The 1-D sliding motion introduces clusters of deamination in ssDNA which is evident in integrated 
proviral genomes (254). One research group has found that A3G does not efficiently deaminate 
closely spaced cytosines and moves between successive targets predominantly through 
intersegmental transfer (205). The efficiency imparted by 3-D movements of A3G such as jumping 
or intersegmental transfer during reverse transcription is that it enables the enzyme to maneuver 
over obstacles such as RNA/DNA hybrids that are left on the (-) DNA due to RNase H 
endonuclease activity (205, 250). The processivity determinants of A3G reside on predicted loop 
7 and helix 6 of the non-catalytic NTD (250). Thus, despite lacking catalytic activity, the NTD 
contributes to A3G deamination activity by mediating the processive scanning mechanism. 
1.9.1.2. A3F mediated restriction 
A3F was discovered as an HIV-1 restriction factor approximately 2 years after the discovery 
of A3G (2, 24). Overexpression of A3F causes a dose-responsive drop in the infectivity of Vif-
null HIV-1, and induces mutations in a GA→AA context (minus strand TC→TT) (2, 21). The 
mutational potency and antiviral effect of  A3F appears to be lower than that of A3G (226, 255), 
but  knockdown and knockout experiments have shown that endogenous levels of A3F can  restrict 
HIV-1 replication and induce mutations in a CD4+ T cell line, and both Human and Rhesus 
macaque A3F have anti HIV-1 ability (223, 256). It has been observed that A3F encapsidates into 
the core of HIV-1 particles more efficiently than A3G, which might be enabled by its ability to 
bind nucleic acids with seven-fold higher affinity than A3G (22, 226, 257). 
In spite of A3F being less effective than A3G in restricting HIV-1 (226, 257, 258), studies 
indicated that antagonization by Vif is required to preserve HIV-1’s replication capacity (259). 
Data has also implied that while HIV-1 can evolve a Vif-independent mechanism to evade A3G 
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restriction, it cannot evolve a Vif-independent mechanism to overcome A3F restriction (260). 
Thus, even if A3F does not have a strong restriction capacity for HIV-1, it does exert an important 
suppressive force on the virus.  
Both Vif binding and cytidine deaminase activity reside within the CTD of A3F, unlike A3G 
where these features are split between the NTD (Vif binding) and CTD (cytidine deaminase 
activity) (211, 261). Mutagenesis and high-resolution structural studies have shown that the Vif 
binding surface of A3F is distinct from A3G and it is more similar to A3C and A3D (262-264).  
1.9.1.3. A3D mediated restriction 
 The role of A3D as an HIV-1 restriction factor and its sensitivity to Vif was first reported 
by Dang et al. (218). A3D had a promiscuous deamination motif preference for the 5′TC and 5′GC 
contexts (218). Single-cycle infectivity assays (218, 223, 265) and spreading infections in primary 
cells (266) demonstrated less HIV-1 restriction ability compared to A3F and A3G. It was shown 
that a single amino acid 320C in the loop7 of CTD loop 7 was responsible for the suppressed 
antiviral activity of A3D (265). Refsland et al. reported that A3F and A3D have similar anti-HIV 
function in the T cell line CEM2n (19).  Like A3G, A3D also shows multimerization through an 
RNA intermediate in cells (267).  
1.9.1.4. A3H mediated restriction 
 In recent years, A3H has received much attention because it was discovered to exist as 
multiple haplotypes in the human population (hap I-VII), each having different cellular stability 
and HIV-1 restriction capability. A3H is also different from other A3 enzymes because it contains 
an evolutionarily distinct zinc coordinating domain (Z-domain). A3H has a Z3 zinc coordinating 
domain whereas A3D and A3F have two Z2 domains and A3G has one Z1 (CTD) and one Z2 
(NTD) domain (210, 268). Evidence indicates that out of seven A3H haplotypes only hap II, hap 
V, and hap VII can restrict Vif-deficient HIV-1 (269, 270). The anti-HIV-1 function of A3H 
haplotypes depends upon the stability of the protein (271, 272), their subcellular localization (273, 
274), binding affinities to RNA (274), and relative levels of virion packaging (269). It has also 
been reported that A3H forms oligomers in vitro and multimerizes on RNA in cells (267, 275). 
The most prevalent form of A3H in the population is hap I, which is a thermodynamically unstable 
protein and inactive against HIV-1 (213). A3H hap II preferentially deaminates ssDNA at 5'TC 
sites, as do A3F and A3D. The mutagenic potential of A3H hap II, demonstrated by both single-
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cycle infectivity assays, spreading infection experiments, and in HIV-1 infected individuals, 
correlates with its HIV-1 restriction ability (213, 219, 276). A higher frequency of the highly active 
and stable A3H hap II is present in populations in Africa, possibly a result of the long-term 
presence of the SIV/HIV in that continent (277-279). Inactive forms of the A3H haplotypes are 
mostly found in people of non-African descent (277, 280). Importantly, Vif from HIV-1 strains 
circulating outside of Africa are not very efficient in degrading stable A3H alleles (270, 277). It 
was proposed that the adaptive changes in HIV-1 Vif sequences happened depending on the 
presence or absence of various A3H haplotypes in a human population and that this determined 
the ability of A3H to act as an infection barrier in that population (272, 276). 
1.9.2. Deamination-independent inhibition of HIV-1 
Initially A3G-mediated deamination was proposed as the sole mechanism of antiviral 
activity against Vif-deficient HIV-1, but subsequent studies have demonstrated that A3G and other 
A3 proteins exert anti-viral activity that is deamination-independent (229, 281-289). Many reports 
indicated deamination-independent A3G-mediated antiviral effects at different stages of viral 
DNA synthesis such as the inhibition of tRNA primer binding, initiation of reverse transcription, 
elongation of reverse transcription, plus-strand DNA synthesis, production of aberrant viral 3′-
LTR ends that suppress tRNAlys3 cleavage and removal, and inhibition of integration (229, 255, 
284-286, 289-291). It was also demonstrated via endogenous reverse transcription assays that A3G 
inhibits the elongation of reverse transcripts rather than enhancing reverse transcriptase 
degradation (229). In addition, a previous study reported that the mutation of amino acid residues 
in the CTD critical for deamination activity (H257R, E259Q, C291S) of A3G failed to significantly 
impair antiviral activity of A3G (281). However, the authenticity of deamination-independent A3G 
restriction activity has been controversial, and several other groups suggested that the deamination 
ability of A3G is required for HIV-1 restriction (291-293). However, these studies should be 
considered with caution as other studies have shown that the A3G E259Q catalytic mutant binds 
RNA about 1.4- to 2-fold less tightly than A3G and such artifacts of the catalytic mutant may result 
in less inhibition of RT (229, 283). Furthermore, using purified A3G protein, one lab suggested 
that A3G may inhibit RT by binding tightly to the ssDNA or RNA template. They demonstrated 
that when A3G encounters ssDNA it initially undergoes a rapid on and off exchange with ssDNA 
followed by stable binding as demonstrated by a slow dissociation mode (294). This slow 
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dissociation mode was proposed to form a roadblock that may physically obstruct viral DNA 
synthesis (288, 294, 295). 
A3F was suggested to have a stronger deamination-independent mode of inhibition of HIV-
1 replication than A3G, and it was presumed that the inhibition of RT polymerization was the 
reason for the observed inhibition (255, 296). A computational study suggested that the A3G 
deamination-independent mode contributes to <1% of its restriction activity whereas for A3F it 
accounted for approximately 30% of its restriction activity (297). However, unlike previous studies 
that used A3F overexpression (255, 296), in two recent studies that stably expressed biologically 
relevant levels of A3F wild-type and catalytic mutants (C280S/C283A and E251Q) there was no 
inhibition of RT (258, 298), suggesting that A3F overexpression artifacts could have influenced 
previous interpretations (255, 296). Despite the possibly inefficient mutagenic function of A3F in 
some studies, it appears that the deamination mode of anti-HIV activity of A3F is dominant to 
deamination-independent mechanisms. Mbisa et al. reported that A3F can reduce 3′ processing of 
viral DNA at the U5 and U3 ends to inhibit HIV-1 integration (299). Using wild-type and a 
catalytic mutant (E251Q) of A3F, their study found that catalytic activity is in part required to 
inhibit HIV-1 integration by producing the aberrant U5 and U3 ends (299).  
1.10. Modes of virus escape from APOBEC3s 
All lentiviruses except equine infectious anemia virus (EIAV) code for Vif. Vif is an A3 
antagonist that protects lentiviruses from replication restriction by several members of the A3 
family of DNA cytosine deaminases. Vif forms a polyubiquitin ligase complex with host proteins 
to induce degradation of A3 enzymes in the proteasome (14). Vif interacts with host protein 
Elongin C and Elongin C is an obligate dimer with Elongin B (referred to as EloB/C) (16, 300-
302). After interaction with ELoB/C, Vif becomes more stable and this promotes recruitment of 
CBFβ (12, 213, 303, 304). This Vif/CBFβ/EloB/C complex interacts with the scaffolding protein 
Cullin 5 (Cul5) (16, 302) and Cul5 interacts with Rbx2. Altogether, this hexamer forms an E3 
ubiquitination complex with Vif as the substrate receptor. Vif binds to an A3 enzyme and the E3 
complex recruits an E2 ligase to polyubiquitinate the A3 enzyme through Lysine 48 linkages which 
signals the protein for proteasomal degradation (Figure 1.12) (12, 213).  
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Figure 1.12. Schematic depicting HIV Vif-mediated polyubiquitination of A3  for escaping viral 
restriction. Vif-mediated polyubiquitination of A3. Vif interacts with Elongin C (EloC), which 
forms an obligate heterodimer with Elongin B (EloB), and Cul5. The transcription cofactor CBFβ 
stabilizes Vif. Cul5 binds to Rbx2 and subsequently recruits an E2 ubiquitin conjugating enzyme. 
Vif is the substrate receptor that recruits A3 enzymes. The 48K-linked ubiquitin chains result in 
proteasomal degradation of the A3. Modified from (213). 
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The ability of a lentiviral Vif to degrade a species’ A3 enzymes influences virus host range. 
Early reports indicated that HIV-1 Vif cannot neutralize A3G from African green monkey (AGM), 
and AGM SIV Vif cannot neutralize A3G from humans (12). Thus, Vif inhibits the antiviral 
activity of A3 enzymes in a species-specific manner (305, 306). More recent support for this comes 
from evolutionary analysis of SIV from chimpanzees and HIV-1 in humans, where it was found 
that SIV from chimpanzee was only able to infect humans if the region of Vif was modified to 
antagonize human A3s (307). Vif interacts with A3 enzymes through a variety of motifs (Figure 
1.13). Vif interacts with A3G through two positively charged regions on Vif, primarily 
40YRHHY44 and secondarily 21WxSLVK26 (308-310). Similarly, various domains in Vif have been 
identified to interact with A3F, specifically, 11WQxDRMR17 is the primary interface and 
74TGERxW79 is the secondary interface (311-314). In addition, Vif also has a 69YWxL72 motif that 
interacts with both A3G and A3F (315). Evidence for these primary interfaces comes from 
experiments that mutated 40YRHHY44 or 14DRMR17 motifs to all alanines and found this was 
sufficient to block Vif-induced A3G or A3F degradation, respectively, suggesting the other 
domains provide a secondary stabilizing interaction (311). The 14DRMR17 motif on Vif is also 
important to bind with A3C and A3D (316, 317). Vif interacts with A3H through another unique 
site that involves amino acid 39F and 48H (318, 319).  
Each A3 has different amino acids that interact with Vif. For human A3G, the charged 
interface was more important for Vif association than the amino acid identity (320). On A3G, 
amino acid D128 is a determining residue since a sole mutation of 128D to 128K can abrogate the 
interaction between A3G and Vif in coimmunoprecipitation studies (320). For A3F, one group 
reported that A3F interacts with Vif through CTD amino acids 289EFLARH294 (321) and another 
group found that 289E was critical for A3F sensitivity to Vif (322). The key amino acid on A3H 
that interact with Vif is D121, similar to A3G (307).  
Although Vif primarily inhibits A3G by inducing its proteasomal degradation, it can also 
inhibit A3G encapsidation or function through a degradation-independent route. Vif can decrease 
A3G mRNA translation in order to lower the steady-state levels of A3G through a Vif and A3G 
mRNA interaction (323, 324). For Vif-mediated translation inhibition of A3G in cells, two stem-
loop structures within the 5′-UTR region of A3G mRNA are critical (324). A3G normally forms 
high molecular mass complexes that are less likely to be packaged into virions and Vif can induce 
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an even higher molecular weight form of A3G which inhibits A3G encapsidation  (325). Vif has 
also been reported to inhibit the deamination activity of virion-encapsidated A3G (326, 327). 
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Figure 1.13. Domain organization of Vif and specific motifs that interact with host proteins. Vif 
uses specific motifs to interact with A3C/A3D/A3F (red, 11WQxDRMR17 and 74TGERxW79), A3H 
(orange, 39F and 48H), and A3G (magenta, 40YRHHY44). Vif uses a common motif (pink, 
21WKSLVK26 and 69YWxL72) to interact with A3F and A3G. The two adjacent motifs of Vif (cyan, 
84GxSIEW89 and 102LADQLI107) interact with CBFβ. The Zinc is coordinated through an 
108H114C133C139H motif with the Zinc finger region (green, amino acids 108-139) to stabilize the 
Vif structure. Vif uses the specific motif 120IRxxL124 to directly interact with Cul5. The BC box 
(green 144SLQYLA149) of Vif mediates an interaction with Elongin C. The PPLP motif (gray, 
163PPLPx4L169) is involved in Vif oligomerization. Slanted lines indicate intervening amino acids 
between the domains. Modified from (213). 
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1.11. Scope and aims of the thesis 
My thesis focused on the host restriction factors A3F and A3G.  The research projects were 
planned to carry out a more comprehensive study on the anti-HIV-1 function of A3F in comparison 
to A3G. The overall goal of my Ph.D. project was to gain greater insights into the anti-viral 
function of A3F and A3G by understanding the mechanism by which these two enzymes restrict 
HIV-1. There were two specific aspects that I have focused on; first, biochemical characterization 
of A3F and A3G and their respective anti-HIV-1 function; and second, how the simultaneous 
presence of both A3F and A3G affects the overall anti-HIV-1 function of these proteins. The 
research was undertaken with the hypothesis that in vivo functions of A3F can be deduced from 
studying A3F in vitro. 
In this Ph.D. research the following aims were addressed:  
Aim 1: Biochemical characterization of A3F in comparison to A3G (chapter 2 and chapter 3) 
Aim 2: Comparison of anti-HIV-1 function of A3F and A3G (chapter 2 to chapter 5)  
Aim 3: Evaluation of deamination independent mode of HIV-1 restriction by A3F and A3G 
(chapter 4 and chapter 5)  
Aim 4: Study on the effects of simultaneous presence of both A3F and A3G on their respective 
deamination and anti-HIV-1 activity (chapter 4 and chapter 5) 
The first part of my project (chapter 2 and chapter 3) revealed that A3F and A3G were 
distinctively processive enzymes and this influenced their anti-HIV function. The data supported 
a model in which the processive DNA scanning mechanism of an A3 enzyme could predict its 
mutagenic potential and suggested key differences in the impact of A3F- and A3G-induced 
mutagenesis on HIV-1. The second part of my project (chapter 4 and chapter 5) mainly focused 
on determining if coexpression of A3F and A3G affected their HIV-1 restriction ability. We used 
a single-cycle infectivity assay and biochemical analyses to determine if coencapsidated A3F/A3G 
differ in their restriction capacity than A3F or A3G alone. The data suggest that the generation of 
hetero-oligomeric A3 species may be a unique antiviral strategy of endogenous A3 enzymes. 
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CHAPTER 2. PREFACE TO CHAPTER 3 
Over the last 15 years, the A3 enzymes have been extensively investigated as host-
restriction factors against HIV-1 (referred to as HIV). The A3 enzymes attracted the most attention 
in the APOBEC field because it was assumed that an understanding of these molecules could 
provide important clues for developing anti-retroviral strategies (178, 328). However, to tip the 
balance in favor of host defenses, more studies were needed to understand the mechanisms of A3 
function and their interaction with viral and host proteins. When my graduate research began, the 
A3 field was characterized by having extensive cell-based studies, and there was a paucity of 
biochemical data, except for A3G (205, 227, 329). A biochemical characterization of A3F had not 
been conducted and the cell-based virology studies that were available at that time suggested a 
disparity between A3F and A3G HIV-1 restriction activities, with A3G being more active than 
A3F (258, 266, 287, 330). However, other reports found an equal capacity of A3F and A3G to 
restrict HIV-1 (2, 19, 21, 23, 24, 223, 331). Chapter 3 constitutes the first comprehensive 
biochemical study that compared A3F with A3G using various synthetic ssDNA substrates. These 
biochemical and mechanistic studies of A3F identified that an “NPM” amino acid motif present in 
the interconnecting domain between the N- and C- terminal domains plays a pivotal role in A3F’s 
ssDNA scanning mechanism. Altogether an analysis of the NPM motif was key to revealing why 
A3F had a different HIV restriction profile than A3G and provided a biochemical explanation for 
the decreased ability of A3F to inactivate HIV-1. In summary, Chapter 3 suggests a biochemical 
model to account for cell-based observations and proposes that the processive ssDNA scanning 
mechanism and the preferred deamination motif of an A3 deoxycytidine deaminases are the major 
determinants of HIV restriction efficiency (226). 
  
 44 
 
 
 
 
 
 
CHAPTER 3. DIFFERENT MUTAGENIC POTENTIAL OF HIV-1 RESTRICTION 
FACTORS APOBEC3G AND APOBEC3F IS DETERMINED BY DISTINCT SINGLE-
STRANDED DNA SCANNING MECHANISMS 
  
Anjuman Ara, Robin P. Love and Linda Chelico 
Department of Microbiology & Immunology, University of Saskatchewan, Saskatoon, 
Saskatchewan, Canada 
 
 
This part of the thesis has been published in PLOS Pathogens 
Different Mutagenic Potential of HIV-1 Restriction Factors APOBEC3G and APOBEC3F Is 
Determined by Distinct Single-Stranded DNA Scanning Mechanisms. Ara A, Love RP, Chelico L 
PLoS Pathog 10(3): e1004024  (2014).  
The PLOS journals state that the published materials are licensed by the respective authors of such 
articles for use and distribution by them subject to citation of the original source in accordance with 
the Creative Commons Attribution (CC BY) license. 
 
All experiments in this chapter were performed by A.A., except Figure 3.16 B-C that were 
performed by R.P.L. A.A. and L.C. conceived and designed the experiments. A.A., L.C., and 
R.P.L. analyzed the data. A.A and L.C. wrote the article. A.A., R.P.L. and L.C. revised the article.  
  
 45 
 
3.1. Abstract 
The A3 deoxycytidine deaminase family functions as host restriction factors that can block 
replication of Vif (virus infectivity factor) deficient HIV-1 virions to differing degrees by 
deaminating cytosines to uracils in single-stranded (-)HIV-1 DNA. Upon replication of the (-)DNA 
to (+)DNA, the HIV-1 reverse transcriptase incorporates adenines opposite the uracils thereby 
inducing C/G→T/A mutations that can functionally inactivate HIV-1. Although both A3F and 
A3G are expressed in cell types HIV-1 infects and are suppressed by Vif, there has been no prior 
biochemical analysis of A3F, in contrast to A3G. Using synthetic DNA substrates, we 
characterized A3F and found that similar to A3G, it is a processive enzyme and can deaminate at 
least two cytosines in a single enzyme-substrate encounter. However, A3F scanning movement is 
distinct from A3G and relies on jumping rather than both jumping and sliding. A3F jumping 
movements were also different from A3G. The lack of sliding movement from A3F is due to a 
190NPM192 motif since insertion of this motif into A3G decreases its sliding movements. The A3G 
NPM mutant induced significantly less mutations in comparison to wild-type A3G in an in vitro 
model HIV-1 replication assay and single-cycle infectivity assay, indicating that differences in 
DNA scanning were relevant to restriction of HIV-1. Conversely, mutation of the A3F 191Pro to 
191Gly enables A3F sliding movements to occur. Although A3F 190NGM192 could slide, the enzyme 
did not induce more mutagenesis than wild-type A3F demonstrating that the unique jumping 
mechanism of A3F abrogates the influence of sliding on mutagenesis. Overall, we demonstrate 
key differences in the impact of A3F- and A3G-induced mutagenesis on HIV-1 that supports a 
model in which both the processive DNA scanning mechanism and preferred deamination motif 
(A3F, 5'TTC; A3G 5'CCC) influences the mutagenic and gene inactivation potential of an A3 
enzyme. 
3.2. Author lay summary 
Human cells possess a family of seven DNA-modification enzymes, termed A3, that 
function as part of our innate immune system. The enzymes modify cytosine in DNA which 
induces mutations. There are particular enzymes, A3D, A3F, A3G and A3H that appear to be most 
relevant to restricting HIV replication in CD4+ T cells using this mutagenic mechanism, if they 
can avoid degradation that is induced by the HIV protein Vif. There has been little biochemical 
analysis of A3 enzymes other than A3G in terms of the mechanism by which these enzymes search 
DNA for target cytosines to deaminate. We conducted a biochemical analysis of A3F. We found 
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that while A3G uses 1-dimensional sliding and 3-dimensional translocations, A3F is restricted to 
3-dimensional translocations. This makes the searching mechanism of A3F superficial and 
detrimental to the induction of a large number of mutations. In addition, gene inactivation was less 
likely to occur upon deamination of the target motif of A3F (5'TTC) in comparison to the target 
motif of A3G (5'CCC). All together the data support a model in which the way these enzymes scan 
DNA can predict the magnitude of mutagenesis induced and the target motif can predict ability to 
cause gene inactivation.  
3.3. Introduction 
A3F and A3G are members of a family of seven single-stranded (ss)DNA cytosine 
deaminases (A3A, A3B, A3C, A3D, A3F, A3G, and A3H) (201) and play a role in restriction of 
the retrovirus HIV-1 (referred to as HIV) (154). Research has been highly focused on primarily 
A3G and secondarily A3F for a number of years since they appeared to be the most efficient 
restrictors of HIV replication (2, 21-24). Although there are documented restrictive effects of A3G, 
and possibly A3F, at an individual level (reviewed in (178), the suppression of HIV by A3G and 
A3F at a population level is lost due to the HIV protein Vif (viral infectivity factor) (6, 24). Vif 
forms an E3 ubiquitin ligase with host proteins and causes A3G and A3F polyubiquitination and 
degradation through the proteasome (15, 24, 332-335).  
The general mechanism by which A3G restricts HIV, which has been a paradigm for other 
A3 enzymes, requires that it be encapsidated with the ribonucleoprotein complex of HIV (6, 217). 
A3G requires its NTD, which can bind nucleic acids, for encapsidation into virions (212). A3G 
catalyzes deaminations through its CTD (211, 212). In the target cells that these virions infect, 
encapsidated A3G can deaminate cytosines to uracils in (-)DNA reverse transcribed from the RNA 
genome, after the reverse transcriptase associated RNaseH activity enables ssDNA regions on the 
(-)DNA to be accessed by the enzyme (216, 336). The uracils in the (-)DNA are used as a template 
by reverse transcriptase during (+)DNA synthesis and result in guanine to adenine mutations. If 
A3G can induce sufficient numbers of these mutations, the resulting proviral DNA will be 
functionally inactivated. The deaminases A3D, A3F, and A3H appear to follow this general 
mechanism of restriction in cell culture, but to differing degrees than A3G (19, 21, 22, 223, 258, 
266, 330). The exceptions are A3A, which inhibits incoming HIV viral particles in myeloid lineage 
cells (180, 206), A3C, which does not appear to restrict HIV in cell culture, unless it contains a 
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rare S188I single nucleotide polymorphism (203, 223, 337, 338), and A3B, which can restrict HIV 
in 293T and HeLa cells, but not SupT1 cells (223, 339). 
Despite a possible role for A3F, A3D and A3H Haplotype II in HIV restriction, it appears 
that A3G is more effective at restricting HIV replication and that perhaps the other A3 enzymes 
function in a collaborative way with A3G (19, 223, 258, 266, 287, 330). In particular there has 
been a recent focus on the restriction capability of A3F. A3F was initially identified as potentially 
being an equal contributor with A3G to the restriction of HIV (2, 21, 23, 24, 331), but current 
research demonstrates, in agreement with an earlier report (22), that A3F may have less antiviral 
activity than A3G (258, 266, 287, 330). Many different experimental protocols, such as analysis 
of stably expressed A3F from a cell line (258), use of primary cell lines (266), and A3F haplotypes 
from donor samples (330) have been applied and demonstrate that A3F has less of an effect on 
HIV infectivity in comparison to A3G. However, another report showed no difference in restriction 
efficiency of A3G and A3F beyond 2-fold using experiments that knocked-down endogenous A3 
expression in a nonpermissive cell line (19). As a result, the role of A3F in restriction of HIV 
remains unclear. 
Among reports demonstrating less of an effect of A3F in restricting HIV replication than 
A3G, there is still no identified reason for why this may occur. From some reports A3F mRNA is 
expressed 10-fold (31) or 5-fold (330) less than A3G mRNA, suggesting less A3F would become 
virion encapsidated. However another report found A3F and A3G mRNA expression was more 
comparable (18). Further, some reports have found a direct correlation with mRNA and protein 
levels (18, 31) whereas other reports have been unable to make such a correlation due to the use 
of different primary antibodies (266). Confounding the interpretation of these data are reports 
which demonstrated that A3F is preferentially encapsidated with the HIV ribonucleoprotein 
complex in comparison to A3G (22, 257). Song et al. concluded that the encapsidation difference 
between A3G and A3F in effect absolves any difference in cellular expression (257). Despite this 
observed more specific packaging of A3F in the ribonucleoprotein complex (257), studies have 
found a minimal contribution of A3F to the hypermutation of HIV genomes or less potency in HIV 
restriction (22, 258, 266, 287, 330). Together these data suggest that if there is a difference in 
restriction efficiency of A3F and A3G, that it is not the physiological conditions which cause 
different effects on HIV infectivity, but an inherent difference in their biochemical characteristics. 
However, there has been no in depth biochemical characterization of A3F to date to determine 
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what might be these differences between A3G and A3F. As such, we have undertaken a 
characterization of A3F in comparison to A3G to identify an underlying biochemical reason for 
these observations.  
In particular, we have focused on characterizing the mechanism A3F uses to scan ssDNA. 
This is because it has been shown that the ssDNA scanning mechanism of A3G is important for 
inducing mutagenesis of (-)DNA formed during reverse transcription of RNA (250). A3G has been 
characterized to scan ssDNA through facilitated diffusion (205, 227, 329). Facilitated diffusion is 
a 3-dimensional scan of DNA by enzymes to locate their target sites for catalysis (248, 249, 340). 
The movement is characterized by sliding, jumping or intersegmental transfer motions. Sliding is 
used to describe short range 1-dimensional scanning motions and can enable an in-depth search of 
a particular area of DNA for a target motif (249, 340). Jumping is a term that describes micro-
dissociations of the enzyme from the DNA with a reassociation on the same DNA substrate, i.e., 
the enzyme does not diffuse into the bulk solution (249, 340). The negative charge of the DNA 
establishes a charged radius around the DNA molecule in which a positively charged enzyme can 
dissociate, diffuse and still return back to the same DNA. These jumping events enable enzymes 
to translocate larger distances than sliding thus making the search of non-target DNA more 
efficient than sliding alone (249, 340). Intersegmental transfer is similar to jumping but describes 
a movement where an enzyme with two DNA binding domains interacts with two distal sites 
simultaneously before dissociating from one of the sites (249, 340). Different research groups, 
including our own, have found A3G to use a combined sliding and jumping search mechanism 
(227, 250, 253, 329), although one report found A3G to use intersegmental transfer (205). We 
have characterized A3G mutants and A3G in complex with different Vif variants that resulted in 
decreases of either sliding or jumping motions and found that the ability of these A3G forms to 
induce mutagenesis of nascent reverse transcribed DNA was decreased (250, 326). We have 
hypothesized that both sliding and jumping are important for inducing mutagenesis because A3G 
needs to conduct local searches (sliding) to effectively deaminate many cytosines, ensuring gene 
inactivation, and also translocate (jumping) over RNA/DNA hybrids to reach distal regions of (-
)DNA (250). The processive scanning of other A3 enzymes has not been reported, except A3A 
which was found to be largely nonprocessive (341).  
This work is the first biochemical characterization of A3F and provides a biochemical 
explanation for the lowered ability of A3F to inactivate HIV, as reported by numerous research 
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groups (258, 266, 287, 330) and within this report. We have found that A3F primarily uses jumping 
movements to scan ssDNA which is detrimental to its ability to cause numerous mutations on (-
)DNA during reverse transcription. The target motif of A3G (5'CCC) also appears to cause more 
inactivating mutations in the HIV protease (prot) than the target motif for A3F (5'TTC), adding 
another level of deficiency in HIV inactivation potential. All together our data provide a model for 
the specific biochemical properties required for efficient restriction of HIV by A3 deaminases. 
3.4. Materials and Methods 
3.4.1. Protein expression and purification 
Recombinant baculovirus production for expression of GST-A3G, GST-A3F (NCBI 
Accession BC038808), GST-A3G CTD (amino acids 197-380), GST-A3F CTD (amino acids 195-
373), GST-A3G NPM, GST-A3F NGM or GST-nucleocapsid protein (NC) in Sf9 cells was carried 
out using the transfer vector pAcG2T (BD Biosciences), as previously described (227, 247, 250). 
Site directed mutagenesis was used to create the A3G NPM and A3F NGM clones. Cloning 
primers for A3 enzymes and the site directed mutagenesis primers were obtained from Integrated 
DNA Technologies and are listed in Table 3.1. Sf9 cells were infected with recombinant virus at a 
multiplicity of infection (MOI) of 1, except for GST-A3F and GST-A3F CTD which were infected 
at an MOI of 2. Recombinant baculovirus infected Sf9 cells were harvested after 72 h of infection. 
Cells were lysed in the presence of RNaseA and the proteins (A3G, A3G NPM, A3G CTD, and 
NC) were purified as described previously (247) to obtain protein that was cleaved from the GST 
tag and 95% pure. The A3F, A3F NGM, and A3F CTD enzymes were eluted from the glutathione-
sepharose resin (GE Healthcare) with the GST tag, as previously described (227). The samples 
were then treated with thrombin (Merck Millipore; A3F and A3F NGM, 0.02 U/µL; A3F CTD, 
0.10 U/µL) for 2-5 hours at 21 °C to cleave the GST tag. A DEAE Fast Flow column (GE 
Healthcare) was then used to purify the A3F, A3F NGM, and A3F CTD from the GST tag and 
thrombin. The proteins were loaded in low salt buffer containing 50 mM Tris pH 8.0, 50 mM 
NaCl, 10% glycerol, and 1 mM DTT. A linear gradient from 50 mM NaCl to 1 M NaCl was used 
to differentially elute the enzymes. The enzymes eluted at approximately 450 mM NaCl and were 
90% pure. The SDS-PAGE gels of the purified A3 enzymes are shown in Figure 3.1. Protein 
fractions were stored at -80 °C. HIV RT (p66/p51) (342) was generously provided by Dr. Stuart 
F.J. Le Grice (NCI, National Institutes of Health). 
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Figure 3.1. Purity of enzymes  Coomassie staining (A3G, A3G NPM, A3F CTD) or Bio-Rad 
Oriole fluorescent stain (A3F, A3F NPM). 
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3.4.2. Size exclusion chromatography 
The oligomerization state of A3 enzymes was determined by subjecting 10-15 µg of the 
purified enzymes to size exclusion chromatography using a 10 mL Superdex 200 (GE Healthcare) 
resin bed contained in a column with a 0.5 cm diameter and 16 cm height. The running buffer used 
was 50 mM Tris pH 7.5 and 200 mM NaCl. The Bio-Rad gel filtration standard set was used to 
generate a standard curve from which molecular masses and oligomerization states were 
calculated.  
3.4.3. Model HIV-1 replication assay 
A3-induced mutagenesis of ssDNA during reverse transcription of an RNA template was 
measured using an in vitro assay, which models reverse transcription from an RNA template and 
second strand synthesis, and was performed as described previously (250). Briefly, a synthetic 
(+)RNA is synthesized that contains a polypurine tract (PPT), 120 nt of the catalytic domain of the 
HIV protease (prot), and lacZα (248 nt). The PPT is used as a primer for (+)DNA synthesis and 
enables synthesis of dsDNA. The lacZα serves as a reporter gene for mutations by blue/white 
screening. The HIV protease gene was obtained by PCR using clone p93TH253.3 obtained through 
the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH from Dr. 
Feng Gao and Dr. Beatrice Hahn (343). The RNA template (50 nM) was annealed to a 24 nt DNA 
primer (250) and incubated with NC (1.5 μM), RT (1.2 μM), and dNTPs (500 μM) in RT buffer 
(50 mM Tris pH 7.4, 40 mM KCl, 10 mM MgCl2, 1 mM DTT) in the presence or absence of 200 
nM of A3G, A3F, A3G NPM or A3F NGM. Synthesized dsDNA was PCR amplified using Pfu 
Cx Turbo Hotstart (Agilent Technologies) that can use uracils as a template with high fidelity. The 
amplicons were cloned into a pET-Blue vector backbone that would allow the experimentally 
synthesized lacZα to be used for α-complementation (250). At least twenty-five mutated clones 
for each condition tested were analyzed. DNA sequencing was carried out at the National Research 
Council of Canada (Saskatoon, Saskatchewan). A t-test was used for statistical analysis of 
sequences.  
3.4.4. Oligonucleotide deamination assays 
The ssDNA substrates were obtained from Tri-Link Biotechnologies and are listed in Table 
3.1. Deaminations were detected by resolving Fluorescein (F)-labeled DNA that had been treated 
with Uracil DNA Glycosylase (New England Biolabs) and heated under alkaline conditions on a 
 52 
 
10%, 16%, or 20% v/v denaturing polyacrylamide gel, as described previously (227). The gel type 
was determined by fragment sizes produced by each substrate. Reactions were carried out under 
single hit conditions, i.e., < 15% substrate usage (344), to ensure that a single ssDNA substrate 
was interacting with at most a single enzyme. Under these conditions, a processivity factor can be 
determined by comparing the total number of deaminations occurring at two sites on the same 
DNA substrate to a calculated theoretical value of the expected deaminations that would occur at 
those two sites if the deaminations were not processive (see reference (227)). In order to obtain 
substrate usage within this range under steady-state conditions, the enzyme and DNA 
concentration were varied based on the enzyme specific activity. For calculating processivity 
consistently between different experiments we only used reactions where the enzyme activity 
resulted in 10-12% substrate usage.  More ssDNA was used with A3G to ensure clear observation 
of all deamination bands despite the large preference for the 5'C. However, the data are not altered 
with ssDNA concentration (data not shown). For A3G and A3G NPM, 30, 40, or 100 nM enzyme 
was incubated with 300 or 500 nM fluorescein (F)-labeled ssDNA. For A3F, A3F NGM, and A3F 
CTD, 100 nM enzyme was incubated with 50 or 100 nM F-labeled ssDNA. For A3G CTD, 1000 
nM enzyme was incubated with 500 nM F-labeled ssDNA. Reactions were incubated at 37°C for 
1 - 50 min. Gel pictures were obtained using a Typhoon Trio (GE Healthcare) multipurpose 
scanner and analysis of integrated gel band intensities used ImageQuant software (GE Healthcare). 
The specific activity was calculated from single-hit condition reactions by determining the 
picomoles of substrate used per minute for a microgram of enzyme. 
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Table 3.1. Primers and DNA substrates 
 
 
 
 
A3F Forward ATG AAG CCT CAC TTC AGA AAC AC 
A3F Reverse TCA CTC GAG AAT CTC CTG CAG 
A3F CTD Forward ATG TAT CCA CAC ATA TTC TAC TTC 
A3F CTD Reverse TCA CTC GAG AAT CTC CTG CAG CTT G 
A3G NPM SDM  Forward GGG GGA GAT TCT CAG AAA CCC GAT GCA CTC GAT GGA TCC ACC 
A3G NPM SDM Reverse GGT GGA TCC ATC GAG TGC ATC GGG TTT CTG AGA ATC TCC CCC  
A3F NGM SDM Forward CTA AAG GAG ATT CTC AGA AAC GGC ATG GAG GCA ATG TAT CCA CAC 
A3F NGM SDM Reverse GTG TGG ATA CAT TGC CTC CAT GCC GTT TCT GAG AAT CTC CTT TAG 
A3G Stop SDM Forward CAG AAT CAG GAA AAC TGA TCT AGA TTT TAC CCA 
A3G Stop SDM Reverse TGG GTA AAA TCT AGA TCA GTT TTC CTG ATT CTG 
A3F Stop SDM Forward CAG GAG ATT CTC GAG TGA AAG GGT CAA GAC AAT TCT G 
A3F Stop SDM Reverse CAG AAT TGT CTT GAC CCT TTC ACT CGA GAA TCT CCT G 
Prot Forward GAC AAG GAA CTG TAT CCT TTA GCT T 
Prot Reverse CTG GTA CAG TCT CAA TAG GAC TAA T 
A3G – 5 AAA GAG AAA GTG ATA CCC A(dT-FAM)A CCC ATA GAG TAA AGT TAG TAA 
GAT GTG TAA GTA TGT TAA 
A3F – 5 AAA GAG AAA GTG ATA TTC A(dT-FAM)A TTC ATA GAG TAA AGT TAG TAA 
GAT GTG TAA GTA TGT TAA 
A3G – 14 AAA GAG AAA GTG AGA CCC AAA GAA (dT-FAM)GA AGA CCC AAA TGT TAG 
AAT TGT TAA TGT GTG TGA TGA TGT TGA 
A3F – 14 AAA GAG TTA GTG AGA TTC AAA AT T (dT-FAM)AG AGA TTC AAA TGT TAG 
ATATGT TAA TGT GTG TGA TGA TGT TGA 
A3G – 30 AAA GAG AAA GTG ATA CCC AAA GAG TAA AGT (dT-FAM) AGA TAG AGA GTG 
ATA CCC AAA GAG TAA AGT TAG TAA GAT GTG TAA GTA TGT TAA 
A3F – 30 AAA GAG AAA GTG ATA TTC AAA GAG TAA AGT (dT-FAM) AGA TAG AGA GTG 
ATA TTC AAA GAG TAA AGT TAG TAA GAT GTG TAA GTA TGT TAA 
A3G – 63 GAA TAT ATG TTG AGA CCC AAA GTA ATG AGA GAT TGA (dT-FAM)TAG ATG 
AGT GTA ATG TGA TAT ATG TGT ATG AAA GAT ATA AGA CCC AAA GAG TAA 
AGT TGT TAA TGT GTG TAG ATA TGT TAA 
A3F - 63 (TTC) GAA TAT AGT TTT TAG TTC AAA GTA AGT GAA GAT AAT (dT-FAM) TAG AGA 
GTT GTA ATG TGA TAT ATG TGT ATG AAA GAT ATA AGA TTC AAA GAG TAA 
AGT TGT TAA TGT GTG TAG ATA TGT TAA 
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Table 3.1 (continued). Primers and DNA substrates 
 
 
 
 
 
 
 
 
 
 
 
 
 
A3F - 63 (ATC) GAA TAT ATG AGT TGA ATC AAA GTA ATG AGA GAG AAT (dT-FAM) TAG 
ATG AGT GTA ATG TGA TAT ATG TGT ATG AAA GAT ATA AGA ATC AAA 
GAG TAA AGT TGT TAA TGT GTG TAG ATA TGT TAA 
Complementary RNA to 
A3F/A3G – 63 
rCrUrU rUrCrA rUrArC rArCrA rUrArU rArUrC rArC 
Trap DNA AAA GAG AAA GTA ATA AGG AAA GAG TAA AGT ATA TTC AAA TAA ACA 
ATC ATT CTA CAC ATT CAT ACA ATT 
A3G – 100 GGA GAT AGA TTA GAA TAC CC A AAA ATG AAT AAA AAG TGT AGT TGA 
ATG TAG AAA AGT GGT TAT TGA ATG ATA AGG ATG GAT GGA A (dT-FAM)G 
ATA TGA AAT GGA GAT AGT GTA GAT GAA AAG ACC CAA AAT GTA GTA 
AGT AGT TTA AGA ATA GGA GAG TAG T 
A3F – 100 GGA GAT AGA TTA GAA TA TTC A AAA AAATAT AAA AAG TGT AGA ATG 
GTG TAG AAA AGT GGT TAT TGA ATG ATA AGG ATG GAT GGA A (dT-FAM)G 
ATA TGA AAT GGA GAT AGT GTA GAT GTT AAG ATT CAA AAT GTA GTA 
AGT AGT TTA AGA ATA GGA GAG TAG T 
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3.4.5. Steady state rotational anisotropy assay 
Steady state fluorescence depolarization (rotational anisotropy) was used to measure 
enzyme-ssDNA binding affinities using the same F-labeled ssDNA substrates (with cytosines 63 
nt apart) that were used for deamination reactions (Table 3.1). Reactions were 60 μL and contained 
F-labeled ssDNA (10 nM) in RT buffer and A3G (0 - 650 nM), A3F (0 - 80 nM), A3F CTD (0 - 
600 nM), A3G NPM (0 - 350 nM), or A3F NGM (0 - 650 nM) were titrated into the reaction. A 
QuantaMaster QM-4 spectrofluorometer (Photon Technology International) with a dual emission 
channel was used to collect data and calculate anisotropy. Measurements were made at 21°C. 
Samples were excited with vertically polarized light at 495 nm (6 nm band pass) and vertical and 
horizontal emissions were measured at 520 nm (6 nm band pass). Apparent dissociation constants 
(Kd) were obtained by fitting to a sigmoidal curve using Sigma Plot 11.2 software. 
3.4.6. Single-cycle infectivity assay 
VSV-G pseudotyped HIV pNL4-3 vif viruses were produced by transfecting 3 × 105 
293T cells per well in a 6-well plate with Qiagen Polyfect reagent. Specifically, transfections used 
1100 ng of pHIVvif (284), which expresses an eGFP reporter gene and 630 ng of pLTR-G 
(Addgene), which expresses the VSV-G protein, in the presence or absence of 220 ng of A3G, 
A3F or A3F NGM or 350 ng of A3G NPM in pcDNA3.1. The transfections used empty pcDNA3.1 
to achieve equivalent amounts of DNA. The cotransfection molar ratio of A3 enzymes in 
pcDNA3.1 to the pNL4-3 vif was 0.33:1 (A3G, A3F, or A3F NGM) or 0.59:1 (A3G NPM). The 
A3G (cat# 9952) and A3F (cat # 10100) expression plasmids were obtained from the NIH AIDS 
Reagent program with C-terminal tags. A stop codon was introduced immediately after the A3G 
or A3F coding sequence to enable expression of native A3 enzymes. The amino acid sequence of 
the A3G and A3F clones were identical to those used in biochemical assays. Subsequently, site 
directed mutagenesis was used to create the A3G NPM and A3F NGM clones. The site directed 
mutagenesis primers were obtained from Integrated DNA Technologies and are listed in Table 3.1. 
Sixteen hours after the transfection, the cells were washed with PBS and the medium replaced. 
Virus-containing supernatants were collected 48 hours after the media change and filtered through 
0.22 µm syringe filters. Virus was quantified by a p24 enzyme-linked immunosorbent assay 
(QuickTiterTM Lentivirus Titer Kit, Cell Biolabs Inc.). Target 293T cells were infected at an MOI 
of 0.5 by spinoculation at 800 x g for 1 h in the presence of 8 µg/ml of polybrene (345). Infection 
 56 
 
levels in 293T cells was determined by flow cytometry by detecting eGFP fluorescence at 48 hours 
post infection and data were normalized to HIVvif infections in the absence of A3 enzymes. 
3.4.7. Sequencing of integrated proviral DNA 
Infected 293T cells were harvested after 48 h and the DNA was extracted using the Qiagen 
DNeasy Blood and Tissue kit. DNA was treated with DpnI (New England Biolabs) to remove 
possible contaminating plasmid DNA and the prot (nt 2280-2631) sequences were amplified by 
PCR using Phusion High Fidelity Polymerase (New England Biolabs). Primers were obtained from 
Integrated DNA and are listed Table 3.1. PCR products were purified and cloned with the Zero 
Blunt TOPO PCR cloning kit (Invitrogen). DNA sequencing was carried out at the National 
Research Council of Canada (Saskatoon, Saskatchewan). 
3.4.8. Quantitative immunoblotting 
The A3G and A3F enzymes were detected in cell lysates (40 µg total protein) and virions 
(130 ng of p24) used for single-cycle infectivity assays using antibodies to the native enzymes. 
For A3G we used the ApoC17 rabbit antiserum (Cat # 10082, NIH AIDS Reagent Program) and 
for A3F we used the C-18 polyclonal rabbit antibody (Cat # 11474, NIH AIDS Reagent Program). 
Loading controls for cell lysates (α-tubulin, Sigma) and virions (p24, Cat #3537, NIH AIDS 
Reagent Program) were detected using mouse monoclonal antibodies. Proteins of interest and 
loading controls were detected in parallel on the same gel by using the Licor/Odyssey system 
(IRDye 680-labeled goat anti-rabbit secondary antibody and IRDye 800-labeled goat anti-mouse 
secondary antibody). Visualization with an Odyssey Infrared Imaging System (Licor) and analysis 
of bands with Odyssey software enabled intensities of bands to be determined. Analysis of a 
titration of purified A3G and A3F with their respective antibodies showed that A3F detection was 
9-fold less sensitive than A3G detection at a 1/1000 antibody dilution. Further, doubling the 
amount of antibody to A3F (1/500) resulted in a doubling of the A3F detection sensitivity in 
comparison to the antibody to A3G (1/1000). Therefore, an appropriate correction factor for the 
antibody dilution was used to adjust the integrated band intensities of A3F to enable comparison 
with A3G. Antibodies were used at a dilution of 1/1000 except for A3F or A3F NGM containing 
cell lysates which required a dilution of 1/500 for detection of A3F or A3F NGM. A t-test was 
used for statistical analysis.  
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3.5. Results 
3.5.1. A3F and A3G distinctively scan ssDNA 
The processive nature of A3G has been shown to be of importance for inducing 
mutagenesis of HIV (-)DNA in a model in vitro system (250, 326) and in cell culture (254). It is 
not known whether A3F is processive. Since multiple lines of evidence from independent labs 
have shown that the effect of A3F on HIV is different than A3G (22, 258, 266, 330), we sought to 
determine if there was an inherent biochemical difference between the two enzymes that could 
account for these observations. Specifically, we determined if there was a difference in the 
processive scanning mechanisms of these two enzymes with processivity being defined as the 
ability to deaminate more than one cytosine on an ssDNA in a single-enzyme substrate encounter. 
Processivity was determined using different synthetic ssDNA substrates containing two 
deamination motifs separated by different distances, 5'TTC for A3F and 5'CCC for A3G. This 
strategy was used since with A3G we have found that closely spaced deamination motifs, i.e., 5 to 
15 nt are deaminated most efficiently through sliding motion and as the distance between 
deamination motifs increases a jumping motion facilitates processive deaminations (250). The 
substrate usage was kept below 15% to ensure single-hit conditions were maintained, which means 
that each ssDNA was only encountered by an enzyme at most once during the reaction (344). 
On a substrate with the target cytosines separated by 30 nt (Figure 3.2, sketch), A3F was 
able to catalyze processive deaminations. The processivity factor is a ratio of the frequency of 
double deaminations on a single substrate to the predicted frequency of double deaminations of a 
nonprocessive enzyme (see Materials and Methods). Therefore, the processivity factor of 3.7 for 
A3F (Figure 3.2A) means that in a single enzyme-substrate encounter A3F was 3.7-fold more 
likely to catalyze a processive deamination than a nonprocessive deamination. On the cognate A3G 
substrate, A3G was 2-fold more likely than A3F to catalyze a processive deamination (compare 
Figure 3.2A, A3F, processivity factor of 3.7 and A3G, processivity factor of 7.9), suggesting that 
the processive mechanisms of A3F and A3G differ. In addition, we observed a difference in the 
ability of A3F and A3G to catalyze 5'-end biased deaminations. Where A3G has been found to 
prefer deaminations towards the 5'-end of ssDNA molecules due to a catalytic orientation 
specificity (227), A3F had a minimal 5'-end bias (Figure 3.2A, compare intensity of 5'C & 3'C 
bands for A3F and A3G). However, the presence or absence of a 5'-end bias does not influence 
the processivity calculation (252). Since A3G has been found to use a dual sliding and jumping 
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motion to scan ssDNA (227, 250, 329), we investigated whether the difference between A3F and 
A3G was due to a difference in the contributions of sliding and jumping or a different mode of 
scanning, e.g., intersegmental transfer.  
First, we investigated the sliding ability of A3F. We conducted deamination assays on 
ssDNA substrates with closely spaced deamination targets, since it has been shown that sliding 
motions increase the frequency of closely spaced deaminations occurring processively (250). With 
cytosines 14- and 5-nt apart, A3F was unable to catalyze any detectable processive deaminations 
(Figure 3.2B-C, A3F, absence of 5'C & 3'C band) indicating that A3F does not use sliding motions 
to catalyze processive deaminations. Of note, outside of single hit conditions (>15% substrate 
usage) we detected the band corresponding to deamination of both 5'TTC motifs on an ssDNA 
(5'C & 3'C band), which demonstrated that multiple molecules of A3F were able to deaminate 
these substrates at both cytosine targets to near completion (data not shown). In contrast, A3G was 
able to processively deaminate closely spaced residues under single-hit conditions by sliding 
(Figure 3.2B-C, A3G, processivity factors of 4.6 and 3.5). 
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Figure 3.2. A3F and A3G are distinctively processive  Processivity of A3F and A3G were tested 
on substrates that contained an internal fluorescein (F)-label (yellow star) and two deamination 
motifs separated by different distances. The A3F substrates had 5'TTC motifs and the A3G 
substrates had 5'CCC motifs. (A) The two target cytosines within the 85 nt ssDNA sequence are 
spaced 30 nt apart. Single deaminations of the 5'C and 3'C are detected as the appearance of labeled 
67- and 48- nt fragments, respectively; double deamination of both C residues on the same 
molecule results in a 30 nt labeled fragment (5'C & 3'C). (B) The two target cytosines within the 
69 nt ssDNA sequence are spaced 14 nt apart. Single deaminations of the 5'C and 3'C are detected 
as the appearance of labeled 51- and 32- nt fragments, respectively; double deamination of both C 
residues on the same molecule results in a 14 nt labeled fragment (5'C & 3'C). (C) The two target 
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cytosines within the 60 nt ssDNA sequence are spaced 5 nt apart. Single deaminations of the 5'C 
and 3'C are detected as the appearance of labeled 42- and 23- nt fragments, respectively; double 
deamination of both C residues on the same molecule results in a 5 nt labeled fragment (5'C & 
3'C). (D) The two target cytosines within the 118 nt ssDNA sequence are spaced 63 nt apart. Single 
deaminations of the 5'C and 3'C are detected as the appearance of labeled 100- and 81- nt 
fragments, respectively; double deamination of both C residues on the same molecule results in a 
63 nt labeled fragment (5'C & 3'C). (E) Deamination of the substrate described for (D), but with a 
20 nt ssDNA annealed between the two target cytosines to block the sliding component of 
processivity. The measurements of processivity (Processivity factor) and the Standard Deviation 
of the mean (S.D.) are shown below the gel. The A3F: DNA ratio was 2:1 except for panel (A) in 
which a 1:1 ratio was used. The A3G: DNA ratio was (A-B) 1:10, (C) 1:2.5, (D-E) 1:20. Enzyme: 
DNA ratios were varied due to different specific activities of the enzyme on a given DNA 
substrate. Values are an average from three independent experiments. 
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Since A3F was processive on the substrate with the target cytosines separated by 30 nt 
(Figure 3.2A, A3F), but not on substrates with closely spaced deamination motifs (Figure 3.2B-C, 
A3F), the data suggested that A3F may use jumping or intersegmental transfer to processively 
deaminate cytosines. To investigate this further we determined the processivity of A3F on an 
ssDNA with the target cytosines separated by 63 nt (Figure 3.2D). On this substrate, A3F exhibited 
a processivity factor of 4.6 (Figure 3.2D, A3F), which is higher than the processivity factor 
obtained on the substrate with the target cytosines separated by 30 nt (Figure 3.2A, A3F, 
processivity factor of 3.7). In contrast, A3G which can slide and jump (227) maintained a 
processivity factor of ~8 (compare Figure 3.2A and D, processivity factors). To confirm that we 
would observe only jumping or intersegmental transfer and not sliding motions, we annealed a 20 
nt complementary DNA in between the target cytosines (Figure 3.2E, sketch). The double-stranded 
DNA portion is not bound as tightly by A3F (Figure 3.3A-B) or A3G (Figure 3.3C and (5, 227, 
329, 346) as ssDNA (Table 3.2) and results in the assay conditions blocking the sliding portion of 
the scanning activity (227, 252). A3G was still processive on this substrate due to the ability to 
translocate on DNA in 3-dimensions by jumping, but we observed a ~2-fold decrease in A3G 
processivity as compared to the analogous ssDNA substrate (Figure 3.2D-E, compare A3G 
processivity factors). We interpret that the ~2-fold decrease in A3G processivity is due to A3G 
molecules attempting to slide over the dsDNA which induces dissociation from the DNA substrate 
and diffusion into the bulk solution. For A3F we observed a 1.8-fold increase in the processivity 
factor when we annealed a 20 nt complementary DNA in between the target cytosines (Figure 
3.2D-E, compare A3F processivity factors), despite having a reduced binding to the double-
stranded (ds)DNA portion (Figure 3.3A-B). The double deaminations became so efficient that the 
5'- and 3'-proximal cytosine deaminations were barely visible on the gel (Figure 3.2E, A3F). A3F 
bound the 118 nt ssDNA substrate (Figure 3.2D) with an apparent Kd of 20 nM (Table 3.2), which 
is ~7-fold lower than the apparent Kd of A3G (Table 3.2, Kd of 130 nM). This indicates that A3F 
is less likely to dissociate from an ssDNA substrate than A3G, but does not fully explain why we 
observed an increase in processivity by annealing a complementary DNA in between the target 
cytosines. Results were not changed by annealing a 20 nt complementary RNA molecule to the 
substrate (Figure 3.4A-B) or by testing A3F on a different partially dsDNA substrate which 
contained two 5'ATC motifs (Figure 3.5). We speculated that the processivity of A3F increased as 
opposed to remaining the same in the presence of the complementary DNA because the structural 
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change in the substrate induced by the dsDNA region made jumping events more successful. This 
could occur if the average jumping distance of A3F were different than A3G and the rigid dsDNA 
region juxtaposed the 5'TTC motifs at a distance which was highly accessible by A3F. 
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Figure 3.3. Binding affinities of A3F and A3G  for single-stranded (ss) DNA or double-stranded 
(ds) DNA. A3F and A3G binding to fluorescein labeled DNA (10 nM) was monitored with 
rotational anisotropy. (A) ssDNA as shown in Figure 3.2D was used as a substrate. A3F binds this 
ssDNA with a high affinity (apparent Kd of 20 ± 1 nM). (B-C) The double stranded region (20 nt) 
created in Figure 3.2E was used as a binding substrate for (B) A3F or (C) A3G. (B) A3F was 
unable to bind the dsDNA to saturation in a concentration range similar to ssDNA. We were unable 
to concentrate A3F sufficiently to titrate in the necessary amount to saturate the dsDNA substrate. 
The apparent Kd is estimated to be >600 nM. (C) A saturation curve for A3G binding to dsDNA 
is shown for comparison. A3G binds the dsDNA with an apparent Kd of 823 ± 11 nM. Values are 
an average from at least two independent experiments.  
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Figure 3.4. Processivity of A3F, A3G, and A3G NPM in the presence of a 20 nt RNA/DNA  
hybrid. Deamination was tested on a 118 nt ssDNA substrate that contained an internal fluorescein 
(F)-label and two deamination motifs separated by 63 nt (sketch). A 20 nt complementary RNA 
was annealed between the two deamination motifs. Single deaminations of the 5'C and 3'C are 
detected as the appearance of labeled 100- and 81- nt fragments, respectively; double deamination 
of both C residues on the same molecule results in a 63 nt labeled fragment (5'C & 3'C). (A) A3F, 
(B) A3G, and (C) A3G NPM are able to processively deaminate the target cytosines by 
transversing the RNA/DNA hybrid region. A3F is 2-fold more processive than A3G and A3G 
NPM on this substrate. The measurements of processivity (Processivity factor) and the Standard 
Deviation of the mean (S.D.) are shown below the gel. The A3F: DNA ratio was 2:1 and the A3G: 
DNA and A3G NPM: DNA ratios were 1:20. Enzyme: DNA ratios were varied due to different 
specific activities of the enzyme on a given DNA substrate. Values are an average from three 
independent experiments. 
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Figure 3.5. Processivity of A3F, A3G, and A3G NPM in the presence of a 20 nt ds DNA  region 
and 5'ATC deamination motifs. Deamination was tested on a 118 nt ssDNA substrate that 
contained an internal fluorescein (F)-label and two 5'ATC deamination motifs separated by 63 nt 
(sketch). A 20 nt complementary DNA was annealed between the two deamination motifs. Single 
deaminations of the 5'C and 3'C are detected as the appearance of labeled 100- and 81- nt 
fragments, respectively; double deamination of both C residues on the same molecule results in a 
63 nt labeled fragment (5'C & 3'C). A3F is able to processively deaminate the target cytosines by 
transversing the dsDNA region. The measurements of processivity (Processivity factor) and the 
Standard Deviation of the mean (S.D.) are shown below the gel. The A3F: DNA ratio was 2:1. 
Values are an average from three independent experiments. 
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Table 3.2. Comparison of apparent dissociation constants (Kd) from ssDNA of A3G and A3F 
wild-type and mutants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enzyme Kd (nM) 
A3G 130  6                  
A3F 20  1  
A3F CTD 288  10                             
A3G NPM 56  4                            
A3F NGM 119  11                            
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To test this hypothesis, we examined the processive deaminations of A3F and A3G on an 
ssDNA substrate with deamination motifs separated by 100 nt. We found that as the distance 
between deamination motifs was increased up to 100 nt, the processivity factors of A3F also 
increased (Figure 3.6A). In contrast, A3G processivity exhibited a plateau when deamination 
motifs were 30- to 63-nt apart and the processivity factor decreased when deamination motifs were 
100 nt apart (Figure 3.6B). These data demonstrate that the average jumping distance of A3F and 
A3G differ. Similar results were also found from analysis of deamination-induced mutations in the 
model HIV replication assay and are discussed later in the text (Table 3.4). To identify a possible 
reason for the different jumping ability of A3F we examined its oligomerization state in 
comparison to A3G. A3G is known to form polydisperse oligomers that are dependent on enzyme 
concentration and buffer conditions (347). Using size exclusion chromatography at low enzyme 
concentrations we found that A3F formed predominantly tetramers (~180 kDa) and higher order 
oligomers whereas A3G eluted as predominantly a monomer (~ 46 kDa) with minor dimeric 
species (Figure 3.6C). The finding that A3F forms more tetramers than A3G is consistent with 
previous sucrose gradient data (348) and data on the CTD portions of these enzymes. The A3F 
CTD can oligomerize more readily than the A3G CTD (247, 263, 349, 350). The A3F oligomers 
remained soluble as high speed centrifugation did not result in a discernable protein pellet. These 
data demonstrated that A3F oligomers are more stable than A3G oligomers at low protein 
concentration and suggest a structural difference that could account for why the A3F jumping 
distance is different than A3G (Figure 3.6A-B). 
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Figure 3.6. A3F translocations on ssDNA are distinct from A3G, but not due to intersegmental 
transfer. (A-B) Summary of processivity factors for (A) A3F and (B) A3G on ssDNA substrates 
where the two deamination motifs were separated by 5- to 100- nt. A3F processivity was not 
observable until the distance between cytosines was greater than 14 nt apart (denoted with x), but 
then increased until 100 nt (filled squares). This was distinct from A3G that was processive when 
cytosines were closely spaced (5- to 14- nt apart), reached a maximum processivity when cytosines 
were 30- to 63- nt apart and then decreased in processivity (filled squares). The grey area represents 
the region where sliding is required for processivity. Jumping has been previously defined to be 
translocations of ≥ 20 nt (351). Gels for the substrate with deamination motifs separated by 100 nt 
are shown in Figure 3.7. (C) Size exclusion chromatography demonstrates that A3F forms 
tetramers (~180 kDa) and higher order oligomers. This is in contrast to A3G which forms 
monomers (~46 kDa) and dimers. (D-E) Processivity of A3F was tested on a substrate that 
contained an internal fluorescein (F)-label (yellow star) and two deamination motifs (5'TTC) 
separated by 63 nt. Single deaminations of the 5'C and 3'C are detected as the appearance of labeled 
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100- and 81- nt fragments, respectively; double deamination of both C residues on the same 
molecule results in a 63 nt labeled fragment (5'C & 3'C). (D) The enzyme: substrate ratio of 1:1 
(E:S) was kept constant, but reaction components increased (100:100, 200:200, 300:300, 400:400 
nM) to investigate whether A3F could transfer between two ssDNA substrates. (E) In the presence 
of an unlabeled ssDNA trap (69 nt) the processivity factor of A3F (E:S of 1:1) remained the same 
regardless of trap concentration (1:0.5, 1:1, or 1:5 ratio of labeled ssDNA to unlabeled trap 
ssDNA). The measurements of processivity (Processivity factor), Standard Deviation of the mean 
(S.D.), and Rate (%/min) are shown below the gels. Values are an average from at least two 
independent experiments.  
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Figure 3.7. Processivity of A3F and A3G on a substrate containing deamination  motifs 100 nt 
apart. Deamination was tested on a 157 nt ssDNA substrate that contained an internal fluorescein 
(F)-label and either two 5'TTC (A3F) or 5’CCC (A3G) deamination motifs (sketch). Single 
deaminations of the 5'C and 3'C are detected as the appearance of labeled 137- and 120- nt 
fragments, respectively; double deamination of both C residues on the same molecule results in a 
100 nt labeled fragment (5'C & 3'C). A3F (left) and A3G (right) are able to processively deaminate 
the target cytosines. The measurements of processivity (Processivity factor) and the Standard 
Deviation of the mean (S.D.) are shown below the gel. The A3F: DNA ratio was 1:1 and the A3G: 
DNA ratio was 1:20. Values are an average from three independent experiments.  
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However, since the A3F ssDNA scanning mechanism is more efficient in distal 
translocations (Figure 3.2), we also investigated whether it was scanning ssDNA by intersegmental 
transfers, rather than or in addition to jumping. This mode of DNA scanning involves an enzyme 
molecule that binds in two distal locations on the DNA before completing the translocation by 
dissociating from one location (249, 340). The intersegmental transfer mechanism requires that 
the enzyme have more than one DNA binding domain. A3F could bind ssDNA with both its NTD 
and CTD on one or many subunits of the oligomer. This is in contrast to jumping which uses 
microdissociations and reassociations to scan ssDNA (249, 340). A key difference between 
jumping and intersegmental transfer is that the probability of an enzyme transferring to another 
DNA substrate is low for jumping but high for intersegmental transfer (249, 340, 352). Therefore, 
to observe whether A3F can scan ssDNA by intersegmental transfer we increased the enzyme and 
substrate concentrations, but kept their ratio constant. Crowding the reaction in this manner with 
enzyme and ssDNA can increase the tendency of the enzyme to translocate to a different ssDNA 
if intersegmental transfer is occurring (352). This would result in a decrease in the observed 
processivity with increasing reaction components. We found that A3F maintained the same 
processivity at a 1:1 E:S ratio at concentrations of 100 nM and 200 nM (Figure 3.6D, processivity 
factor of 4.7 and 4.8). At a 1:1 E:S ratio using concentrations of 300 nM and 400 nM the 
processivity of A3F decreased ~1.5-fold from 4.7 to 3.0 or 3.3 (Figure 3.6D), providing evidence 
that A3F can use intersegmental transfer to scan ssDNA. However, the decrease in A3F 
processivity is small (~1.5 fold), does not decrease gradually with increasing enzyme and substrate 
concentration, and is not completely abolished (processivity factor remains above 1) suggesting 
that intersegmental transfer is not the primary mechanism of DNA scanning, but can occur in a 
minority of ssDNA-A3F interactions. Importantly, intersegmental transfer should result in an 
increase in the reaction rate with increasing DNA concentration since the rate of searching is 
enhanced by increasing the apparent off rate, which allows more rapid sampling of DNA (352). 
However, the reaction rate of A3F decreased with increasing enzyme and substrate concentrations 
(Figure 3.6D, Rate) and supports the conclusion that intersegmental transfer is not a primary mode 
of scanning ssDNA. In further support of this interpretation is that we only observed evidence of 
intersegmental transfer with increasing enzyme and substrate concentration (Figure 3.6D), not 
when the ssDNA concentration alone was increased (Figure 3.6E, processivity factors of 4.2 to 
4.6), which indicates that A3F does not readily transfer to another ssDNA without high local 
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concentrations of enzyme, i.e., the intersegmental transfer is not inherent to A3F but requires 
excessive crowding of reaction conditions. A3G showed no decrease in processivity with 
increasing concentration of enzyme and substrate, despite also containing both a NTD and CTD 
(Figure 3.8). This difference may arise since the CTD of A3G binds ssDNA in the micromolar 
range (247, 350, 353), in contrast to the CTD of A3F that can bind DNA in the nanomolar range 
(Table 3.2, apparent Kd of 288 nM). All together the data supported the conclusion that A3F 
primarily utilized jumping and not intersegmental transfer to scan ssDNA.  
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Figure 3.8. Increasing the total concentration of enzyme and substrate  does not decrease the 
processivity of A3G. Deamination was tested on an 85 nt ssDNA substrate that contained an 
internal fluorescein (F)-label (yellow star) and two deamination motifs separated by 30 nt (sketch). 
Single deaminations of the 5'C and 3'C are detected as the appearance of labeled 67- and 48- nt 
fragments, respectively; double deamination of both C residues on the same molecule results in a 
30 nt labeled fragment (5'C & 3'C). The processivity of A3G was not significantly changed when 
the enzyme: substrate (E:S) ratio (1:16) was kept constant, but reaction components increased (3: 
50 nM, 30: 500 nM, 60: 1000 nM). The measurements of processivity (Processivity factor) and 
the Standard Deviation of the mean (S.D.) are shown below the gel. Values are an average from 
three independent experiments.  
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3.5.2. The A3F DNA scanning mechanism does not enable efficient mutagenesis of (-)DNA 
Our biochemical data on synthetic substrates (Figure 3.2) predicts that A3F will not 
efficiently catalyze deaminations during proviral DNA synthesis due to a predominant jumping 
movement that would result in a superficial scan of the ssDNA (250, 326). Importantly, we 
observed this predominant jumping movement when A3F encountered an RNA/DNA hybrid 
(Figure 3.4A), such as would be encountered during synthesis of the HIV provirus. To test this 
prediction we used our model in vitro HIV replication system. Since this system reconstitutes 
reverse transcription of (-)DNA and synthesis of (+)DNA, it allows us to observe the ability of A3 
enzymes to induce mutagenesis in a dynamic system, such as occurs in vivo, but with the advantage 
of controlling the amount of enzyme added to the reaction system. Specifically, this system uses 
an in vitro synthesized RNA which contains (from the 5'-end) a polypurine tract (PPT), part of the 
protease gene (prot) of HIV, and a lacZα reporter. The RNA is reverse transcribed to (-)DNA by 
reverse transcriptase and after RNaseH-mediated removal of the RNA, the PPT enables (+)DNA 
synthesis without the addition of an exogenous primer. In this manner we can achieve the salient 
properties of HIV replication that A3 enzymes must contend with, a finite time to access single-
stranded (-)DNA and a heterogeneous substrate that is interspersed with RNA fragments.  
The A3G data demonstrated the potential amount of mutations that could occur in this 
system. A3G had a clonal mutation frequency of 2.63 x 10-2 mutations/bp which is 10-fold over 
the background mutation frequency of reverse transcriptase (RT) (Table 3.3). 
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Table 3.3. A3-mediated mutation frequencies in a model HIV replication system. 
 
The ratio of white colonies to total colonies is defined as the population mutation frequency. The 
average number of G→A mutations per base pair in the 368 nt prot-lacZα construct is defined as 
the clone mutation frequency. For RT alone (no A3), all base changes were used to calculate the 
clone random mutation frequency which established a baseline of 0.27 x10-2 mutations/bp. The 
RT alone condition produced a population mutation frequency of 0.07. 
a Significant difference was p≤0.001 versus A3G values. 
b Significant difference was p≤0.01 versus A3G values. 
c Significant difference was p≤0.05 versus A3G values. 
 
 
 
 
  
Enzyme 
Population 
mutation 
frequency 
 
Base pairs 
sequenced 
 
Total number of 
G→A mutations 
Clone mutation 
frequency  
(x 10-2mutations/bp) 
A3G 0.89 11 040 290 2.63 
A3F 0.61a 10 304 78 0.76a 
A3G NPM 0.14a 9200 27 0.29a 
A3F NGM 0.80 10 672 36 0.34 a 
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Further, the A3G mutation spectra have clear hot-spots at 5'CCC or 5'CC motifs in both 
the prot and lacZα with some sites being mutated in 100% of clones (Figure 3.9A, e.g., 245 nt). 
Due to the PPT being nearest the prot, this region is converted to dsDNA the fastest and incurs 
less mutations than regions nearer the center or 3'-end of the (+)DNA (Figure 3.9A). As such, we 
can recover white colonies indicating a mutation in the lacZα reporter but upon sequencing find 
no mutations in the prot. Therefore, the number of clones with mutations in the prot is a measure 
of how efficiently an A3 enzyme can induce mutations. The lacZα remains single stranded longer 
and can therefore be visited by multiple A3 enzymes multiple times. In the prot region, A3G was 
found to induce no mutations in 13% of clones, but the majority of clones had either 1-2 mutations 
(47%) or 3-4 mutations (37%) (Figure 3.9C). In the lacZα, A3G-induced mutagenesis resulted in 
>7 mutations in the majority of clones (Figure 3.9D, 60%).  
Addition of A3F to the model HIV replication assay resulted in a modest 2.8-fold increase 
over the background mutation frequency (Table 3.3). Examination of the mutation spectrum 
demonstrated that A3F could induce mutagenesis at a number of 5'TTC or 5'TC sites along the 
prot and lacZα, but that there were no clear hot-spots, except possibly at position 305 nt of lacZα 
(Figure 3.9B). This may be due to the random binding of A3F to the (-)DNA and an inefficient 
search of the enzyme by jumping without local scanning by sliding (Figure 3.2), which would 
make interaction with multiple 5'TTC or 5'TC motifs less likely to occur. Of note, the mutation 
frequencies induced by A3F and A3G did not increase with the addition of more enzyme to the 
reaction demonstrating that both A3F and A3G are present at saturating levels (data not shown). 
Analysis of the distances between A3F-induced mutations demonstrated that 75% of the mutations 
were separated by more than 20 nt (Table 3.4), confirming that A3F was using jumping this assay 
system, in agreement with the data on the synthetic oligonucleotide substrates (Figure 3.2). 
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Figure 3.9. A3F exhibits low mutagenic potential in a model HIV replication system. (A-B) 
Spectra of mutations are plotted as the percentage of clones containing a mutation at a particular 
location (nt) in the 368 nt prot-lacZα construct for (A) A3G or (B) A3F. (C-F) Histograms illustrate 
the disparity between the number of mutations that can be induced by A3G versus A3F in the (C, 
E) prot region that is single stranded for a shorter time than the (D, F) lacZα region. 
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In contrast, only 50% of A3G-induced mutations were separated by more than 20 nt (Table 
3.4), providing confirmation that A3G is capable of recognizing sites that are more closely spaced 
(Figure 3.6A-B). The analysis in Table 3.4 included all clones (highly mutated and sparsely 
mutated). To ensure we did not bias our analysis we also examined only sparsely mutated clones 
for both A3G and A3F (2-5 mutations) and obtained similar results for frequency of mutations 
separated by more than 20 nt (A3G, 60% and A3F, 85%). In addition, we hypothesized that the 
tight binding of A3F to ssDNA (Table 3.2), would prevent A3F from frequently dissociating into 
the bulk solution and reassociating with different (-)DNAs. In agreement with the binding data, 
A3F increased the population mutation frequency (frequency of white colonies) only 9-fold over 
the background whereas A3G caused a 12-fold increase in the population mutation frequency 
(Table 3.3). Although the overall level of mutagenesis induced by A3F was low, we did observe 
slightly more mutations in the lacZα than the prot region due to the replication kinetics (Figure 
3.9E-F). In the majority of A3F clones (64%) there were no mutations in the prot region (Figure 
3.9E). In the lacZα region the majority of clones only had 1-2 mutations (Figure 3.9F, 36%). 
However, 29% of clones did not have a G→A mutation and were recovered due to an RT induced 
error (Figure 3.9F, 0-0). These data demonstrated that A3F was inefficient at inducing mutagenesis 
during reverse transcription even in areas where the enzyme had ample time to access ssDNA 
(lacZα) and especially in regions that are single-stranded the shortest time (prot) (Figure 3.9E-F).  
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Table 3.4. Analysis of distances between G→A mutations for A3G and A3F 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enzyme 
Frequency of clones with 
mutations >20 nt apart 
A3G 0.51                             
A3F 0.75a                    
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3.5.3. Inactivation of HIV-1 protease by A3F and A3G  
The increased distance between A3F-induced mutation sites in the HIV replication assay 
(Table 3.4) in combination with the data on synthetic oligonucleotide DNA indicating that A3F 
prefers to use jumping (Figure 3.2) provides evidence that the decreased mutagenic ability 
observed for A3F in cell culture may be due to an inefficient search mechanism on DNA. However, 
these observations are inconsequential if each mutation by A3F were to inactivate the prot gene, 
which is used here as a predictor of HIV inactivation potential. We gauged the probability that the 
prot of HIV would be inactivated by A3F by determining the mutated amino acid sequences and 
comparing this to an extensive mutagenesis study of the prot conducted by Loeb et al. (354). 
Consistent with A3F inducing a low number of mutations (Figure 3.9 and Table 3.3), there were 
no A3F-induced mutations in 64% of clones (Figure 3.10B). On a per clone basis, A3F-induced 
mutations resulted in protease inactivation only 50% of the time (Figure 3.10B, 18% active and 
18% inactive). The high number of clones remaining active was due to two reasons. First, some 
clones incurred mutations in regions where any amino acid is tolerated (354), even 
nonconservative changes, e.g., E21K, so the mutation was insignificant (Table 3.5). Second, some 
clones incurred a mutation that resulted in a conservative change to the amino acid which enabled 
the protease to retain full or partial activity, depending on the proximity to the active site residues 
(354) (Table 3.5). For example, the M46I mutation was induced by A3F in 11% of clones, but 
results an active and drug resistant protease. The remainder of the A3F-induced mutations were 
found only in single clones and 36% of those mutations resulted in an active protease (Table 3.5).  
Altogether, A3F was not efficient at inactivating the HIV protease and could also induce 
resistance to protease inhibitors (Table 3.5, D30N and M46I). This was in contrast to A3G which 
caused inactivation of 84% of the clones and left only 3% of clones active (Figure 3.10A). A3G 
also did not mutate some prot clones, but only 13% of the time (Figure 3.10A). A3G did induce 
protease drug resistant mutations in 10% of the population (Table 3.5, D30N), but the examination 
of these clones individually demonstrated that they were inactivated by other mutations. Overall, 
we found that per mutation A3G was more likely to cause an inactivating mutation than A3F. This 
appeared to be due to the ability of a 5'CCC motif to cause more nonconservative mutations than 
5'TTC in the prot (Table 3.5). For example, A3G had clear hot spots that caused inactivation of 
the protease, e.g., W42 STOP, 20% of clones; G51R, 36% of clones; G52S, 52% of clones (Table 
3.5).   
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Figure 3.10. Predicted ability of A3F and A3G to inactivate HIV protease.  Each prot clone was 
individually analyzed to determine the percentage of clones that resulted in a mutated and inactive 
(red) prot, mutated and active prot (green) or prot with no mutations (black) after exposure to (A) 
A3G or (B) A3F. (A) A3G was able to inactivate the prot in 84% of clones and left an active prot 
in 3% of mutated clones. A3G did not induce any mutations in the prot in 13% of clones. (B) A3F-
induced mutagenesis was less effective than A3G due to no mutations being induced in 64% of 
clones. Of the 36% of clones with a mutation, 18% left the prot active and 18% inactivated the 
prot. 9, 12, 19 and 35 d of age.  
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Table 3.5. A3-induced mutagenesis in HIV prot region synthesized in a model HIV 
replication assay 
Protease enzyme activity was inferred from a mutational study carried out by Loeb and colleagues 
(354) where double plus (++) is active, plus (+) is partially active and minus (–) is inactive in 
comparison to wild-type protease. Protease inhibitor resistance information is from 
http://hivdb.stanford.edu. No recorded value is used to indicate that no clones were found with a 
mutation at that particular site.  
 
Protease 
Amino 
Acid 
Position 
Nucleotide 
change  
Amino 
Acid 
change 
Predicted 
protease 
activity 
Protease 
inhibitor 
resistance 
Mutated 
A3F 
clones 
(%) 
Mutated 
A3G 
clones  
(%) 
Mutated 
A3G 
NPM 
clones 
(%) 
Mutated 
A3F 
NGM 
clones 
(%) 
19 CTG→CTA L→L ++   7   
21 GAA→AAA E→K +  4    
22 GCT→ACT A→T -  4 3   
25 GAT→AAT D→N ++  4 7  3 
27 GGA→GAA 
GGA→AGA 
G→E 
G→R 
- 
- 
  3 
10 
 3 
28 GCA→ACA A→T -  4   10 
29 GAT→AAT D→N -      
30 GAT→AAT D→N + Yes 4 10  3 
34 GAA→AAA E→K ++  11   7 
35 GAT→AAT D→N +  4   7 
38 TTG→TTA L→L ++      
40 GGG→GAG 
GGG→AGG 
GGG→GAA 
GGG→GGA 
G→E 
G→R 
G→E 
G→G 
- 
- 
- 
+ 
  7 
13 
 
 
  
42 TGG→TAG 
TGG→TGA 
TGG→TAA 
W→STOP 
W→STOP 
W→STOP 
- 
- 
- 
 
 
4 
4 
17   
46 ATG→ATA M→I + Yes 11    
48 GGG→AGG 
GGG→AGA 
GGG→GAG 
GGG→GGA 
G→R 
G→R 
G→E 
G→G 
++ 
++ 
+ 
++ 
  13 
3 
3 
7 
  
49 GGA→AGA 
GGA→GAA 
G→R 
G→E 
- 
- 
  3   
51 GGA→AGA 
GGA→AAA 
GGA→GAA 
G→R 
G→K 
G→E 
- 
- 
- 
  
4 
4 
33 
7 
3 
  
52 GGT→AGT G→S -  4 47 4  
         
 83 
 
3.5.4. Determinants of processivity for APOBEC3 enzymes 
To investigate the A3F DNA scanning mechanism further we made mutants in A3G and 
A3F to alter their processive scanning behavior. For A3G, the only other A3 double Z-domain 
enzyme studied with regards to processivity, the NTD domain acts as a processivity factor (250). 
The A3G CTD domain alone is non-processive (Figure 3.11A-B and (247, 349)). In order to focus 
in on the determinants of processivity, we recombinantly expressed the CTD domain of A3F and 
tested its processivity using ssDNA substrates as in Figure 3.2. We found that the CTD of A3F 
could not processively deaminate cytosines that were spaced 63- or 30- nt apart, similar to the 
CTD of A3G (Figure 3.11A-B, absence of 5'C & 3'C band). The A3F CTD could also not 
processively deaminate target cytosines 14- or 5-nt apart (Figure 3.11C-D, absence of 5'C & 3'C 
band), similar to the full-length A3F enzyme (Figure 3.2B-C). These data indicated that the NTD 
of A3F was a processivity factor. 
To determine the specific amino acids within the NTD that differentiate the processive 
scanning behaviors of A3F and A3G we aligned their amino acid sequences and looked for 
differences in the predicted helix 6 and loop 7 (Figure 3.12) since these regions have been shown 
to influence the scanning behavior of A3G (250). Specifically, it was found that helix 6 mediated 
sliding movements and loop 7 mediated jumping movements (250). Since we could not observe 
any scanning by sliding for A3F (Figure 3.2B-C), we hypothesized that residues within or near 
predicted N-terminal helix 6 would be different from A3G. For A3G, His186 was found to be 
essential for sliding movements (250). Although A3F has a His181 equivalent to A3G (His186) at 
the end of the predicted helix 6 in the connection domain between the NTD and CTD, A3F has an 
additional three amino acids, 190NPM192, in comparison to A3G (Figure 3.13A).  
To test whether the 190NPM192 motif prevents A3F from sliding, we inserted the NPM motif 
into the equivalent position in A3G (195NPM197) creating an A3G NPM mutant. We then tested if 
A3G NPM was still able to undergo scanning by sliding. Using the ssDNA substrates with target 
cytosines close together enables the observation of processive deaminations by sliding (250). On 
the substrate with cytosines separated by 5 nt, A3G NPM retained its processivity at an equivalent 
frequency to that of the wild-type A3G (compare Figure 3.6B and Figure 3.1C, processivity 
factors). On the substrate with cytosines separated by 14 nt, A3G NPM was essentially not 
processive, as evidenced by a processivity factor of 1 which means that A3G NPM double 
deaminations occurred at the same frequency as expected if they were uncorrelated (Figure 3.13C). 
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Figure 3.11. Similar to the A3G CTD, the A3F CTD does not deaminate cytosines processively.  
Processivity of A3F CTD and A3G CTD were tested on substrates that contained an internal 
fluorescein (F)-label (yellow star) and two deamination motifs separated by different distances. 
The substrates had 5'TTC motifs (A3F CTD) or 5'CCC motifs (A3G CTD). (A) The two target 
cytosines within the 118 nt ssDNA sequence are spaced 63 nt apart. Single deaminations of the 
5'C and 3'C are detected as the appearance of labeled 100- and 81- nt fragments, respectively. 
Double deamination of both C residues on the same molecule, which would result in a 63 nt labeled 
fragment (5'C & 3'C), could not be detected indicating that A3F CTD and A3G CTD are not 
processive on these ssDNA substrates. (B) The two target cytosines within the 85 nt ssDNA 
sequence are spaced 30 nt apart. Single deaminations of the 5'C and 3'C are detected as the 
appearance of labeled 67- and 48- nt fragments, respectively. Double deamination of both C 
residues on the same molecule, which would result in a 30 nt labeled fragment (5'C & 3'C), could 
not be detected indicating that A3F CTD and A3G CTD are not processive on these ssDNA 
substrates. (C) The two target cytosines within the 69 nt ssDNA sequence are spaced 14 nt apart. 
Single deaminations of the 5'C and 3'C are detected as the appearance of labeled 51- and 32- nt 
fragments, respectively. Double deamination of both C residues on the same molecule, which 
would result in a 14 nt labeled fragment (5'C & 3'C), could not be detected indicating that A3F 
CTD is not processive on this ssDNA substrate. (D) The two target cytosines within the 60 nt 
ssDNA sequence are spaced 5 nt apart. Single deaminations of the 5'C and 3'C are detected as the 
appearance of labeled 42- and 23- nt fragments, respectively. Double deamination of both C 
residues on the same molecule, which would result in a 5 nt labeled fragment (5'C & 3'C), could 
not be detected indicating that A3F CTD is not processive on this ssDNA substrate. The A3F CTD: 
DNA and A3G CTD: DNA ratios were 2:1. A representative gel from three independent 
experiments is shown.  
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Figure 3.12. Model of the N-terminal domain (NTD) of A3G.  Model (grey) shows loop 7 and 
helix 6 (both in red). The amino acids NPM were inserted at the end of predicted helix 6. Zinc 
atom is a dark grey sphere. The predicted model of A3G NTD was obtained by using the automated 
SWISS-MODEL program using the homologous A3G CTD (PDB: 3IQS) structure as a template. 
Figure was made using PyMOL (The PyMOL Molecular Graphics System, Version 1.5.0.5, 
Schrödinger, LLC.). 
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Figure 3.13. Decreased processivity of A3G NPM was attributable to changes in sliding, but  not 
jumping movements. (A) The A3G NPM mutant was created by inserting the NPM motif found 
in A3F into A3G immediately after Arg 194. (B-E) Processivity of A3G NPM was tested on 
substrates that contained an internal fluorescein (F)-label (yellow star) and two deamination motifs 
separated by different distances. The substrates had 5'CCC motifs. (A) The two target cytosines 
within the 60 nt ssDNA sequence are spaced 5 nt apart. Single deaminations of the 5'C and 3'C are 
detected as the appearance of labeled 42- and 23- nt fragments, respectively; double deamination 
of both C residues on the same molecule results in a 5 nt labeled fragment (5'C & 3'C). (C) The 
two target cytosines within the 69 nt ssDNA sequence are spaced 14 nt apart. Single deaminations 
of the 5'C and 3'C are detected as the appearance of labeled 51- and 32- nt fragments, respectively.  
Double deamination of both C residues on the same molecule results in a 14 nt labeled fragment 
(5'C & 3'C) and were detected at a low level resulting in a processivity factor of 1 (below gel). 
Since the processivity factor is a ratio between the observed double deaminations and the 
theoretical deaminations expected to occur for a nonprocessive enzyme (see Materials and 
Methods), the results indicated that the A3G NPM mutant was not processive on this substrate. 
(D) The two target cytosines within the 118 nt ssDNA sequence are spaced 63 nt apart. Single 
deaminations of the 5'C and 3'C are detected as the appearance of labeled 100- and 81- nt 
fragments, respectively; double deamination of both C residues on the same molecule results in a 
63 nt labeled fragment (5'C & 3'C). (E) Deamination of the substrate described for (D), but with a 
20 nt ssDNA annealed between the two target cytosines to block the sliding component of 
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processivity. The measurements of processivity (Processivity factor) and the Standard Deviation 
of the mean (S.D.) are shown below the gel. The A3G NPM: DNA ratio was (B) 1: 2.5, (C) 1:10, 
(D-E) 1:20. Enzyme: DNA ratios were varied due to different specific activities of the enzyme on 
a given DNA substrate. Values are an average from three independent experiments. 
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This was in contrast to wild-type A3G that was able to processively deaminate cytosines 
located 14 nt apart (Figure 3.2B, processivity factor 4.6). These data indicated that the NPM 
insertion had decreased the sliding distance of A3G. To ensure that jumping was not affected, we 
tested the A3G NPM mutant on a substrate with cytosines separated by 63 nt without or with a 
complementary DNA or RNA annealed. First, we established the processivity on this substrate 
when fully single-stranded. Accordingly, the A3G NPM which had a decreased ability to slide, 
had a decreased processivity factor on this substrate in comparison to wild-type A3G (compare 
Figure 3.13D, processivity factor of 5.1 to Figure 3.2D, processivity factor of 8.1), but similar to 
A3F (Figure 3.2D, processivity factor of 4.6). When a complementary DNA was annealed the 
processivity of the A3G NPM was not decreased (Figure 3.13E, processivity factor of 4.4) 
demonstrating that the jumping motion of A3G NPM was not affected. Similar results were found 
when a complementary RNA was annealed to the substrate (Figure 3.4C). This was in contrast to 
the characteristic 2-fold decrease in processivity observed with A3G when a complementary DNA 
or RNA is annealed in between two target cytosines (Figure 3.2D-E and Figure 3.4B) consistent 
with the hypothesis that attempts to slide over the dsDNA region by wild-type A3G results in 
dissociation of the enzyme into the bulk solution. That we did not see an increase in the jumping 
efficiency for the A3G NPM (Figure 3.13E), in contrast to A3F (Figure 3.2E) is in agreement with 
published data that suggest the determinants of jumping are separate from sliding and localized to 
predicted loop 7 (Figure 3.12 and (250)). Further, the oligomerization state of A3G NPM is 
equivalent to wild-type A3G (data not shown), not A3F and this may influence the jumping 
distance of an A3 enzyme (Figure 3.6A-C).  
To ensure that the effects on processivity were due to specific changes to the residues 
interacting with ssDNA while scanning, rather than solely due to a poor affinity for ssDNA, we 
examined A3G NPM by circular dichroism (CD) spectroscopy and the ability of A3G NPM to 
bind ssDNA using rotational anisotropy. The CD analysis confirmed that A3G NPM and A3G 
were structurally similar (data not shown). Interestingly, addition of the NPM residues to A3G 
resulted in a 2-fold increase in the binding affinity of A3G for the ssDNA, implicating these 
residues in the ssDNA-NTD interaction (Table 3.2, A3G, Kd of 130 nM; A3G NPM, Kd of 56 nM). 
The specific activity of A3G NPM was decreased ~3-fold in comparison to A3G (Table 3.6, A3G, 
15 pmol/µg/min; A3G NPM, 5.5 pmol/µg/min). 
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Table 3.6. Specific activities of A3G and A3F wild-type and mutants 
 
 
 
 
 
 
 
 
The specific activity was determined using the substrate with target cytosines separated 
by 63 nt (118 nt substrate) and the values are shown with the standard deviation that was 
calculated from three independent experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Enzyme 
Specific Activity 
(pmol/µg/min) 
A3G 15  1                             
A3F 0.14  0.03                    
A3G NPM 5.5  1 
A3F NGM 0.20  0.02                    
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To further investigate the influence of the NPM motif in A3F, we attempted a reciprocal 
mutation, i.e., deleting the NPM motif from A3F. However, the mutant A3F did not express well 
in the Sf9 expression system indicating that the NPM deletion caused a structural instability. To 
circumvent this we made a conservative mutation in A3F to change the NPM motif to an NGM 
motif. We hypothesized that the Pro would have a significant influence on the functionality of the 
motif since Pro gives structural rigidity. We then tested the ability of the A3F NGM to processively 
deaminate two closely spaced deamination motifs by sliding. We found that A3F NGM was able 
to processively deaminate cytosines that were 5 nt and 14 nt apart (Figure 3.14A-B, processivity 
factors of 2.1 and 2.4), in contrast to A3F (Figure 3.2B-C). When the distance between the 
cytosines was increased to 30 nt or 60 nt apart, A3F NGM was able to undergo processive 
deaminations similarly to A3F (compare Figure 3.14C-D to Figure 3.2A & D). Interestingly, the 
apparent Kd of A3F NGM was 119 nM, which is 6-fold larger than the Kd of A3F (Table 3.2, 20 
nM) further implicating these residues in the enzyme-ssDNA interaction. The specific activity of 
A3F NGM was ~1.5-fold higher than A3F (Table 3.6). The A3F NGM and A3G NPM results 
demonstrated that the presence of an NPM motif blocks the ability of both A3F and A3G to 
processively slide on ssDNA.  
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Figure 3.14. A3F NGM is able to slide on ssDNA to catalyze processive deaminations.  
Processivity of A3F NGM was tested on substrates that contained an internal fluorescein (F)-label 
(yellow star) and two deamination motifs separated by different distances. The substrates had 
5'TTC motifs. (A) The two target cytosines within the 60 nt ssDNA sequence are spaced 5 nt apart. 
Single deaminations of the 5'C and 3'C are detected as the appearance of labeled 42- and 23- nt 
fragments, respectively; double deamination of both C residues on the same molecule results in a 
5 nt labeled fragment (5'C & 3'C). (B) The two target cytosines within the 69 nt ssDNA sequence 
are spaced 14 nt apart. Single deaminations of the 5'C and 3'C are detected as the appearance of 
labeled 51- and 32- nt fragments, respectively.  Double deamination of both C residues on the 
same molecule results in a 14 nt labeled fragment (5'C & 3'C). (C) The two target cytosines within 
the 85 nt ssDNA sequence are spaced 30 nt apart. Single deaminations of the 5'C and 3'C are 
detected as the appearance of labeled 67- and 48- nt fragments, respectively; double deamination 
of both C residues on the same molecule results in a 30 nt labeled fragment (5'C & 3'C). (D) The 
two target cytosines within the 118 nt ssDNA sequence are spaced 63 nt apart. Single deaminations 
of the 5'C and 3'C are detected as the appearance of labeled 100- and 81- nt fragments, respectively; 
double deamination of both C residues on the same molecule results in a 63 nt labeled fragment 
(5'C & 3'C). The measurements of processivity (Processivity factor) and the Standard Deviation 
of the mean (S.D.) are shown below the gel. The A3F NGM: DNA ratio was 1:1. Values are an 
average from three independent experiments.staining (A3G, A3G NPM, A3F CTD) or Bio-Rad 
Oriole fluorescent stain (A3F, A3F NPM) 
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2.5.5. Contribution of processivity to efficient mutagenesis of (-)DNA 
Our model predicts that the A3G NPM mutant should be a poor inducer of mutagenesis 
during (-)DNA synthesis due the decreased ability of this mutant to slide on ssDNA (Figure 3.13). 
In agreement with the model, the A3G NPM induced mutagenesis poorly in the model HIV 
replication system (Figure 3.15A), similar to A3F (Figure 3.9B), but in contrast to wild-type A3G 
(Figure 3.9A). The A3G NPM mutant had a mutation frequency in the HIV replication assay 
(Table 3.3, 0.29 x 10-2 mutations/bp), which was 9-fold less than wild-type A3G (Table 3.3, 2.63 
x 10-2 mutations/bp). The spectrum and sequence analysis demonstrated that the sparse mutations 
induced by A3G NPM were still in 5'GG or 5'GGG contexts, but that much fewer occurred (Figure 
3.15A and Table 3.5). The A3G NPM mutant rarely induced mutations in the prot (Figure 3.15C) 
and mutations in the lacZα region were less than A3F (compare Figure 3.15D and Figure 3.9F). 
Notably, the A3G forms had a 100- (A3G) to 40- (A3G NPM) fold greater specific activity than 
A3F (Table 3.6). However, since A3G NPM and A3F similarly induced less mutations (Figure 
3.15A and Figure 3.9B) than A3G (Figure 3.9A), the data indicated that the ssDNA searching 
mechanism, but not the specific activity was a primary determining factor in levels of A3-induced 
mutagenesis.  
Our model, which is based on mutagenesis data from A3G, predicted that the mutation 
frequency of A3F NGM should increase in comparison to A3F. However, despite the A3F NGM 
mutant being able to slide (Figure 3.14), we found that A3F NGM remained inefficient at inducing 
mutagenesis in the in vitro HIV replication assay (Figure 3.15B). The induced mutagenesis of A3F 
NGM (Table 3.3, 0.34 x 10-2 mutations/bp) was more similar to A3F than A3G (Table 3.3). This 
could be due to A3F NGM sliding being ~2-fold less efficient than A3G (compare Figure 3.14A-
B and Figure 3.2B-C) or that the recovery of sliding alone in A3F is not sufficient for increasing 
the levels of mutagenesis.  The latter possibility suggested another determining factor specific to 
A3F may affect its mutagenic ability. Specifically, A3F NGM retained two distinct properties of 
A3F, the formation of tetramers and higher order oligomers (data not shown) and an increase in 
processivity with increasing distance between deamination motifs (Figure 3.14 and data not 
shown). Therefore, we propose that the jumping mechanism of A3F that is retained in A3F NGM 
and distinct from that of A3G is detrimental to efficient mutagenesis and remains as such even the 
presence of sliding movements. With this being considered, the contributing factors to the 
efficiency of A3-induced mutagenesis is not only the balance between sliding and jumping, as 
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exemplified by A3G, but also the type of jumping movements, as exemplified by A3F. The A3F 
NGM mutant also retained the 5'TTC specificity characteristic of A3F and induced similar 
mutations in HIV prot (Table 3.5). 
2.5.6. APOBEC3 processive scanning mechanism determines ability to restrict HIV-1 in 
single-cycle replication assays 
The biochemical data support the hypothesis that the processive scanning mechanism of 
the A3 enzyme can determine its mutagenic potential during reverse transcription. However, the 
in vitro HIV replication assay used in our experiments cannot account for how the HIV capsid 
environment may influence A3 enzyme-induced mutagenesis. Therefore, we used a single-cycle 
replication assay to test whether mutagenesis induced in the prot of HIVvif proviral DNA by the 
deamination activity of A3G, A3F and their mutant derivatives would recapitulate the results of 
A3-induced prot mutagenesis in the model HIV replication assay. In agreement with the 
biochemical data, in the HIV vif proviral DNA the A3G-induced mutations/kb were 6- to 8-fold 
higher than those of A3F, A3G NPM or A3F NGM (Table 3.7). Upon analysis of codon changing 
mutations, we found that the A3G hotspot in the prot was the Trp 42 codon, which was mutated 
to a stop codon in all clones containing a mutation, except one clone (Table 3.8). Clones mutated 
by A3G-catalyzed deaminations also contained other inactivating mutations such as G51R/E or 
G86R (Table 3.8). In regards to hotspots, the data were similar for A3G NPM, although fewer 
mutations were recovered (Table 3.7 and Table 3.8).  
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Figure 3.15. Cytosine deamination-induced mutagenesis by mutant A3F and A3G in a model  HIV 
replication system. (A-B) Spectra of mutations are plotted as the percentage of clones containing a 
mutation at a particular location (nt) in the 368 nt prot-lacZα construct for (A) A3G NPM or (B) 
A3F NGM. (C-F) Histograms show the number of mutations per prot or lacZα region for (C-D) 
A3G NPM or (E-F) A3F NGM. 
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Table 3.7. Analysis of A3-induced mutagenesis of prot DNA from integrated HIVvif 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enzyme 
Base pairs 
sequenced 
Total number of 
G→A mutations 
G→A mutation 
frequency 
(mutations/kb) 
A3G 6318 37 5.9 
A3F 7371 5 0.7 
A3G NPM 7020 7 1.0 
A3F NGM 9126 8 0.9 
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These data supported our biochemical data in which the decrease in sliding by A3G NPM 
in comparison to A3G resulted in a decrease of mutagenic potential (compare Figure 3.9A and 
Figure 3.15A). The prot clones exposed to A3F or A3F NGM had mutations that at best resulted 
in partial inhibition of protease activity, e.g., D30N or M46I, and none that resulted in complete 
inactivation of protease activity (Table 3.8). It is interesting that A3F NGM induced ~1.3-fold 
more mutations/kb than A3F, suggesting that there was a slight positive effect of the A3F NGM 
sliding ability on mutagenesis (Table 3.7). Overall, the prot sequencing data from HIV vif 
proviral clones was consistent with the conclusions from the in vitro model HIV replication assay 
and many deamination hotspots were common between the two assays (compare Tables 3.5 and 
3.8). Differences may have resulted from different temporal dynamics of reverse transcription 
(355) and that the in vitro assay used a smaller segment of the prot gene. The observation from in 
vitro data that the 5'TTC motif was less able to cause inactivating mutations than the 5'CCC motif 
was consistent with HIV vif proviral DNA exposed to A3F or A3G (Table 3.8). Not only was 
the 5'CCC motif able to cause more inactivating mutations by overlapping with the Trp codon 
(5'TGG), which results in a stop codon, as previously observed (216), but also because it was more 
likely to cause nonconservative mutations in comparison to the 5'TTC motif (Table 3.8 and Ref 
(341)). 
The impact of A3G- and A3F-induced mutations on the infectivity of the proviral DNA 
was also examined using the eGFP reporter gene contained in the HIV pNL4-3 vif construct. 
Consistent with sequencing data from the prot region, the eGFP reporter gene of the integrated 
provirus from the same assays was inactivated 3- to 4-fold more in HIV vif virions exposed to 
A3G in comparison to A3F, A3G NPM or A3F NGM (Figure 3.16A).  
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 Table 3.8. A3-induced mutagenesis in integrated proviral HIV-1vif prot DNA 
Protease enzyme activity was inferred from a mutational study carried out by Loeb and colleagues 
(354) where double plus (++) is active, plus (+) is partially active and minus (–) is inactive in 
comparison to wild-type protease. Protease inhibitor resistance information is from 
http://hivdb.stanford.edu. No recorded value is used to indicate that no clones were found with a 
mutation at that particular site.  
 
 
 
 
Protease 
Amino 
Acid 
Position 
Nucleotide 
change  
Amino 
Acid 
change 
Predicted 
protease 
activity 
Protease 
inhibitor 
resistance 
Mutated 
A3F 
clones  
Mutated 
A3G 
clones  
Mutated 
A3G 
NPM 
clones  
Mutated 
A3F 
NGM 
clones  
20 AAG→AAA K→K ++   2 1  
21 GAA→AAA E→K ++  1    
30 GAT→AAT D→N + Yes 1 1   
34 GAA→AAA E→K ++  1 1  2 
35 GAA→AAA E→K +     1 
36 ATG→ATA M→I +  1   3 
41 AGA→AAA R→K ++  1 1  1 
42 TGG→TAG 
TGG→TGA 
W→STOP 
W→STOP 
- 
- 
 
 
 5 
1 
1  
46 ATG→ATA M→I + Yes  1  1 
48 GGG→AGA 
GGG→AGG 
GGG→AAA 
GGG→GGA 
G→R 
G→R 
G→K 
G→G 
++ 
++ 
++ 
++ 
  1 
1 
1 
1 
 
 
 
 
 
51 GGA→AGA 
GGA→GAA 
G→R 
G→E 
- 
- 
  3 
1 
2  
52 GGT→AGT G→S -   2   
57 AGA→AAA R→K ++   1   
60 GAT→AAT D→N ++   1   
65 GAA→AAA E→K -   2   
73 GGT→AGT G→S ++   2   
78 GGA→AGA G→R -   1   
86 GGA→AGA G→R -   3 2  
87 AGA→AAA R→K ++   1   
90 TTG→TTA L→L ++   1   
94 GGC→AGC G→S +    1  
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Figure 3.16. A3 enzyme processivity influences the HIV vif restriction efficiency.  (A) Virus 
infectivity was measured by eGFP expression in 293T cells infected with HIVΔvif that was 
produced in the absence or presence of A3G, A3F, A3G NPM or A3F NGM. Results normalized 
to the no A3 condition are shown with the Standard Deviation of the mean calculated from at least 
three independent experiments. (B-C) Quantitative immunoblotting was used to determine the 
levels of A3G, A3F, A3G NPM, or A3F NGM expressed in cells and encapsidated into HIVΔvif 
virions. (B) The detection capabilities of antibodies to A3G (Apo C17, NIH AIDS Reagent 
Program) or A3F (C-18, NIH AIDS Reagent Program) was determined by detecting 10 ng of 
purified A3G or A3F with a 1/1000 dilution of the appropriate antibody. At this dilution, the 
antibody to A3F was found to be 9-fold less sensitive than the antibody to A3G. This data was 
used as a correction factor during quantitation of blots (see Materials and Methods). The loading 
control for cell lysates was α-tubulin and for virions was p24. (C) Blots from at least three 
independent experiments were analyzed using Odyssey software to determine the band intensity 
in the cell lysate (black bars) or virions (gray bars). Loading controls were confirmed during 
quantification to not be significantly different (data not shown). The error bars represent the 
Standard Deviation of the mean. A t-test determined that there were no significant differences in 
enzyme expression or encapsidation. 
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To ensure this was not due to differences in encapsidation efficiency between these A3 
enzymes we conducted quantitative immunoblotting on virions and cell lysates. Since we had 
transfected untagged A3 enzymes for these experiments to avoid the potential effects a tag may 
have on processivity (Figure 3.17), we initially standardized the antibodies for native A3G and 
A3F. Using equivalent amounts of purified protein and antibody dilutions, we determined that the 
antibody to A3F was 9-fold less sensitive than the antibody to A3G (Figure 3.16B). To ensure this 
was not due to differences in encapsidation efficiency between these A3 enzymes we conducted 
quantitative immunoblotting on virions and cell lysates. Since we had transfected untagged A3 
enzymes for these experiments to avoid the potential effects a tag may have on processivity (Figure 
3.17), we initially standardized the antibodies for native A3G and A3F. Using equivalent amounts 
of purified protein and antibody dilutions, we determined that the antibody to A3F was 9-fold less 
sensitive than the antibody to A3G (Figure 3.16B). As a result, we used this as a correction factor 
in the calculated amounts of these enzymes in virions and cells (Figure 3.16C). The immunoblot 
results demonstrated that A3G and A3F were expressed in 293T cells and encapsidated into vif 
virions to a similar level (Figure 3.16B-C). Therefore, the data support that there is a bone fide 
difference in the inherent mutagenic abilities of A3G and A3F. We also confirmed that A3G and 
its NPM mutant and A3F and its NGM mutant were expressed in cells and encapsidated in virions 
similarly (Figure 3.16B-C) enabling comparisons to be made between the mutant and wild-type 
forms of the enzymes. The analysis of A3G or A3F mutants from single-cycle infectivity assays 
was consistent with biochemical data. The A3G NPM mutant that had diminished sliding ability 
was less able to restrict HIV replication than A3G (Figure 3.16A, 3-fold). A3F NGM was able to 
decrease HIVvif infectivity 10% more than A3F, suggesting a slight positive effect of its sliding 
ability, but this was not statistically significant (Figure 3.16A). These data provided evidence that 
the processive scanning mechanism of the A3 enzyme influences the capacity to restrict HIV in a 
single cycle of replication.  The disparity in HIV restriction efficiency was confirmed to be due to 
differences in mutational load by sequencing the HIVvif integrated provirus eGFP reporter gene 
(Figure 3.18). 
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Figure 3.17. GST-A3F is not processive.  Deamination was tested on an 85 nt ssDNA substrate 
that contained an internal fluorescein (F)-label (yellow star) and two deamination motifs separated 
by 30 nt (sketch) Single deaminations of the 5'C and 3'C are detected as the appearance of labeled 
67- and 48- nt fragments, respectively; double deamination of both C residues on the same 
molecule results in a 30 nt labeled fragment (5'C & 3'C). GST-A3F is not processive on this 
substrate as evidenced by the absence of a double deamination band (5'C & 3'C, 30 nt). The A3F: 
DNA ratio was 1:1. A representative gel from three independent experiments is shown.  
 
 
 
 
 
 
 
 
 
 
 
 
 
C C 5' 3' 
17 nt 30 nt 36 nt 
5′ C & 3′ C 
5′ C 
3′ C 
85 nt 
48 nt 
30 nt 
67 nt  
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Figure 3.18. Representative eGFP sequences of integrated proviruses.  Representative eGFP 
sequences from the single-cycle infectivity assay (Figure 3.16A) are shown. Mutations are in 
bold. Alignment was made using CLUSTAL W. 
 
A3G             GTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGC 60 
A3F             GTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGC 60 
A3G NPM         GTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGC 60 
A3F NGM         GTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGC 60 
REFERENCE       GTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGC 60 
                ************************************************************ 
  
A3G             GACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGC 120 
A3F             GACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGC 120 
A3G NPM         GACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGC 120 
A3F NGM         GACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGC 120 
REFERENCE       GACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGC 120 
                ************************************************************ 
  
A3G             AAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTC 180 
A3F             AAGCTGACCCTGAAGTTCATCTGCACCACCGACAAGCTGCCCGTGCCCTGGCCCACCCTC 180 
A3G NPM         AAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTC 180 
A3F NGM         AAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTC 180 
REFERENCE       AAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTC 180 
                *******************************.**************************** 
  
A3G             GTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAG 240 
A3F             GTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAG 240 
A3G NPM         GTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAG 240 
A3F NGM         GTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAG 240 
REFERENCE       GTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAG 240 
                ************************************************************ 
  
A3G             CACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTC 300 
A3F             CACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTC 300 
A3G NPM         CACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTC 300 
A3F NGM         CACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTC 300 
REFERENCE       CACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTC 300 
                ************************************************************ 
  
A3G             AAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGAGCGACACCCTGGTG 360 
A3F             AAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTG 360 
A3G NPM         AAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTG 360 
A3F NGM         AAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTG 360 
REFERENCE       AAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTG 360 
                *********************************************.************** 
  
A3G             AACCGCATCGAGCTGAAAGGCATCGACTTCAAGGAGGACGGCAACATCCTAAGGCACAAG 420 
A3F             AACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG 420 
A3G NPM         AACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG 420 
A3F NGM         AACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG 420 
REFERENCE       AACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG 420 
                *****************.********************************..******** 
  
A3G             CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGC 480 
A3F             CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGC 480 
A3G NPM         CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGC 480 
A3F NGM         CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGC 480 
REFERENCE       CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGC 480 
                ************************************************************ 
  
A3G             ATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGAC 540 
A3F             ATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGAC 540 
A3G NPM         ATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGAC 540 
A3F NGM         ATCAAGATGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGAC 540 
REFERENCE       ATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGAC 540 
                ******.***************************************************** 
  
A3G             CACTACCAGCAGAACACCCCC-ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTA 599 
A3F             CACTACCAGCAGAACACCCCC-ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTA 599 
A3G NPM         CACTACCAGCAGAACACCCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTA 600 
A3F NGM         CACTACCAGCAGAACACCCCC-ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTA 599 
REFERENCE       CACTACCAGCAGAACACCCCC-ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTA 599 
                ********************* ************************************** 
  
A3G             CCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCT 659 
A3F             CCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCT 659 
A3G NPM         CCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCT 660 
A3F NGM         CCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCT 659 
REFERENCE       CCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCT 659 
                ************************************************************ 
  
A3G             GCTGGAGTTCGTGACCGCCGCCAGGATCACTCTCGGCATGGACGAGCTGTACAAG 714 
A3F             GCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAG 714 
A3G NPM         GCTGGAGTTCGTGACCGCCGCCAGGATCACTCTCGGCATGGACGAGCTGTACAAG 715 
A3F NGM         GCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAG 714 
REFERENCE       GCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAG 714 
                **********************.******************************** 
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Figure 3.19. A3F CTD mutagenesis in a model HIV replication system  (A) Spectrum of mutations 
are plotted as the percentage of clones containing a mutation at a particular location (nt) in the 368 
nt prot-lacZα construct. (B-C) Analysis of the number of mutations induced by A3F-CTD in the 
(B) prot or (C) lacZα regions.  
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Figure 3.20. GST-A3F mutagenesis is comparable to A3F CTD in a model HIV replication 
system.  (A) Spectrum of mutations are plotted as the percentage of clones containing a mutation 
at a particular location (nt) in the 368 nt prot-lacZα construct. (B-C) Analysis of the number of 
mutations induced by GST-A3F in the (B) prot or (C) lacZα regions. 
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Figure 3.21. A3F CTD is not processive in the presence of NC and RT.  Deamination was tested 
on an 118 nt ssDNA substrate that contained an internal fluorescein (F)-label (yellow star) and two 
deamination motifs separated by 63 nt (sketch). Single deaminations of the 5'C and 3'C are detected 
as the appearance of labeled 100- and 81- nt fragments, respectively; double deamination of both 
C residues on the same molecule results in a 63 nt labeled fragment (5'C & 3'C). A3F CTD is 
unable to processively deaminate the target cytosines as evidenced by the absence of a 63 nt labeled 
fragment above background (5'C & 3'C). The A3F CTD: DNA ratio was 2:1. Three independent 
experiments were conducted.  
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3.6. Discussion 
Reports have demonstrated that A3F is less effective than A3G at restricting HIV 
replication and leaves less of a mutational footprint (258, 266, 287, 330). This could be due to 
many reasons such as differences in mRNA/protein expression levels (31, 330), virion 
encapsidation levels (22, 257), deamination site preference (22, 216), or the inherent biochemical 
characteristics of the enzymes that govern deamination activity during proviral DNA synthesis. 
There is no consensus in the literature regarding whether any of the variables determined by 
cellular conditions, e.g., mRNA expression levels, create disparity between A3F and A3G HIV 
restriction activities. In addition, other reports have found an equal capacity of A3F and A3G to 
restrict HIV (2, 19, 21, 23, 24, 223, 331). To account for these differences in the literature we 
undertook a biochemical characterization of A3F in comparison to A3G. The data have enabled 
us to form a biochemical model to account for cell-based observations and propose that the 
processive DNA scanning mechanism and the preferred deamination motif of A3 deoxycytidine 
deaminases are determinants of HIV restriction efficiency.  
The data support the hypothesis that a balanced sliding and jumping scanning mechanism 
is a major contributor to efficient restriction of HIV (250) and A3F has less potential to restrict 
HIV because it does not slide and uses a jumping translocation mechanism that is different than 
A3G (Figure 3.2 and Figure 3.6). Analysis of A3G and A3F mutants further support the model in 
which the mechanism that the enzymes scan DNA and not their specific activity can fully account 
for differences observed in HIV restriction (Table 3.6, Figure 3.9, Figure 3.15, and Figure 3.16).  
In addition, A3F-induced mutations in preferred 5'TTC /5'TC motifs were less efficient at inducing 
gene inactivation than the preferred A3G 5'CCC/5'CC motifs, similar to what was identified for 
A3A (prefers 5'TTC /5'TC) (341), adding another distinction in the mutagenic ability of A3F 
(Tables 3.5 and 2.8).  
However, the data cannot support that A3F has no effect on HIV since it is suppressed by 
Vif (24), but there is evidence that the restriction abilities are distinct from A3G in regards to 
mutagenic load, selection pressure on HIV and contribution of deamination-independent HIV 
restriction (255, 259, 260, 266, 287, 299). It was initially recognized by Zennou and Bieniasz that 
per mutation, A3G could cause a much larger decrease in HIV infectivity than A3F (22). This early 
study on A3F (22) was in contrast to other early studies published showing A3F was similar in 
effectiveness to A3G (2, 21, 23, 24, 331). Such incongruent data still remains in the literature (19, 
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258, 266, 287, 330) and may be due to different experimental systems. Specific to our data, we 
observed that the HIVvif retained 51% infectivity in the presence of A3F and 13% infectivity in 
the presence of A3G, suggesting that A3F is not as effective as A3G at restricting HIV (Figure 
3.16A). However, Albin et al. found that over multiple replication cycles, A3F restricted HIV 
replication similarly to A3G and selected for Vif mutant revertants (259). It may be that A3G 
requires only one exposure to HIV for high level restriction compared to A3F that may require 
multiple cycles for strong HIV restriction, but the end point is the same. Importantly, multiple 
infection rounds more closely mimics how A3 enzymes would interact with HIV in vivo. 
Nonetheless, our data propose that the mechanism by which A3G and A3F reach this end is 
different and that A3F has the potential to cause more sequence diversification of HIV than A3G. 
This idea is supported by Chaipan et al. that found that A3F suppressed HIV in multiple rounds of 
replication but required a longer period of exposure to HIV before the level of suppression reached 
that of A3G (266). This is consistent with our sequence data from the prot of integrated proviruses 
(Table 3.8). As such, the role of A3F may be to supplement mutagenesis induced by A3G (19, 
287) since their effects have been shown to be additive (2) or be distinct from A3G and perhaps 
rely on a deamination-independent mechanism, such as inhibition of reverse transcription and 
integration (255, 299, 356). A3F has been reported to exert a larger deamination-independent 
inhibition of HIV replication than A3G, but this is not as effective as deamination-mediated 
restriction of HIV (255, 299).  
To characterize the mechanism by which A3 enzymes induce mutagenesis we studied the 
A3G NPM mutant. The A3G NPM mutant demonstrated that the scanning mechanism on DNA 
and not specific activity is a primary determinant in mutation induction during reverse 
transcription. Since A3F had a lower specific activity than A3G (Table 3.6), it could be argued 
that this was contributing to the lower level of induced mutagenesis (Figure 3.9). However, the 
A3G NPM mutant, which had decreased sliding in comparison to wild-type A3G (compare Figure 
3.2 and Figure 3.13), retained a specific activity more similar to that of A3G than A3F (Table 3.6), 
but induced a very low level of mutagenesis (Figure 3.15A, C-D) and decreased HIV infectivity 
only 2-fold versus A3G that decreased HIV infectivity 8-fold (Figure 3.16A). These data suggest 
that specific activity is not a determinant in the ability to cause mutations during reverse 
transcription and is supported by previous data in which the specific activity of the enzyme was 
inconsequential during reverse transcription (326). This appears to be because the activity of the 
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enzyme during reverse transcription is instead determined by factors such as (-)DNA synthesis and 
RNaseH activity (326). The A3G NPM mutant further confirmed that the determinants within the 
NTD for sliding involve residues near A3G predicted helix 6 and that this is distinct from the 
determinant for jumping (Figure 3.13D-E), which in A3G is loop 7 (Figure 3.12). Of note, the 
NPM motif is predicted to be at the end of NTD helix 6, which is a connection point between the 
NTD and the CTD domains (357, 358). Through amino acid sequence alignment we identified that 
A3D is the only other double domain A3 deaminase to contain an NPM motif at the end of 
predicted helix 6, suggesting that A3D would also lack sliding movements while scanning ssDNA, 
similarly to A3F. Some specific residues within helix 6 have previously been shown to affect 
specific activity (250, 358), possibly because of structural changes in the connection between the 
NTD and CTD that can affect the catalytic activity of the CTD or DNA binding affinity. Insertion 
of the NPM motif into A3G immediately after the predicted helix 6 ends (Figure 3.13A) did not 
cause a large disruption in structure based on CD spectra (data not shown), but did result in a ~3-
fold decrease in specific activity (Table 3.6) and ~2-fold increase in binding affinity for ssDNA 
(Table 3.2).  
To confirm a role of the NPM motif in blocking sliding movements we mutated this region 
in A3F to create an A3F NGM mutant with the hypothesis that removing the rigid proline residue 
would enable the enzyme to slide on ssDNA and deaminate closely spaced residues. Consistent 
with the hypothesis, closely spaced residues were processively deaminated by A3F NGM (Figure 
3.14A-B). However, the ability to slide did not enable A3F NGM to induce high levels of 
mutagenesis similar to A3G in vitro (Figure 3.15) or in a single-cycle infectivity assay (Figure 
3.16A and Table 3.7). This does not preclude that jumping and sliding are important for inducing 
mutagenesis in virus infected cells since the A3G NPM mutant that had decreased sliding restricted 
HIV similarly to A3F in single cycle infectivity assays (Figure 3.16A). Rather, these data indicated 
that the ability to slide and jump is necessary, but not sufficient to induce high levels of 
mutagenesis. The data supported the conclusion that the type of sliding and jumping movements, 
e.g., distance transversed was also important. Namely, we found that A3F processivity on ssDNA 
increased with increasing distance between deamination motifs, in contrast to A3G, demonstrating 
that the average jumping distance of A3F was larger than A3G (Figure 3.6A-B). This was 
confirmed with sequence analysis from the model HIV replication assay in which a larger number 
of deaminations were >20 nt apart for A3F than A3G (Table 3.4). Thus, the A3F NGM mutant 
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could slide, but was not truly a mimic of A3G. Altogether, it appears that the sliding and jumping 
mechanism of A3G is specifically optimal to induce a large number of deaminations during reverse 
transcription of DNA. 
An important note regarding the study of A3F is that we found N-terminally tagged GST-
A3F was not processive (Figure 3.17), despite binding ssDNA with a Kd of 46 ± 4 nM. That the 
binding affinity of GST-A3F was more similar to A3F (Table 3.2, Kd of 20 nM) than A3F CTD 
(Table 3.2, Kd of 288 nM) indicated that the GST-A3F was able to bind ssDNA with both NTD 
and CTD domains, despite a lack of processivity. This suggested that the GST tag caused steric 
hindrance on amino acid determinants for processivity in the NTD. Interestingly, we observed that 
nonprocessive A3F forms, both A3F CTD and GST-A3F, induced more mutations than wild-type, 
processive A3F (compare Figure 3.9 and Figures 3.19 and 3.20). We also found that A3A, which 
is largely nonprocessive, induced slightly less mutations than A3G in the in vitro HIV replication 
assay (341), but more than A3F. Although this initially seems difficult to reconcile, it is consistent 
with the overall hypothesis that processivity is related to mutagenic potential, since processive 
A3G is still the most efficient at inducing mutagenesis. It is only that a lack of processivity appears 
to be better than an “ineffective” processive enzyme such as A3F. This is not due to differences in 
the assay systems for characterizing processive deaminations on ssDNA oligonucleotides and the 
model HIV replication assay since addition of NC and RT to the ssDNA oligonucleotides in a 
deamination reaction did not change our observations regarding A3F CTD processivity (Figure 
3.21). In comparison to the nonprocessive A3F CTD and GST-A3F, processive A3F leaves many 
potential deamination motifs unmodified (compare Figure 3.9 and Figures 3.19 and 3.20). 
Although there is inefficiency in the GST-A3F and A3F CTD having to dissociate and reassociate 
with the substrate many times, the reassociations can be much closer to the previous dissociation 
resulting in a more thorough search of the DNA. For example, we found that in the model HIV 
replication assay, 61% of A3F CTD-induced mutations were >20 nt apart in contrast to A3F where 
75% of induced mutations were >20 nt apart (Table 3.4 and data not shown). Since the HIV 
replication assay is not conducted under single hit conditions, the results emphasize the 
inefficiency of the searching mechanism used by A3F. Since the binding affinity of A3F for 
ssDNA is tighter than A3G or A3F CTD (Table 3.2), it is conceivable that A3F may also have a 
lack of frequent movements or excursions on the ssDNA that contribute to the inefficient search 
for deamination motifs. However, resolution of this speculation awaits single-molecule analysis. 
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In sum, the data demonstrated that the interactions of A3F with ssDNA are essentially detrimental 
to its ability to induce a high mutation frequency. 
Our data demonstrate two main points. First, the data provide a biochemical reason for the 
inefficiency with which A3F-induces mutagenesis of HIVvif as observed in this report and by 
others (258, 266, 330) by demonstrating that the processive scanning behavior of A3F is 
detrimental to its mutagenic potential. The data establish that a balanced sliding and jumping 
ssDNA scanning mechanism similar to A3G is required for the most efficient induction of HIV 
mutagenesis. Secondly, the data show that deamination of 5'CCC/5'CC has more gene inactivating 
potential than 5'TTC/5'TC providing an additional reason for less restriction of HIV by A3F than 
A3G, in agreement with previous reports (22, 216, 341). The data does not preclude that A3F can 
effectively restrict HIV and is in agreement with studies showing that A3F can restrict HIV in 
multiple rounds of infection (259, 266), but since the number of mutations induced has been 
correlated to HIV inactivation (236, 254), the data support the interpretation that A3F inactivates 
HIV less efficiently than A3G in a single round of infection.  
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CHAPTER 4. PREFACE TO CHAPTER 5 
In Chapter 3,  the data showed that A3F is less potent than A3G at inhibiting HIV-1 (referred to 
as HIV) because of its distinct scanning mechanism and that A3F also has a different preference 
for the sequence context surrounding the deamination site (226). This was eluded to an early 
publication by Zennou and Bieniasz (22), confirmed by our group (226) and others (331, 359). 
A3F and A3G are commonly coexpressed in human tissues (31, 32) and it has been recently 
reported that they can coencapsidate into HIV-1 virions (220). However, whether the 
coencapsidated A3F and A3G work independently, additively or synergistically had not been 
investigated in-depth (2, 220, 360). Therefore, Chapter 5 was designed to investigate if 
coexpressed A3F and A3G have an independent, additive, or synergistic ability to restrict HIV 
replication. This investigation entailed a systematic dissection of the mechanisms by which A3F 
and A3G interact in vitro and in cells. To develop an A3F/G coexpression model, previous studies 
used A3F and A3G containing separate plasmids to transfect cells in either an equimolar (2) or 
non-equimolar ratio (220). In such transfection approaches using separate plasmids, equimolar co-
transfection is not in reality possible. The resulting transfected cells will have various molar ratios 
of A3F and A3G on a single-cell basis. As a result, HIV virions generated from such strategies 
will produce a mosaic (heterogeneous) population of virus with different combinations and levels 
of A3 proteins encapsidated. To circumvent the problem of a mosaic population of viruses and 
ensure equimolar expression of A3F and A3G on a single-cell basis, we applied a novel strategy 
that expressed A3F and A3G from the same plasmid but using separate promoters. This approach 
resulted in more uniform expression and virion coencapsidation of both A3F and A3G. For the 
first time we have shown that A3G and A3F hetero-oligomerize in the absence of RNA. Although 
A3G and A3F are known to function alongside each other, these data provided evidence for an 
A3F/G hetero-oligomeric A3 with distinct properties when compared to the individual 
counterparts. Thus, the generation of hetero-oligomeric A3 species may be a unique antiviral 
strategy of endogenous A3 enzymes. 
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5.1. Abstract 
The A3 enzymes, A3G and A3F, are coordinately expressed in CD4+ T cells and can 
become coencapsidated into HIV-1 virions, primarily in the absence of the viral infectivity factor 
(Vif). A3F and A3G are deoxycytidine deaminases that inhibit HIV-1 replication by inducing 
guanine to adenine hypermutation through deamination of cytosine to form uracil in (-)DNA. The 
effect of the simultaneous presence of both A3G and A3F on HIV-1 restriction ability is not clear. 
Here, we used a single cycle infectivity assay and biochemical analyses to determine if 
coencapsidated A3G and A3F differ in their restriction capacity than A3G or A3F alone. Proviral 
DNA sequencing demonstrated that compared to each A3 alone, A3G and A3F when combined 
had a coordinate effect on hypermutation. Using size exclusion chromatography, rotational 
anisotropy, and in vitro deamination assays we demonstrate that A3F promotes A3G deamination 
activity by forming an A3F/G hetero-oligomer, in the absence of RNA, which is more efficient at 
deaminating cytosines. Further, A3F caused the accumulation of shorter reverse transcripts due to 
decreasing reverse transcriptase efficiency, which would leave single-stranded (-)DNA exposed 
for longer periods of time enabling more deamination events to occur. Although A3G and A3F are 
known to function alongside each other, these data provide evidence for an A3F/G hetero-
oligomeric A3 with unique properties when compared to each individual counterpart.  
5.2. Author lay summary 
The A3 enzymes A3F and A3G act as a barrier to HIV-1 replication in the absence of the 
HIV-1 viral infectivity factor (Vif) protein. After A3 enzymes are encaspidated into virions they 
deaminate cytosines in (-) DNA which forms promutagenic uracils that induce transition mutations 
or proviral DNA degradation. Even in the presence of Vif, footprints of A3-catalyzed deaminations 
are found demonstrating that A3s still have discernable activity against HIV-1 in infected 
individuals. We undertook a study to better understand the activity of coexpressed A3F and A3G. 
The data demonstrate than an A3F/A3G hetero-oligomer can form that has unique properties 
compared to each A3 alone. This hetero-oligomer has increased efficiency of virus hypermutation, 
raising the idea that we may still not fully realize the antiviral mechanisms of endogenous A3 
enzymes. Hetero-oligomerization may be a mechanism to increase their antiviral activity in the 
presence of Vif. 
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5.3. Introduction 
A3 enzymes are a family of deoxycytidine deaminases that can act as host restriction 
factors for HIV-1 (referred to as HIV) (213). To restrict HIV replication, A3 enzymes must first 
become encapsidated in HIV virions from a producer cell (361-363). In the next cell that is 
infected, the HIV genomic RNA is reverse transcribed to form the (-) DNA. During this time, 
single-stranded (-) DNA is vulnerable to A3 deaminations of cytosine that form uracil (216, 361, 
362). The reverse transcriptase is forced to use uracil as a template during (+) DNA synthesis 
which induces C/G  T/A mutations and can functionally inactivate the virus or lead to its 
degradation through DNA repair pathways that excise uracil (13). The effect of A3 enzymes on 
HIV replication in infected individuals is severely dampened by the viral infectivity factor (Vif) 
that interacts with A3 enzymes, recruits an E3 ubiquitin ligase complex, and induces A3 
ubiquitination and degradation in the proteasome (15, 16, 334, 335, 364, 365).  From the seven 
human A3 enzymes, there are four, A3D, A3F, A3G, and A3H that can inhibit HIV replication in 
the absence of Vif (223). These four enzymes are coordinately expressed in CD4+ T cells and 
induced upon T cell activation (31, 32). 
However, even in the presence of Vif, there is evidence of A3 deaminations inducing 
hypermutation of integrated proviral genomes (26, 366-372). There are two ways in which this 
occurs. In one route, the A3s are encapsidated in the presence of Vif, but at a much lower amount 
(205). Additionally, viruses can adapt to have a less fit Vif that is less efficient at inducing A3 
degradation (373). From these proviral DNA sequences, GA mutations have been attributed to 
specific A3s through identification of their preferred sequence contexts surrounding the mutations 
by both cellular and in vitro studies (2, 216-219, 362, 374). The sequence contexts showed that 
A3G uniquely prefers to deaminate the 3′C in 5′CC motifs, resulting in a GGGA mutation 
signature (216, 217). A3D, A3F, and A3H all deaminate in 5′TC motifs, resulting in a GAAA 
mutation signature (2, 218, 219). More detailed analysis of the signatures revealed that A3G is 
most active at a 5′CCC motif and A3D can be differentiated from A3F and A3H by examining a 
larger surrounding sequence 3′ of the cytosine (220). Studies that sequenced integrated proviral 
genomes have shown that proviral DNAs contain mutations at multiple sequence contexts 
suggesting that multiple A3s can mutate the same genome (26, 366-372). However, what was 
unable to be concluded from these studies was if the mutations induced from multiple A3s occurred 
in a single round of replication or multiple rounds of replication. If they occurred in a single round 
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of replication, then the A3s would need to be coencapsidated into HIV virions. Recently, it was 
found that A3G is primarily encapsidated into virions by binding nonspecifically to cellular RNAs 
(221). The only requirement for being virion encapsidated was that HIV Gag was also bound to 
the same RNA (375). In this model, the encapsidation is not competitive and multiple A3s should 
be coencapsidated. However, a computational study determined from sequence analysis of proviral 
DNA that A3G and A3F rarely comutate the same genome (376). This endpoint analysis is in 
contrast to cellular studies that have identified that A3 enzymes are able to coencapsidate and some 
studies have found that there is a synergistic effect where more mutations or more viral restriction 
than expected by an additive relationship are induced (2, 220, 360). Despite this synergistic effect 
being identified, a mechanism for how multiple A3 enzymes can result in more than additive 
mutations or virus restriction has not been determined.  
Based on previous findings, there are two possible mechanisms by which coencapsidated 
A3s could result in higher levels of mutations. One mechanism is to slow down the reverse 
transcriptase to keep the (-) DNA single-stranded for longer to allow A3s more time to scan the 
DNA for their preferred deamination motif (283, 287, 294). This is thought to be accomplished by 
A3 enzymes binding to the template and blocking the progression of reverse transcriptase. A 
second mechanism is to increase the processivity of the A3 enzyme (226, 250). The processivity 
is the ability of an enzyme to deaminate multiple cytosines in a single enzyme-substrate encounter. 
A3 enzyme processivity is mediated by facilitated diffusion (213). Facilitated diffusion is a term 
that describes Brownian motion driven diffusion and results in enzymes moving along the DNA 
phosphate backbone by sliding, diffusing within the charged domain of the DNA by a mechanism 
termed jumping, and moving between DNA segments through a doubly bound state termed 
intersegmental transfer (248, 249). The DNA scanning enables the A3 enzyme to search and find 
the cytosine among the nontarget nucleotides and enables the continuation of the search after a 
deamination, without completely dissociating from the DNA. The sliding movements cover small 
distances, approximately up to 20 nt (226, 250). For A3G, the average sliding distance is 12 nt 
(253). The jumping and intersegmental transfer movements enable the enzyme to move distally, 
e.g., 100 nt or more (226, 227).  
We initiated this study to investigate if coexpressed A3F and A3G have an additive or 
synergistic ability to restrict HIV replication. We focused on A3F and A3G since these enzymes 
are most commonly expressed together in the human population and are active against HIV (31, 
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32). While A3H Haplotypes II, V, and VII are highly restrictive of HIV, they occur less frequently 
in the overall population, i.e., Haplotype II, 26.5%; Haplotype V, 20%; Haplotype VII, 0.9% (270, 
277). A3D is much less active against HIV than A3F and A3G (266). In the present work, the data 
show that A3F and A3G are able to induce a combined increase in mutations in HIV DNA and 
synergistic decrease in HIV infectivity in single cycle infectivity assays. The mechanism for this 
cooperation was two-fold. First, A3F and A3G can hetero-oligomerize in the absence of RNA and 
this A3F/G hetero-oligomer has improved processivity. Second, the A3F/G hetero-oligomer can 
decrease the efficiency of reverse transcriptase, which provides increased time for A3-catalyzed 
deaminations. All together the data suggest that A3F and A3G are able to function together with 
distinct and improved properties from the individual enzymes.  
5.4. Material and Methods  
5.4.1. Protein expression and purification 
Recombinant baculovirus production for expression of GST-A3G, GST-A3F and GST-
nucleocapsid protein in Sf9 cells was carried out using the transfer vector pAcG2T(BD 
Biosciences), as previously described (226, 227, 250). Sf9 cells were infected with recombinant 
virus at a multiplicity of infection (MOI) of 1 for GST-A3G and GST-NC and a MOI of 2 for GST-
A3F. After 72h of infection, recombinant baculovirus infected Sf9 cells were harvested for protein 
purification. The A3G and NC were purified in the presence of RNaseA and the GST tag cleaved 
on the affinity column, as previously described (247).  The A3F was purified in the presence of 
RNaseA and the GST tag cleaved in solution, as previously described (226, 227). Proteins are 
estimated to be approximately 95% pure by SDS-PAGE. 
The E. coli strain containing the plasmids to express HIV reverse transcriptase and HIV 
protease was provided by Dr. Stuart Le Grice (National Cancer Institute). Expression of the HIV 
reverse transcriptase and protease were carried out as previously described (342). Cell lysates 
produced using sonication were clarified by centrifugation and then purified using a HisTrap FF 
crude column (GE Healthcare) and HiTrap Heparin HP (GE Healthcare) as described previously 
(342). 
5.4.2. Expression of A3G and A3F in 293T cells 
To express both A3F-V5 and A3G-HA on a single-cell basis, we used an expression 
plasmid, pVIVO2 (Invivogen), with two transcription units in a single vector. A3G and A3F were 
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PCR amplified from pcDNA3.1 vectors previously used in the lab with primers that contained a 
C-terminal 1X HA-tag sequence (for A3G) or C-terminal V5-tag sequence (for A3F) (226). A3F-
V5 was cloned using an XbaI site in MCS1. A3G-HA was cloned using an EcoRI site in MCS2. 
Using this cloning strategy, plasmids containing both A3F-V5 and A3G-HA (pVIVO2 A3F-
V5/A3G-HA), A3F-V5 alone (pVIVO2 A3F-V5), and A3G-HA alone (pVIVO2 A3G-HA) were 
constructed. These constructs were also used as a template for site directed mutagenesis to create 
catalytic mutants of A3F and A3G that resulted in pVIVO2 A3F-V5 E251Q/A3G-HA E259Q, 
pVIVO2 A3F-V5 E251Q, and pVIVO2 A3G-HA E259Q. Primer sequences are listed in Table 
5.1. 
5.4.3. Coimmunoprecipitation (co-IP) assay 
Coimmunoprecipitation (co-IP) assays were conducted as described previously (275). 
Briefly, the 293T cells (2.5×106 cells per 75 cm2 flask) were transfected with 1 µg of total DNA. 
Equal amounts of each plasmid pVIVO2 A3G-HA, pVIVO2-A3F-V5, or pVIVO2 A3F-V5/A3G-
HA were used to transfect the cells. GeneJuice transfection reagent (EMD Millipore) was used 
according to the manufacturer’s instructions. At 64 h post transfection, the cells were washed with 
PBS and lysed in co-IP buffer (50 mM Tris-Cl pH 7.4, 1% Nonidet-P40, 0.1% sodium 
deoxycholate, 10% glycerol, 150 mM NaCl) supplemented with RNaseA (20 µg/ml; Roche) and 
EDTA-free protease inhibitor (Roche). Clarified supernatants were precleared with protein A-
agarose-conjugated normal rabbit IgG (2 µg, Santa Cruz Biotechnology) in the presence of RNase 
A (20 µg/ml; Roche). One half of the precleared supernatant was then incubated with protein A-
agarose-conjugated polyclonal rabbit anti-HA antibody (2 µg; Sigma) and another half (mock) was 
incubated with protein A-agarose-conjugated normal rabbit IgG (2 µg, Santa Cruz Biotechnology) 
at 4°C for 2 h. Resin was washed and the samples were then resuspended in Laemmli sample 
buffer and prepared for SDS-PAGE. 
After SDS-PAGE, proteins were transferred to a nitrocellulose membrane. For detection 
of A3G-HA and A3F-V5 in cell lysates, the nitrocellulose membrane was probed with polyclonal 
Rabbit HA (1:1000; Sigma) and monoclonal mouse V5 antibodies (1:1000, Sigma), respectively. 
For the loading control, monoclonal mouse anti-α-tubulin (1:1000; Sigma) was used. HA- and 
rabbit IgG- immunoprecipitated lysates were probed with anti-V5 mouse monoclonal antibodies. 
After incubation with Horse Radish Peroxidase (HRP) conjugated secondary antibodies, the blots 
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were visualized with X-ray film using Super Signal West Pico chemiluminescence substrate 
(Thermo-Scientific). 
5.4.4. Size exclusion chromatography 
To determine the oligomerization state of the A3 enzymes, we used size exclusion 
chromatography (SEC). A 10 mL Superdex 200 (GE Healthcare) resin bed contained in a column 
with a 0.5 cm diameter and 16 cm height was used. The running buffer used contained 50 mM Tris 
pH 8.0, 200 mM NaCl, and 1 mM DTT. The molecular masses and oligomerization states were 
calculated from the standard curve obtained by using Bio-Rad gel filtration standard set. For A3G 
or A3F alone, a total of 15 µg of the purified A3 enzyme was loaded on the column. For the 
combined run of A3F and A3G, 15μg of each purified enzyme was preincubated at 21C for 3 
minutes, before loading onto the column. Protein in fractions were detected by western blot 
analysis by using anti-A3G (ApoC17 rabbit antiserum (Cat # 10082, NIH AIDS Reagent Program) 
and anti-A3F (Cat # GTX47211, GeneTex) antibodies 
5.4.5. Steady state rotational anisotropy assay 
To measure protein-protein and protein-ssDNA binding interactions, we used steady state 
fluorescence depolarization (rotational anisotropy), where one of the binding partners was 
fluorescein (F)-labeled. Data were collected using a QuantaMaster QM-4 spectrofluorometer 
(Photon Technology International) with a dual emission channel. Measurements were made at 
21°C. Samples were excited with vertically polarized light at 495 nm (6 nm band pass) and vertical 
and horizontal emissions were measured at 520 nm (6 nm band pass). Apparent dissociation 
constants (Kd) were obtained by fitting to a sigmoidal curve using Sigma Plot 11.2 software. 
For binding to ssDNA, we measured the ability of A3F alone, A3G alone and A3F/A3G to 
bind to a 118 nt F-labeled ssDNA, as described previously (226). Reactions were performed in a 
60 μl total volume, which contained F-labeled ssDNA (10 nM) in RT buffer (50 mM Tris pH 7.5, 
40 mM KCl, 10 mM MgCl2, 1 mM DTT) and A3G (0 - 900nM), A3F (0 - 75nM), or A3F/A3G in 
combination (0 - 340nM). For the A3F/A3G binding in combination, the enzymes were first mixed 
at an equimolar ratio and preincubated at 21 C for 3 min before titration into the reaction.  
To measure protein-protein binding, A3G was F-labeled using the Fluorescein-EX Protein 
Labeling Kit (Life Technologies) and used as the binding substrate for A3F. This assay was carried 
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out in 60 µl total volume that contained 25 nM F-labeled A3G in the presence of RT buffer and 
increasing amount of A3F (0 - 250nM).  
5.4.6. Quantitative immunoblotting 
The 293T cells expressing A3G-HA and A3F-V5 from single-cycle infectivity assays were 
detected using anti-HA and anti-V5 antibodies (Sigma) in cell lysates (40 µg total protein) and 
virions. Virions were prepared for immunoblotting by concentration using Retro-X concentrator 
(Clontech) and 20 µl of concentrated virus was used. Loading controls for cell lysates (α-tubulin, 
Sigma) and virions (p24, Cat #3537, NIH AIDS Reagent Program) were detected using mouse 
monoclonal antibodies. Proteins of interest and loading controls were detected in parallel on the 
same gel by using the Licor/Odyssey system (IRDye 680-labeled goat anti-rabbit secondary 
antibody and IRDye 800-labeled goat anti-mouse secondary antibody). 
5.4.7. Single-cycle infectivity assay 
In order to generate VSV-G pseudotyped HIV Δvif NL4-3 viruses, 3×105  293T cells were 
transfected using GeneJuice (EMD Millipore) transfection reagent as previously described (226). 
Cells were transfected with 500 ng of pNL4-3 HIV vif, which expresses an eGFP reporter gene 
(377), 200ng of pMDG, which expresses the VSV-G protein (331, 378), in the presence of empty 
pVIVO2, pVIVO2 A3F-V5/A3G-HA (A3F/A3G combined), pVIVO2 A3F-V5 (A3F-V5 alone), 
or pVIVO2 A3G-HA (A3G-HA alone). A titration of A3 expression vector was used (25, 50, 100 
ng). We used empty pVIVO2 vector to achieve a total of 800 ng DNA. Sixteen hours after the 
transfection, the medium (DMEM with 10% FBS) was replaced after washing the cells with PBS. 
Virus-containing supernatants were collected 48 h after the media change and filtered through 0.45 
µm PVDF syringe filters. Virus was quantified by a p24 enzyme-linked immunosorbent assay 
(QuickTiterTM Lentivirus Titer Kit, Cell Biolabs Inc. or HIV-1 p24 ELISA kit XpressBio). Target 
293T cells were infected with virus by spinoculation at 800 x g for 1 h in the presence of 8 µg/ml 
of polybrene (345). Infection levels in 293T cells were determined by flow cytometry by detecting 
eGFP fluorescence at 48 h post infection and normalized to HIVvif infections in the absence of 
A3 enzymes (226). Statistical significance of results was determined using an unpaired t-test. 
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5.4.8. Intracellular detection of A3F-V5 and A3G-HA in 293T cells by flow cytometry 
Single-cell suspensions of untransfected 293T cells and A3F-V5 and A3G-HA transfected 
293T cells were prepared in PBS containing 2% FBS and 0.05% sodium azide. Intracellular 
staining was performed following an established procedure (379). Briefly, transfected and 
untransfected cells were fixed using BD Cytofix/Cytoperm buffer containing 4.2% 
paraformaldehyde. Fixed cells were permeabilized with BD 1X Perm/Wash buffer containing 
saponin and FBS. Cells were stained with rabbit anti-V5-CF543 and rabbit anti-HA-CF640R 
antibodies (Biotium Inc.) in BD Perm/Wash buffer for 30 min at 4 ºC.  After three washes with 
BD Perm/Wash buffer, cells were resuspended in PBS containing 2% FBS and 0.05% sodium 
azide. Data were acquired by flow cytometry on a FACSCalibur using CellQuest software (BD 
Biosciences), and analyzed with FlowJo software (TreeStar). 
5.4.9. Sequencing of integrated proviral DNA 
After 48 h of infection, total DNA from infected 293T cells was extracted using DNAzol 
reagent (Life Technologies). DNA was treated with DpnI (New England Biolabs) for 1 h at 37 °C 
to remove possible contaminating plasmid DNA, and the protease (prot) (nt 2280–2631) 
sequences were amplified by PCR using Q5 polymerase (New England Biolabs). Primers are have 
been published previously (226). PCR products were purified and cloned with the CloneJET PCR 
cloning kit (Thermo). DNA was sequenced with kit-specific primers and carried out at the National 
Research Council of Canada (Saskatoon, Canada). Analysis of the sequence context of the 
mutations was done using Original Hypermut (380). 
5.4.10. Quantification of late reverse transcript formation during HIV replication 
For quantifying late reverse transcripts (LRT) by quantitative real-time PCR (qPCR) we 
followed the method of Belanger et al. (284). HIV Δvif infected 293T cells were harvested 8 h 
post-infection and total DNA was extracted, then treated with Dpn1. For each reaction, 0.9 
pmol/ml of each primer (as listed in (284)), 0.25 pmol/ml of the probe (as listed in (284)) and 10 
ng of template DNA were used in a 20 µl of reaction volume. Reactions were performed in 
triplicate with TaqMan Gene Expression master mix (Applied Biosystems). qPCR cycling 
conditions were 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. qPCR 
was carried out using StepOnePlus Real-Time PCR system (Applied Biosystems). The copy 
numbers in each sample were normalized for DNA input using human RNaseP copy number assay 
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(cat# 4403326, Applied Biosystems). Relative LRT quantitation was calculated following the 
comparative Ct method (∆∆Ct method).  
5.4.11. In vitro deamination assay 
All the ssDNA substrates used in this study were synthesized from Tri-Link 
Biotechnologies and have been published previously (226). In brief, substrates all contain two 
deamination motifs, either 5′CCC for A3G or 5′TTC for A3F, and a fluorescein labeled thymidine 
in between the motifs. Reactions were carried out under single-hit conditions, i.e.,  < 15% substrate 
usage, to ensure that a single ssDNA substrate was interacting with at most a single enzyme (344). 
Under these conditions, a processivity factor can be determined. The processivity factor is a ratio 
of the quantified total number of deaminations occurring at two sites on the same ssDNA substrate 
with a calculated theoretical value of deaminations that would occur at these two sites if the 
deamination event were not processive (see reference (227)). For A3F deamination reactions, 100 
nM A3F was incubated with 100 nM ssDNA. For A3G, 30nM A3G was incubated with 100 nM 
substrate. Due to differences in specific activity on different substrates, sample times ranged from 
1 to 30 min after incubation at 37C in RT buffer. The time points where only 10-11% of the 
substrate was deaminated were considered in processivity factor determination. For experiments 
using A3F and A3G in combination, we first preincubated the enzymes at an equimolar ratio for 3 
min at 21 °C before addition to the reaction. Reactions were stopped using phenol and chloroform 
extractions. The ssDNA was then treated with Uracil DNA Glycosylase (New England Biolabs) 
and heated under alkaline conditions to induce DNA breakage at deaminated motifs. The DNA 
fragments were then resolved on a 10% or 20% v/v denaturing polyacrylamide gel depending on 
the expected sizes. Gel pictures were obtained using a Typhoon Trio multipurpose scanner (GE 
Healthcare) and gel band intensities were quantified by ImageQuant software (GE Healthcare).  
5.4.12. Primer extension assay 
An RNA template encompassing the primer binding site (PBS) and upstream region near 
the 5′-end of the HIV genome (nt 571–674) was generated as described previously (283). An 18 
nt 32P-labeled RNA primer to mimic tRNALys,3 primer was heat annealed to the 106 nt template 
RNA containing the PBS as described previously (283). Reactions were conducted in the presence 
of 10 nM primer/template, RT buffer, 200 µM dNTPs, 175 nM nucleocapsid, and 480 nM reverse 
transcriptase in the absence or presence of A3G alone, A3F alone or A3F and A3G in combination. 
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Each A3 alone was used at concentrations of 40, 80, and 320 nM. For A3F and A3G in 
combination, an equimolar ratio was pre-incubated for 3 min at 21C and then added to reactions 
to achieve a final concentration of 40, 80, or 320 nM enzyme complex. Reactions were 
preincubated at 37°C for 1 min before the addition of dNTPs which started the reaction. A negative 
control was used which contained all reaction components except reverse transcriptase to ensure 
there was no contaminating polymerase activity. Reactions were stopped by adding a 5-fold excess 
of 20 mM EDTA and 95% formamide. Primer extension was visualized by resolving samples on 
a 16% denaturing 8 M urea polyacrylamide gel. Gel band intensities were measured by 
phosphorimaging with a Bio-Rad FX scanner. The integrated gel band intensities of all bands in a 
lane were calculated with ImageQuant software (GE Healthcare) and used to determine the relative 
amounts of extended and unextended primers as well as fully extended product (82 nt). Statistical 
significance of primer extension assay results was determined using an unpaired t-test. 
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Table 5.1. Primers, probes and DNA substrate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Name Sequence 
pVIVO2-A3G-HA 
forward 
5' TTTGAATTCATGAAGCCTCACTTCAGAAACACAGTGGAGCGAATGTATC 
3' 
pVIVO2-A3G-HA 
reverse 
5'GAATTCTTAAGCATAATCTGGAACATCATATGGATAGTTTTCCTGATTCTG
GAG 3’ 
pVIVO2-A3F-V5 
forward 
5' 
TTTTCTAGAATGAAGCCTCACTTCAGAAACACAGTGGAGCGAATGTATCGA
GACAC 3’ 
pVIVO2-A3F-V5 
reverse 
5'TCTAGATCACGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAGGCTTA
CCCTCGAGAATCTCCTGCAG 3' 
qHIV forward 5’-CAAGTAGTGTGTGCCCGTCTGT-3’ 
qHIV reverse 5’-CGAGTCCTGCGTCGAGAGA-3’ 
qHIV probe 5’-FAM-CAGTGGCGCCCGAA-3’ 
PBS template 
primer (Forward) 
TGT TAG GAC TCT GGT AAC TAG AG 
PBS template 
primer (Reverse) 
GTC CCT ATT AAC TTT CGC TTT CAA G  
PBS template UGU UAG GAC UCU GGU AAC UAG AGA UCC CUC AGA UCA CUC UAG 
ACU GAG UAA AAA UCU CUA GCA GUG GCG CCC GAA CAG GGA CUU 
GAA AGC GAA AGU UAA UAG GGA C 
PBS Primer GUC CCU GUU CGG GCG CCA  
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5.5. Results 
5.5.1. A3F and A3G can hetero-oligomerize in an RNA independent manner 
A3F and A3G have been shown to hetero-oligomerize on RNA in an RNA-dependent 
manner (24). However, A3F and A3G can also form homo-oligomers in the absence of RNA (226, 
247, 381). Here, we examined if A3F and A3G could also form hetero-oligomers in the absence 
of RNA. We used A3F and A3G enzymes purified in the presence of RNaseA to remove the bound 
cellular RNA that causes the enzymes to form higher order oligomers, i.e., >650 kDa (227, 348). 
Based on comparison to a calibration curve, the size exclusion chromatography (SEC) confirmed 
the absence of higher order oligomers (Figure 5.1A-B). For the SEC, we used relatively low 
concentrations of enzymes (1 μM) and detected the enzymes by quantitative immunoblotting to 
avoid potential artifacts caused by high concentrations of A3G and A3F. A monomer of A3G or 
A3F is predicted to be 46.4 or 45 kDa, respectively, based on the amino acid sequences. Consistent 
with previous reports, A3G was present in both monomer and dimer fractions (Figure 5.1B, 
fraction 20, dimers, 101 kDa; fraction 22, monomers, 48 kDa). A3F was present in trimer and 
dimer fractions (Figure 5.1B, fraction 19, trimers, 153 kDa; fraction 20, dimers, 101 kDa) (247). 
To examine whether A3F and A3G can hetero-oligomerize we mixed together an equal 
amount of each enzyme before loading onto the column. The A3F/G blots show the SEC profile 
for the combined run where either A3G (anti-A3G) or A3F (anti-A3F) was detected (Figure 5.1B). 
These bands were quantified and plotted for comparison to SEC of each enzyme alone (Figure 
5.1C-D). For A3F, the peak fraction of trimers (fraction 19) shifted to a peak fraction of tetramers 
(fraction 18, 207 kDa) in the presence of A3G (Figure 5.1B-C). Additionally, the dimer peak 
(fraction 20) of A3F was decreased (Figure 5.1B-C). These data suggest that A3F, which is 
predominantly a trimer, can interact with one molecule of A3G to form a tetrameric A3F/G hetero-
oligomer. To investigate this further, we analyzed the A3G SEC data. The A3G alone 
predominantly fractionated as a monomer (Figure 5.1B and D, fraction 22). In the presence of 
A3F, and concomitant with A3F and A3G forming a hetero-oligomer, the A3G peak fraction 
shifted to the tetrameric fraction (Figure 5.1B and D, fraction 18, 207 kDa). However, a significant 
amount of A3G monomers are still present in the presence of A3F, supporting the conclusion that 
there are less A3G molecules than A3F molecules in the A3F/G hetero-oligomer (Figure 5.1B). 
Together with the A3F SEC and immunoblotting, the data support that a trimer of A3F interacts 
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with a monomer of A3G and that this complex is a protein-protein interaction and not mediated by 
RNA. 
To determine if this interaction would be relevant in cells we used two additional 
approaches. In one experiment, we conducted a co-IP to determine if A3G-HA expressed in 293T 
cells could immunoprecipitate A3F-V5. Cells transiently expressing A3G-HA, A3F-V5, or A3G-
HA and A3F-V5, were lysed, incubated with RNaseA, and then incubated with anti-HA antibody 
or normal rabbit IgG (mock) and Sepharose A beads. Even in the absence of RNA, A3G-HA was 
able to immunoprecipitate A3F-V5 indicating that A3F and A3G associate through a protein-
protein interaction in cells (Figure 5.1E). In another experiment, we quantified the strength of the 
interaction between A3F and A3G using fluorescence depolarization to measure the rotational 
anisotropy of fluorescein-labeled A3G (F-A3G) in the presence of increasing amounts of A3F. As 
the A3F formed a complex with the F-A3G, the anisotropy increased and reached saturation where 
all of the F-A3G was bound. From this saturation curve, an apparent dissociation constant (Kd) of 
135 nM was calculated by fitting the curve to a Sigmoidal equation by regression analysis (Figure 
5.1F). These data indicated that A3F and A3G interacted with a high affinity and further support 
that they could interact in cells. That the binding curve best fit a Sigmoidal equation rather than a 
rectangular hyperbola by least squares analysis further supports that multiple A3F molecules are 
binding to A3G, consistent with the SEC data (Figure 5.1B-D). 
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Figure 5.1. A3F and A3G hetero-oligomeric.  (A-D) Size exclusion chromatography was 
conducted with a 10 mL G200 Superdex column. (A) A calibration curve was used to calculate 
the molecular weights and oligomerization states of the enzymes. (B) The A3G, A3F, and A3F/G 
SEC experiments used quantitative immunoblotting to detect A3G or A3F with antibodies to the 
native proteins. The integrated band intensities calculated using Licor/Odyssey software were used 
to generate chromatograms. The T, D, and M notations indicate peak fractions for tetramers, 
dimers, and monomers, respectively. (C) The integrated band intensities for A3F indicated that 
A3F alone was primarily a trimer (Fraction 19, 153 kDa) with a minority of dimers (fraction 20, 
101 kDa). The A3F in the A3F/G combined run was primarily a tetramer (fraction 18, 207 kDa). 
(D) The integrated band intensities for A3G indicated that A3G alone was primarily a monomer 
(fraction 22, 46 kDa) with a minority of dimers (fraction 20, 101 kDa). The A3G in the A3F/G 
combined run maintained a population of monomers (fraction 22), but also was able to fractionate 
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with the peak fraction corresponding to tetramers (fraction 18, 207 kDa). (E) 
Coimmunoprecipitation of A3F-V5 with A3G-HA. The A3G-HA and A3F-V5 were transfected 
alone or in combination. The immunoprecipitation of cell lysates used either anti-HA antibody or 
Rabbit IgG (mock) and immunoblotted with antibodies against α-tubulin, HA, and V5. Cell lysates 
show the expression of α-tubulin, HA, and V5. (F) Steady state fluorescence depolarization was 
used to measure the rotational anisotropy of F-A3G interacting with A3F. Rotational anisotropy 
was normalized to fraction F-A3G bound. An apparent Kd was calculated by regression analysis 
of the saturation curve from three independent experiments. A sigmoidal fit was chosen by least 
squares analysis and resulted in an apparent Kd of 135 ± 13 nM. 
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5.5.2. A3F and A3G co-expression results in higher levels of HIV restriction 
To determine if the A3F/G hetero-oligomer influences the ability of the A3 enzymes to 
restrict HIV replication, we conducted single-cycle infectivity assays. To model cellular conditions 
where A3F and A3G are coexpressed we used a plasmid that has two transcription units enabling 
the combined expression of both A3F-V5 and A3G-HA on a single-cell basis. Flow cytometry to 
detect the V5 and HA tags demonstrated a distinct population of cells that expressed both A3F-V5 
and A3G-HA when A3F-V5 and A3G-HA were expressed from the same plasmid (Figure 5.2A). 
The population of cells expressing both A3F-V5 and A3G-HA showed a normal distribution of 
cells with low (L, 26%), medium (M, 52%), and high (H, 22%) coexpression on a single-cell basis 
(Figure 5.2A). In contrast, a cotransfection strategy using separate plasmids expressing A3F-V5 
and A3 
G-HA showed a skewed distribution of the cell population with predominantly a low 
amount of cells coexpressing A3F-V5 and A3G-HA (Figure 5.2A, 62% low (L), 34% medium 
(M), and 4% high (H)).  As a result, the virions generated from cell populations with a normal 
distribution of A3F-V5 and A3G-HA coexpression will be more likely to encapsidate more 
homogenous levels of each A3 enzyme across the population than the virions generated from cell 
populations with a skewed distribution of A3F-V5 and A3G-HA coexpression. Thus, our 
experiments used only A3F-V5 and A3G-HA that were coexpressed from one plasmid. 
Using increasing amounts of A3 plasmid for A3G-HA (A3G), A3F-V5 (A3F) and A3G-
HA/A3F-V5 coexpressed (A3F/G) we observed that the maximum amount of restriction occurred 
at a lower level of transfected plasmid when A3F and A3G were coexpressed (Figure 5.2B). 
Specifically, only 25 ng of the A3F/G plasmid was required for restriction of HIV compared to 50 
ng of A3G plasmid or 100 ng of A3F plasmid. A3F mediated viral restriction was consistently less 
than A3G, as previously reported (2, 22, 226, 266). However, most notable was that for the 25 ng 
plasmid transfection experiment the combined expression of A3F and A3G resulted in 4- to 6- fold 
greater restriction than either A3G or A3F alone (Figure 5.2B, 25 ng). At 50 ng and 100 ng of 
transfection plasmid, the restriction of A3G was not significantly different than the combined 
restriction of A3F/G (Figure 5.2B, 50 ng and 100 ng). The infectivity data demonstrate that at 
lower levels of A3G and A3F expression, when their restriction effect is not saturated, their 
combined action is better than their individual action in inhibiting HIV infectivity. This effect is 
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similar to previous reports (2, 360), although the reason for this enhancement of restriction has not 
been previously investigated. 
To investigate if the enhanced effect was a result of higher encapsidation levels of A3G or 
A3F we analyzed cell lysates and virions by immunoblotting (Figure 5.2C). Since the A3s have 
different tags they were blotted with different antibodies and as a result we are unable to compare 
A3G to A3F. However, we can determine if the same amount of A3G or A3F is encapsidated under 
the different expression conditions. The virus blot showed that the same amount of A3G was 
encaspsidated in both the A3G and A3F/G experiments (Figure 5.2C). Similarly, A3F was 
encapsidated at the same level whether it was expressed alone or with A3G (Figure 5.2C). These 
results indicate that the enhanced restriction was not due to higher levels of enzymes being 
encapsidated and suggested that coencapsidated A3G and A3F were able to synergistically restrict 
HIV replication. 
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Figure 5.2. Coexpressed A3F and A3G enhances the restriction of HIV replication.  (A) Flow 
cytometry was used to detect the A3G-HA or A3F-V5 in individual cells after transient 
transfection using fluorescently labeled anti-HA or anti-V5 antibodies. Cells were either 
transfected with one pVIVO2 vector expressing both A3G-HA and A3F-V5 or individual pVIVO2 
vectors each expressing A3G-HA or A3F-V5. (B) HIV Δvif infectivity was measured by eGFP 
expression in 293T cells infected with HIVΔvif that was produced in the absence or presence of 
A3G-HA (A3G), A3F-V5 (A3F), or coexpressed A3F-V5 and A3G-HA (A3F/G). Results 
normalized to the no A3 condition are shown with the Standard Deviation of the mean calculated 
from at least three independent experiments. Designations for significant difference of values were 
p≤0.001 (***), p≤0.01(**), or p≤0.05 (*). (C) Immunoblotting of HA and V5 tags was used to 
detect A3 enzymes expressed in cells and encapsidated into HIV Δvif virions. The cell lysate and 
virion loading controls were α-tubulin and p24, respectively. 
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5.5.3. Enhanced mutagenesis of HIV Δvif induced by coencapsidated A3F and A3G 
Recently it was shown that A3F and A3G are indeed able to be coencapsidated into HIV 
virions (220). To identify if one or both A3s were increasing the level of mutagenesis when 
coencapsidated we sequenced a portion of the proviral DNA. We used proviral DNA from the 25 
ng A3 plasmid transfection experiment to avoid analyzing proviral DNA that may be saturated 
with mutations and PCR amplified the protease region for DNA sequencing. The mutation 
frequencies showed that A3G mutated the proviral DNA more than A3F (Table 5.2, A3G, 7.5 
mutations/kb; A3F, 1.6 mutations/kb). When A3G and A3F were coexpressed, the mutation 
frequency was 14 mutations/kb (Table 5.2). If coencapsidated A3G and A3F were acting 
independently of each other the mutation frequency would be expected to be the sum of each 
mutation frequency alone (estimated 9.1 mutations/kb). That the mutations/kb when A3G and A3F 
were combined was 1.5-fold more than the sum of each mutation frequency alone suggests that 
A3G and A3F can coordinate to restrict HIV replication. When 50 ng of plasmid was transfected, 
we observed that for the A3F/G condition, the mutations were 2-fold greater than the sum of the 
mutations of A3G and A3F alone (data not shown). At 100 ng of plasmid, there was no increase 
in mutations in the A3F/G condition compared to the A3G and A3F alone, presumably because 
the restriction was reaching saturation which would make it difficult to differentiate between the 
conditions (Figure 5.2B, 100 ng and data not shown).  
Since A3G causes mutations in the (+)DNA predominantly at GG sites and A3F 
predominantly at GA sites, sequence analysis can determine which A3 was inducing the increases 
in mutational load (2, 216). Consistent with previous observations, we found that A3G alone 
mutated GG sites for 91% of the mutations (Table 5.2, 6.8 mutations/kb) and mutated GA sites for 
9% of the mutations (Table 5.2, 0.7 mutations/kb). A3F predominantly mutated GA sites (Table 
5.2, 94% of GA sites, 1.5 mutations/kb), but could also mutate GG sites at a low level (Table 5.2, 
6% of mutations, 0.1 mutations/kb). This meant that we could use the sequence context to 
determine which A3 was inducing increases in the mutational load. For the 25 ng transfection 
condition, the combined mutation frequency (14 mutations/kb) was composed of 11 mutations/kb 
at GG sites (A3G induced) and 2.6 mutations/kb at GA sites (A3F induced) (Table 5.2). This is a 
1.6-fold or 1.7-fold increase in GG mutations (Table 5.2, 6.8 mutations/kb increased to 11 
mutations/kb) or GA mutations (Table 5.2, 1.5 mutations/kb increased to 2.6 mutations/kb), 
respectively. When A3F and A3G were coexpressed, we recovered both GG and GA mutations in 
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the same clone more frequently than when each A3 was expressed alone indicating that indeed 
both A3F and A3G were coencapsidated (Figure 5.3A). Specifically, for the A3F/G cotransfection 
(25 ng), 52% of mutated clones were comutated (Figure 5.3A). Of those not comutated, the 
mutations recovered contained only A3G-induced mutations at GG sites, consistent with there 
being a low mutation efficiency of A3F (Figure 5.3A and Table 5.2). For the 50 ng and 100 ng 
transfections, 75% of mutated clones were comutated (data not shown). 
Despite only a 1.5-fold increase in mutagenesis, there was a 4-fold (A3G) to 6-fold (A3F) 
increase in restriction ability when the two enzymes were coexpressed in virus producer cells and 
coencapsidated in virions (Table 5.2 and Figure 5.2B). This inconsistency may be due to the ability 
of A3G to induce the formation of numerous stop codons in (+)DNA which would be able to 
completely ablate virus replication with only a single mutation (216). Stop codons arise from 
deamination of cytosines in (-)DNA Trp codons, e.g., 5'CCA. When the (-) DNA is deaminated to 
5'UCA or 5'CUA the sequence becomes 5'TGA or 5'TAG in (+) DNA and results in a stop codon. 
Within the 351 nt long protease region that we sequenced, there was one Trp codon that was a 
hotspot for mutagenesis. A3G alone induced stop codon formation in 32% of the clones, A3F alone 
induced stop codon formation in 6.9% of the clones, and coencapsidated A3F/A3G induced stop 
codon formation in 50% of the clones (nucleotide positions 152 or 153). There are also numerous 
other A3-induced missense mutations that can inactivate protease (226, 250, 341). The inactivation 
of protease as a result of missense mutations was inferred from results from an extensive protease 
mutagenesis study conducted by Loeb et al. (354). Taking into account both stop codons and 
inactivation by missense mutations, we found that A3G alone inactivated 56% of mutated protease 
and left 8% percent of mutated protease active (Figure 5.3B). Due to the low A3 plasmid 
transfection level used in the experiment (25 ng), we recovered protease clones that were not 
mutated 36% of the time (Figure 5.3B). In contrast, A3F inactivated only 20% of mutated protease 
and left 14% mutated and active and 66% not mutated (Figure 5.3C). When A3F and A3G were 
coexpressed, there were no protease clones that were mutated and active (Figure 5.3D). There were 
81% of protease clones that were mutated and inactivated and 19% left unmutated. This means 
that when A3F and A3G are coexpressed they are able to more efficiently inactivate the proviral 
DNA. Thus, although the combined effect of A3F/G on mutations was at most 2-fold, this enabled 
a larger decrease in infectivity (4- to 6-fold) and further supports that coencapsidation of A3G and 
A3F enhances HIV restriction from each A3 alone (Figure 5.2B and Table 5.2). 
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The mutations per clone were plotted to visualize the mutations across the sequenced 
protease region of the integrated provirus. Of the 351 nt clone, there are distinct hotspots in which 
A3G induces mutations (Figure 5.3E). The hotspots are deaminated in at least 20% of clones and 
there are 8 of these sites at positions 86, 151, 168, 170, 177, 243, 258, and 282. In the combined 
A3F/G condition, the same hotspots are deaminated in more clones, but no new hotspots were 
identified (Figure 5.3E and G, see hashed reference line). The increases in deamination at each of 
the sites ranged from 1.3-fold (nucleotide position 168) to 2.1-fold (nucleotide positions 86 and 
243), suggesting that deamination activity across the protease gene was increased similarly (Figure 
5.3E and G). For A3F, there were no distinct hotspots due to the low level of induced mutagenesis 
(Figure 5.3F). Increases in deamination for A3F in the A3F/G condition occurred at new sites or 
sites deaminated when A3F was expressed alone (Figure 5.3F-G, new sites: 106, 114, 129, 148, 
and 178). However, in accordance with the overall mutation frequency the increases were not high. 
The higher mutation frequency of A3F in the A3F/G condition was primarily due to new site 
mutations. All together the data indicate that for A3G and A3F, coexpression increases their 
mutagenic activity, but for A3G there is no change in the deamination hotspots, in contrast to A3F 
that is able to mutate more new sites during (-)DNA synthesis. Since A3G and A3F can form an 
A3F/G hetero-oligomer (Figure 5.1), we interpreted the mutation data to suggest that the A3F/G 
hetero-oligomer is working to increase deamination activity (observed for A3G) and accessibility 
to ssDNA (observed for A3F). 
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Figure 5.3. Coexpressed A3F and A3G commutate the same HIV proviral genome.  (A-C) 
Individual analysis of each protease clone for (A) A3G, (B) A3F, and (C) A3F/G enabled 
determination of the percentage of clones that would result in a mutated and inactive (blue) or 
mutated and active (orange) protease. The percentage of clones that were not mutated are shown 
in grey. (D) Spectral plot generated by Hypermut (56) demonstrates the ability of coexpressed 
A3G and A3F to comutate the same genome. Representative samples from the 25 ng A3G, A3F, 
and A3F/G infectivity experiment were plotted. Across the protease gene, GG→AG (expected 
A3G induced mutation) are shown by a red line, GA→AA (expected A3F induced mutations) are 
shown by a cyan line, and GT→AT mutations (a single site) is shown in magenta. (E-G) 
Mutational spectra for all clones shows the percentage of clones with a mutation at a particular site 
in the protease gene for (E) A3G, (F) A3F, and (G) A3F/G. The GG→GA (red) and GA→AA 
(cyan) mutations are distinguished with color and demonstrate the specificity of the deamination 
targets for A3G and A3F.  
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Table 5.2. Analysis of A3-induced mutagenesis of protease DNA from integrated HIVΔvif 
A3 
enzyme 
Base Pairs 
Sequenced 
Total 
GA 
mutations 
Total 
GGAG 
mutations 
Total 
GAAA 
mutations 
Deaminations 
per kb 
GGAG 
mutations 
per kb 
GAAA 
mutations 
per kb 
A3G 8775 66 60 6 7.5 6.8 0.7 
A3F 10179 16 1 15 1.6 0.1 1.5 
A3F/G 9126 129 104 24 14 11 2.6 
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5.5.4. A3G when part of an A3F/G hetero-oligomer has an improved ability to jump over 
RNA/DNA hybrids 
To test our hypothesis that the A3F/G hetero-oligomer can increase the activity of A3G, 
we conducted in vitro deamination and binding assays on synthetic oligonucleotides. Using 
fluorescence depolarization, we found the A3F/G hetero-oligomer bound fluorescein labeled 
ssDNA with an apparent Kd that was unique from either A3F or A3G alone (Figure 5.4A). The 
A3F/G hetero-oligomer was formed by preincubating equal amounts of A3F and A3G. The A3F/G 
hetero-oligomer bound ssDNA with an apparent Kd of 114 nM, which is 3-fold less affinity than 
A3F and 2.5-fold more affinity than A3G alone. Since the binding experiment is conducted under 
steady state, the apparent Kd of the A3F/G hetero-oligomer is an average of all possible 
associations, A3F/G, A3G, and A3F. However, the data support the conclusion that the A3F/G 
hetero-oligomer may have distinct biochemical properties from A3G and A3F. 
Previously we have shown that the processive scanning mechanism of the A3 enzymes that 
is used to search for the preferred deamination motifs in the DNA substrate can be a predictor of 
mutagenic potential (226). Therefore, we hypothesized that since one A3G appeared to interact 
with three molecules of A3F (Figure 5.1A-D), that A3F may be able to influence the processive 
scanning mechanism of A3G. A3F is able to jump larger distances than A3G (226). Jumping 
movements are required for overcoming in a processive manner RNA/DNA hybrid obstacles left 
on (-)DNA by RNaseH activity (213). To examine the processivity and scanning mechanism of 
the A3, the reactions are conducted under single-hit conditions where an ssDNA is encountered 
by only one enzyme during the course of the reaction (344). To characterize processivity and 
scanning movement we used an ssDNA with either two CCC motifs (for A3G activity) or two 
TTC motifs (for A3F activity) separated by differing distances. Under our reaction conditions we 
observed no deamination of CCC motifs by A3F or TTC motifs by A3G (data not shown). Thus, 
we examined how the A3F/G hetero-oligomer could improve activity of either A3G or A3F by 
using the relevant substrate. To form the hetero-oligomer, we preincubated A3F and A3G together, 
added the enzymes to the reaction buffer and started the reaction by the addition of ssDNA. We 
did not subsequently purify the A3F/G hetero-oligomer from unbound A3F or A3G to simulate 
cellular conditions where there is likely to be an “average” population of A3F, A3G and the A3F/G 
hetero-oligomer. 
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To examine jumping we used deamination motifs that were distantly spaced (61 nt). On 
the CCC motif containing ssDNA, A3G and the A3F/G hetero-oligomer had the same processivity 
factor of approximately 8 (Figure 5.4B). This processivity factor is calculated using the integrated 
gel band intensity of the 5'C & 3' C deamination band and means that the enzyme is 8-fold more 
likely to make a processive deamination than a nonprocessive deamination (see Material and 
Methods). To challenge the jumping ability of A3G and the A3F/G hetero-oligomer we annealed 
a complementary 20 nt RNA between the two CCC motifs (Figure 5.4C, sketch). Since A3G and 
A3F cannot bind to this RNA/DNA hybrid, the enzyme complex must jump over the obstacle to 
undergo processive deamination of both CCC motifs (226). A3G had a characteristic decrease in 
processivity due to the obstacle (Figure 5.4B-C, 2.5-fold) (226, 326). When in complex with A3F, 
the A3G processivity only decreased 1.3-fold (Figure 5.4B-C). Thus, for A3G, being in complex 
with A3F (A3F/G) can improve the jumping ability. We also conducted the equivalent experiment 
for A3F, but used the TTC motif containing ssDNA. For A3F alone, the processivity is enhanced 
by annealing a complementary RNA molecule, presumably due to the annealed portion enabling 
the TTC sites to be juxtaposed at an optimal distance for A3F jumping movements, as previously 
observed (Figure 5.4D-E) (226). There was no change in the A3F processivity factor on either 
DNA substrate in the presence of A3G (Figure 5.4D-E, A3F or A3F/G). 
To examine processive sliding movements we used an ssDNA with closely spaced 
deamination motifs (3 nt apart). On the CCC containing ssDNA we found no change in the A3G 
processivity in the presence of A3F (Figure 5.4F). A3F is not able to processively slide to 
deaminate closely spaced TTC motifs, thus, on the substrate with the TTC motifs separated by 3 
nt we observed no deamination of both the 5C' & 3'C (Figure 5.4G). Despite A3G being able to 
slide, there was no 5'C & 3'C band detected for the A3F/G hetero-oligomer on the TTC containing 
ssDNA (Figure 5.4G). Altogether, the data demonstrate that A3F influences the processive 
jumping movements of A3G when they form a hetero-oligomer, but A3F processivity is not 
influenced by A3G. This is consistent with there being more A3F molecules in the A3F/G hetero-
oligomer that could exert more of an effect on A3G than vice versa (Figure 5.1).  
These data are also consistent with the A3F/G hetero-oligomer having 1.7-fold higher 
specific activity on CCC motif ssDNA than A3G alone and no effect on the specific activity on 
TTC motif ssDNA. Specifically, this was tested by using an ssDNA substrate that had either a 
deamination motif for A3F (5'TTC) or A3G (5'CCC) and the ratio of the enzymes were varied. We 
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found that there was no appreciable effect of increasing A3G concentration on the deamination 
mediated by A3F on ssDNA containing two 5'TTC motifs (Figure 5.5A). However, for A3G, we 
found that the addition of A3F (ratios of A3G:A3F of 1:1 and 1:2) enhanced the rate A3G 
deamination on the 5'CCC containing ssDNA substrate containing up to 1.7-fold (Figure 5.5B). 
After A3F reached high concentrations, e.g., ratio of 1:5, the rate of A3G-mediated deamination 
decreased (Figure 5.5B). These results suggest that over a certain A3G:A3F ratio, A3F can impede 
A3G-mediated deamination. This may be due to the higher binding affinity of A3F for ssDNA that 
occludes A3G deamination sites (Figure 5.4A). 
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Figure 5.4. Biochemical properties of the A3F/G hetero-oligomer are distinct from   A3F and 
A3G. Fluorescence depolarization was used to detect changes in rotational anisotropy of a F-
labeled 118 nt ssDNA upon titration of A3G, A3F, or an A3F/G hetero-oligomer into the solution. 
The rotational anisotropy was normalized to fraction F-ssDNA bound and analyzed by regression 
analysis. The binding curves fit to a sigmoidal binding curve as determined by least squares 
analysis. The apparent Kd values were calculated to be 286 ± 17 nM for A3G, 39 ± 6 nM for A3F, 
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and 114 ± 20 nM for A3F/G. Error bars represent the Standard Deviation of the mean from three 
independent experiments. (B-G) Processivity of A3G, A3F, or A3F/G was tested on ssDNA 
substrates that contain a fluorescein-labeled deoxythymidine (yellow star) between two 5′CCC 
(for A3G) or 5′TTC (for A3F) deamination motifs separated by different distances. (B) 
Deamination of a 118 nt ssDNA substrate with two 5′CCC deamination motifs spaced 61 nt apart. 
Single deaminations of the 5′C & 3′C are detected as the appearance of labeled 100- and 81- nt 
fragments, respectively; double deamination of both C residues on the same molecule results in a 
63 nt labeled fragment. (C) Deamination of the same substrate shown in (B), but with a 20 nt 
complementary RNA annealed between the two 5′CCC motifs. (D) Deamination of the same 
substrate shown in (B), but with two 5′TTC motifs. (E) Deamination of the same substrate shown 
in (D), but with a 20 nt complementary RNA annealed between the two 5′TTC motifs. (F) 
Deamination of a 60 nt ssDNA substrate with two 5′CCC motifs spaced 3 nt apart. Single 
deaminations of the 5′C & 3′C are detected as the appearance of labeled 42- and 23- nt fragments, 
respectively; double deamination of both C residues on the same molecule results in a 5 nt labeled 
fragment. (G) Deamination of the same substrate shown in (F), but with two 5′TTC motifs. The 
notation “ND” means Not able to Determine due the absence of a detectable 5′C & 3′C band. The 
measurements of enzyme processivity (processivity factor) and the S.D. are shown below the gel. 
All values are calculated from three independent experiments.  
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A  
B  
Figure 5.5. A3F influences the deamination activity of A3G.  The deamination activity of A3F/G 
on a (A) 5'TTC or (B) 5'CCC substrate was determined in the presence of (A) 30 nM A3F with 
increasing concentration of A3G (30, 60, 90, 120, and 150 nM) or (B) 30 nM A3G with increasing 
concentrations of A3F (30, 60, 90, 120, and 150 nM). (A) A3G does not affect A3F deamination 
activity (gray bar), but (B) A3F can increase A3G deamination activity 1.7-fold at an equimolar 
ratio (black bar).  
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5.5.5. A3F and A3F/G decrease reverse transcripts more efficiently than A3G 
Despite A3F induced mutations being increased in the presence of A3G (Table 5.2), the 
reason for this did not appear to be due to an increase in the processive search mechanism of A3F. 
Another mechanism by which A3 induced mutations can be increased is if reverse transcription 
was slowed down, which would leave (-)DNA single-stranded for a longer time (355, 382, 383). 
It is known that both A3G and A3F can decrease reverse transcriptase efficiency, which results in 
less late reverse transcript (LRT) formation and less proviral integration (229, 255, 281, 284, 287-
289, 291, 294, 296, 384, 385). We hypothesized that the A3F/G hetero-oligomer would inhibit 
reverse transcriptase more efficiently and this would allow more time to search for and deaminate 
TC motifs in (-)DNA. 
To investigate this we conducted experiments that quantified the LRT in infected 293T 
cells and in vitro primer extension of HIV reverse transcriptase from a PBS primer in the presence 
and absence of A3s. The relative LRT formed in the presence of the A3s was decreased for all 
conditions with A3G, A3F, or A3F/G. Consistent with previous findings, A3F inhibited LRT 
formation more than A3G (Figure 5.6A, 1.6-fold difference) and the inhibition of LRT formation 
was independent from deamination ability (Figure 5.6A, catalytic E→Q mutants) (229, 255). The 
A3F/G hetero-oligomer suppressed LRT formation approximately 2-fold more than A3F alone. 
These data were consistent with a primer extension assay in which purified HIV reverse 
transcriptase was used to extend the 18 nt PBS primer from a 106 nt template that had a nucleotide 
sequence matching the corresponding region of the HIV genome (Figure 5.6B, sketch). For the 
A3F/G condition, equimolar amounts of A3F and A3G were preincubated before adding to the 
reaction. In all reactions there was the same total moles of A3 for each titration. By titrating 
increasing amounts of A3 into the reaction we observed an increasing amount of inhibition of 
DNA polymerization (Figure 5.6B). Analysis of the primer extended showed that each A3 
inhibited total primer extension similarly (Figure 5.6C). However, visual inspection of the gel for 
the 4:1, 8:1, and 32:1 A3:primer/template (p/t) conditions demonstrated that A3F and the A3F/G 
hetero-oligomer can inhibit the formation of full length products (82 nt) at the 4:1 molar ratio 
whereas at least 2-fold more A3G is required for the same inhibition (Figure 5.6B and D). 
Altogether, the data indicate that the presence of either A3F or the A3F/G hetero-oligomer can 
slow down RT catalyzed DNA synthesis and this probably occurs by a “road-block” mechanism 
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that has previously been proposed (Figure 5.7) (294). This may enable the A3 enzymes more time 
to deaminate the (-) DNA. 
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Figure 5.6. A3 enzymes can decrease reverse transcriptase efficiency.  (A) Quantification of late 
reverse transcripts (LRT) by qPCR demonstrated that A3G, A3F, and A3F/G and their catalytic 
mutants can decrease LRT relative abundance. The E/Q notation means an E259Q mutation for 
A3G or an E251Q mutation for A3F. Error bars represent the standard deviation of the mean from 
three independent experiments. (B) An 18 nt 32P-labeled RNA primer containing a sequence 
complementary to the HIV PBS was annealed to a 106 nt RNA containing the PBS (sketch). 
Complete extension of the primer results in a product of 82 nt (sketch). The p/t was used at a 
concentration of 10 nM. Primer extension by reverse transcriptase (480 nM) in the absence (0∶1) 
or presence (4∶1, 8∶1, 32∶1) of increasing amounts of A3G, A3F, or A3F/G relative to the p/t 
concentration. Reactions were sampled at 2.5 and 60 min. (C) Quantification of primer extension 
(%) shown in panel B from gels shown in panel B for no A3, A3G, A3F, and A3F/G at 60 min. 
(D) Quantification of fully extended 82 nt product (%) for no A3, A3G, A3F, and A3F/G at 60 
min. (C-D) Error bars represent the Standard Deviation of the mean from three independent 
experiments. (A, C-D) Designations for significant difference of values were p≤0.001 (***), 
p≤0.01(**), or p≤0.05 (*).  
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Figure 5.7. A road-block model for decreasing reverse transcriptase efficiency by A3.  Step 1. A3 
binds (blue) with the RNA genome (orange), blocking the synthesis of negative strand DNA 
(black) synthesis by RT (green). Step 2. A3 enzymes induce deaminations on exposed ssDNA. 
Step 3. A3 binding of ssDNA can also block RT-mediated plus-strand DNA (red) synthesis. 
Modified with permission from (294).  
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5.6. Discussion 
A3 enzymes are coexpressed in CD4+ T cells and have been shown to coordinately restrict 
HIV replication (19, 24, 31, 32). However, the mechanism of this coordinate restriction is not clear. 
For A3G and A3F it has been proposed that each contributes individually to HIV mutagenesis due 
to not being coencapsidated (376), that A3F and A3G enzymes are coencapsidated but act 
independently of one another (2, 220), and that A3 enzymes can enhance each other’s activity (2, 
360). Thus, we undertook a study of A3F and A3G to examine how they may coordinately restrict 
HIV infectivity when expressed in the same HIV producer cell. We observed that A3F and A3G 
can form an A3F/G hetero-oligomer in cells and in vitro in the absence of an RNA intermediate 
and inferred that they can frequently coencapsidate into HIV particles due to 52-75% of proviruses 
being comutated. Overall, our data shows that the A3F/G hetero-oligomer has enhanced ability to 
decrease the infectivity of HIV through increased mutagenic activity resulting from unique 
biochemical properties of the A3F/G hetero-oligomer compared to the individual enzymes. 
5.6.1. A3F/G oligomerization 
We determined that A3F and A3G hetero-oligomerize using several methods. Using 
uniquely tagged versions of A3F and A3G we conducted a co-IP similar to what was done 
originally by Wiegand et al., except that we added RNaseA to the cell lysates (24). Even in the 
absence of RNA A3G-HA could immunoprecipitate A3F-V5 indicating that they hetero-
oligomerized in cells (Figure 5.1E). The complex has a high affinity association in the nanomolar 
range and is stable enough to be identified through SEC (Figure 5.1A-D and F). We previously 
determined by SEC that A3F was approximately 158 kDa in the peak fraction, which would be a 
trimer or tetramer (3.5-fold the molecular weight of a monomer) (226). However, using a similar 
method and column, but with quantitative immunoblotting to better visualize the bands, we 
identified the A3F peak fraction more exactly to be 153 kDa, which confirmed that the molecular 
weight is closer to that of a trimer than a tetramer. The oligomerization of A3F does not appear to 
be concentration dependent since it formed these trimers at protein concentrations in the low 
micromolar range (Figure 5.1B-C, 1 μM A3F used for SEC). In contrast the oligomerization of  
A3G is concentration dependent. In the absence of RNA at low concentrations A3G is 
primarily a monomer and at higher concentrations it forms predominantly dimers (Figure 5.1) 
(205, 226, 247, 381). This dynamic nature of A3G oligomerization may facilitate the ability to 
oligomerize with A3F (Figure 5.1). Conversely, the stable oligomer of A3F may inhibit multiple 
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A3G molecules from binding. With 50% amino acid similarity between A3F and A3G it is 
reasonable to assume that they may similarly oligomerize. However, making a Y131A/W132A 
mutant in A3F, which is equivalent to the dimer disruption mutant F126A/W127A of A3G, did 
not disrupt A3F oligomerization (data not shown) suggesting that A3F oligomerizes in a manner 
unique form A3G. A crystal structure of rhesus A3G N-terminal domain (NTD) shows that A3G 
(NTD) dimerizes using helix 6 and loop 7, where F126/W127 are located, confirming previous 
mutational studies (246, 247, 386). Further this dimerization of rhesus A3G NTD is distinct from 
any of the existing A3F dimer models that have resulted from A3F C-terminal domain structures 
(263, 314, 387, 388). It remains to be determined how full length A3F oligomerizes in solution. 
However, since A3F does not tetramerize by itself (Figure 5.1B-C), this suggests that for a tetramer 
to form, a different association interface must be used. Since the A3F/G hetero-oligomer formed 
in cell lysates, it is likely to also form in virions where the apparent concentration of the 
components is estimated to be in the high micromolar range due to the restricted volume of the 
capsid (Figure 5.1E) (389). 
5.6.2. A3G and A3F cooperate to restrict HIV replication 
All studies to date on A3G and A3F coencapsidation have found different results. Most 
recently Desimmie et al. showed on a single virion level that A3G and A3F are indeed 
coencapsidated (220). In the experimental system the authors transfected an HIV plasmid and 
separate plasmids for each A3G and A3F. This resulted in ~50% coencapsidation (220). The 
coencapsidation in our study is implied by our data in which we recovered proviruses that had 
mutations at both GG and GA, representing mutation sites due to A3G and A3F deamination, 
respectively. However, we observed that 52-75% of the proviruses were comutated, depending on 
the transfection conditions. At the same approximated restriction conditions, we recovered 1.5-
fold more comutated viral genomes than Desimmie et al.(220) (compare 75% in this study with 
49.6%). In contrast to our study, the authors found that coencapsidated A3G and A3F had an 
additive, not cooperative effect (220). This may be due to the different A3 expression strategy. 
Desimmie et al. used separate plasmids to express the two A3s whereas our study used one plasmid 
to express A3G and A3F thereby ensuring each transfected cell had both enzymes expressed, 
which may have resulted a more defined transfection population (Figure 5.2A) (220).  
Further, we titrated our expression plasmids to avoid saturation of the mutations that may 
obscure any cooperative effects (Figure 5.2B). Interestingly, Krisko et al. found that in a BLT 
 147 
 
humanized mouse model that consistent HIV Δvif restriction required the combined antiviral 
activities of A3G and A3F and that A3F was contributing through a deamination independent 
mechanism (360). Despite more consistent HIV restriction in the presence of both A3F and A3G, 
the mutations were predominated by GG→GA and the GA→AA represented only ~1% (360). 
These data are in agreement with our observation that A3G deamination activity is being enhanced 
by A3F and that A3F deamination activity was low (Figure 5.3E-G). Our studies are in further 
agreement that A3F has a more robust activity to inhibit reverse transcriptase polymerization than 
A3G when acting alone or in the presence of A3G (Figure 5.6). However, data from Krisko et al. 
are in contrast to another humanized mouse model study in which HIV proviral DNA was found 
to contain mutations that resulted from only A3G deamination or predominantly A3F deamination, 
suggesting that A3G and A3F act individually (390). In the earliest study to combine A3G and 
A3F plasmids in the producer cell, Liddament et al. showed a synergistic 2.7-fold increase in the 
mutations caused by A3G and A3F coexpression compared to each expressed alone, but only an 
additive effect on infectivity (2). Thus the authors concluded that A3G and A3F have both an 
independent and synergistic (which they termed “dependent”) ability to induce mutagenesis of 
proviral DNA (2). Although we observed a synergistic effect for infectivity (4- to 6- fold) and a 
lesser effect on mutagenesis (~2-fold), the conclusions of Liddament et al. are in agreement with 
ours (2). 
5.6.3. Independent and dependent modes of A3F and A3G restriction 
As discussed, previous studies on A3F and A3G coencapsidation and corestriction are 
largely complimentary to our work. However, our study identified possible mechanisms that can 
enable coencapsidated A3F and A3G to act cooperatively. Although A3F and A3G were identified 
to be coexpressed in CD4+ T cells and hetero-oligomerize in an early study, the role of RNA in 
mediating the hetero-oligomerization was not clear (24). Defining if their interaction was mediated 
by an RNA intermediate is important to identify because it provides information on whether they 
act independently while coencapsidated, such as A3F inhibiting reverse transcriptase 
polymerization while A3G deaminates the (-)DNA or if they are dependent on each other through 
forming a hetero-oligomer. 
That we identified A3F and A3G to form a hetero-oligomer in the absence of RNA in vitro 
and in cells (Figure 5.1), led us to investigate a dependent mechanism of cooperation. The SEC 
indicated that there were likely more molecules of A3F in the hetero-oligomer than molecules of 
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A3G (Figure 5.1B-D). These data imply that if equal amounts of A3G and A3F are coencapsdiated, 
that there would be a population of free A3G molecules, A3F/G hetero-oligomers, and a minority 
of free A3F molecules. We tested if the A3F/G hetero-oligomer had properties that could enhance 
HIV restriction and found that A3G in the A3F/G hetero-oligomer was better able to processively 
scan ssDNA with a RNA/DNA hybrid region than A3G alone (Figure 5.4B-C). The processive 
scanning mechanism of an A3 has been shown to be a determinant of restriction efficiency (226).  
The A3F/G hetero-oligomer was able to slow down the polymerization efficiency of 
reverse transcriptase (Figure 5.6B-D). In the primer extension assay, we kept the total moles of 
enzyme equal for experiments with A3G, A3F, and A3F/G. Thus in the A3F/G condition, there is 
half the amount of A3F compared to the A3F alone condition. Despite this, the A3F/G hetero-
oligomer could inhibit synthesis of full length product as efficiently as A3F, further supporting the 
conclusion that the A3F/G hetero-oligomer has distinct biochemical properties and functionality. 
None of the conditions resulted in the inhibition of primer initiation, consistent with other studies 
that were focused on A3G (Figure 5.6C) (229, 283, 288). However, A3G, A3F and A3F/G could 
inhibit synthesis of full length product (Figure 5.6D). The analysis of inhibition of full length 
product formation are consistent with cellular data and demonstrate that the ability of A3F to 
inhibit reverse transcriptase is greater than A3G (Figure 5.6A and D). This may be due to A3F 
binding ssDNA with higher affinity than A3G (Figure 5.4A). Consistent with the A3G model that 
oligomers on the ssDNA block reverse transcriptase progression, both A3F and the A3F/G hetero-
oligomer form trimers and tetramers in solution, respectively, and bind ssDNA cooperatively 
indicating that they further oligomerize on ssDNA, suggesting a mechanism of action similar to 
A3G (Figure 5.4A) (294). The slower reverse transcription that occurred in vitro and in cells in the 
presence of the A3s could provide more time to deaminate (-)DNA resulting in an independent 
mechanism of synergy where one A3 oligomer is inhibiting the reverse transcriptase and another 
is deaminating the DNA (Figure 5.6A-B). This may facilitate increased deamination of A3F in the 
A3F/G hetero-oligomer. The A3F/G hetero-oligomer bound ssDNA with approximately 2-fold 
less affinity than A3F alone (Figure 5.4A). The high affinity of A3F for ssDNA has been suggested 
to inhibit its movement on DNA, adding to its inefficiency with which it searches the substrate for 
deamination motifs (226). The higher Kd of the A3F/G hetero-oligomer may increase the ability 
of A3F in the A3F/G hetero-oligomer to search the (-)DNA before it becomes double stranded 
(226). In combination with the decrease in reverse transcriptase efficiency imposed by A3 
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enzymes, this provides an explanation for the increased number of A3F induced mutations when 
A3F and A3G are coexpressed (Figure 5.3, Figure 5.6, and Table 5.2). 
5.7. Conclusion 
Overall, the data support that A3F and A3G in cells can form a hetero-oligomer with unique 
properties from the individual enzymes. The extent to which A3F and A3G oligomerize with each 
other in HIV infected CD4+ T cells could not be determined due to the lack of a high sensitivity 
antibody for A3F. However, it is likely that these interactions identified here in cell culture and in 
vitro may contribute to the hypermutation identified in proviral genomes of HIV infected people 
since the higher mutagenic activity could enable more efficient mutagenesis despite the presence 
of Vif (178, 220). It is also possible that other A3s may hetero-oligomerize and synergistically 
restrict HIV. All together our data identify a mechanism that may contribute to enhanced activity 
of A3s and raises the idea that we may still not fully realize all the antiviral mechanisms of 
endogenous A3 enzymes. 
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CHAPTER 6. GENERAL DISCUSSION AND FUTURE DIRECTIONS 
In the past 15 years, there has been an explosion of knowledge on the ability of human 
antiviral restriction factors, including the A3 family of enzymes that act as the first line of host 
defense against retroviral infections. In the absence of Vif-mediated degradation, A3 enzymes 
inhibit viral replication by causing lethal levels of mutagenesis as well as through a deamination-
independent mechanism that includes physical inhibition of reverse transcription and integration 
(289, 291). Out of seven, only four A3 (A3D, A3F, A3G and A3H) have been found to be relevant 
for HIV-1 (referred to as HIV) restriction in the majority of people. In people of African origin, it 
has been found that 10% of the population can carry an A3C S188I polymorphism that enables 
A3C to restrict HIV (203, 338).  
When I started my graduate thesis research, the A3 proteins were characterized by 
extensive cell-based studies for their HIV restriction ability. Yet, there was considerable disparity 
among the reports regarding HIV restriction ability of A3F compared to A3G. Most of these studies 
compared A3F and A3G based on end-point analysis, i.e., infectivity assays and mutational 
analysis of proviral DNA (258, 266, 287, 330). However, there are three key steps that A3 enzymes 
must complete to be an efficient HIV restriction factor. First A3 enzymes must escape Vif 
antagonism, Second, A3 enzymes must be available for binding RNA that will become virion-
encapsidated. Third, A3 enzymes must have a mechanism to search the nascent HIV (−) DNA. 
However, it was not clear whether the differential HIV restriction by A3F and A3G was the result 
of their distinct DNA searching ability or levels of virion encapsidation.  
 We undertook a biochemical study of A3F in comparison with A3G for investigating the 
underlying mechanisms behind the different restriction ability of these two proteins. A previous 
biochemical study on A3G-mediated deamination showed that A3G uses sliding and jumping 
motions along the ssDNA to locate and processively catalyze multiple target motifs (227). In this 
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study, using a series of synthetic ssDNA substrates, we provided the first biochemical model for 
A3F-catalyzed processive CU deamination. The DNA scanning mechanisms of A3F relies 
heavily on jumping motions, which is different than both the jumping and sliding motions of A3G. 
Mechanisms of A3G-catalyzed processive deaminations of ssDNA were questioned by Nowarski 
et al., 2009 (205). They suggested a model in which A3G uses intersegmental transfer mechanisms 
to deaminate its motifs (205). However, using more sensitive deamination assays, we provided the 
evidence that A3F but not A3G may undergo intersegmental transfer to a minor extent. The 
discrepancy may be that Nowarski et al. did not use any salt in their buffers. Our buffers have 10 
mM MgCl2 and 40 mM KCl, which creates a more competitive electrostatic environment for 
enzyme-DNA interactions and is more physiologically relevant. Thus, our data support the sliding 
and jumping model (227), and refutes the intersegmental model (205) of A3G-mediated 
deamination.  
Interestingly, we also found that A3F lacks sliding motions on ssDNA due to a single Pro 
at 190NPM192 motif which is present in the interconnecting domain between NTD and CTD. The 
recent crystal structure of A3F CTD includes the 190NPM192 sequence shows that it is a kinked 
region of a loop structure (263). Our study suggests that the Pro in the 190NPM192 motif probably 
provides rigidity to the structure since the replacement of 191P to 191G enabled A3F sliding 
movements to occur. Of note, insertion of 195NPM197 motif between NTD and CTD of A3G 
abrogated its sliding motion on ssDNA, suggesting that the interconnecting domain may be 
important in coordinating NTD and CTD for sliding. The importance of sliding is also evident 
from another study by our lab where Feng and Chelico., 2011 showed that the H186R mutant of 
A3G is less mutagenic due to lack of sliding motion (250). Furthermore, Browne et al., 2009 
reported clusters of A3G-induced deaminations in integrated proviral genomes and we assume 
based on our data that such clustered mutations are indicative of processive deaminations 
accomplished by sliding motions (254). In our in vitro and cellular experiments, we did not observe 
A3F deaminations that were clustered, supporting data that A3F does not slide on ssDNA. 
At the beginning of this study, we had the assumption that tighter enzyme binding to the 
substrate would correlate with higher deaminase activity. In this study, we found that the binding 
affinity of A3F for ssDNA was tighter than A3G, but contrary to our assumption, we found that 
the specific activity of A3F was 100-fold lower in comparison to A3G. Thus, the notion that 
associating with high affinity to the substrate will lead to high enzyme activity may not be true in 
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the case of A3 enzymes whose activity during HIV-1 proviral DNA synthesis largely depends on 
the efficient search of target motifs within a short window of time. It is conceivable that the high 
ssDNA affinity of A3F may be a bottleneck for excursions or frequent movements on the ssDNA 
that attribute to the inefficient search for deamination motifs. However, resolution of this 
assumption awaits single-molecule analysis.  
Other than the scanning mechanisms, A3G also has the advantage of being more effective 
in restricting HIV because it has a preferred deamination site of 5'CC. The 5'CC in the (-)DNA 
overlaps with the only Trp codon (5'CCA/TGG) and results in a stop codon upon deamination of 
either cytosine in the motif (216). For example, deamination of 5'CUA would result in 5'TAG, an 
“amber” stop codon. In contrast, mutations induced by A3F are mostly missense mutations which 
may or may not lead to inactivation of the encoded protein. Overall, our findings support a model 
in which both the processive DNA scanning mechanism and preferred deamination motif (A3F, 
5'TTC; A3G 5'CCC) influences the mutagenic and gene inactivation potential of an A3 enzyme, 
consistent with data from other labs (331, 359). 
In agreement with several previous reports (2, 19, 21, 23, 215), our data suggest that both 
A3F and A3G have anti-HIV potential, but A3G is more effective. In contrast to our results in 
Chapter 3, and previous findings (2, 21, 23, 215), Miyagi et al., 2010 suggested that A3F has 
negligible antiviral activity (258). Miyagi et al. argued that studies reporting anti-HIV potential of 
A3F had used transient overexpression of A3F as opposed to their stable physiological expression. 
However, using highly sensitive flow cytometry and mutational spectra of proviral DNA, Refsland 
et al. reported that endogenous levels of A3F restrict HIV in the CEM T-cell line (19). Recently a 
study by Ping et al., 2016, provided the in vivo evidence for an anti-HIV function of A3F in HIV 
natural cohorts and reported that an A3F I231V variant that is resistant to Vif degradation is 
associated it with slow progression of AIDS in European American patients (391). Based on our 
results from Chapter 5, differences in these findings between labs may be due the amount of A3G 
that was expressed in the cell lines used in experiments, since A3F restricts HIV better in the 
presence of A3G. In our cell-based studies, we suggested that A3F may contribute to viral 
evolution due to the induced missense mutations. This was also supported by the literature at the 
time (235-244). However, a new study using different methods and computational analysis of 
hypermutated proviral DNA from HIV+ individuals suggests that A3F- and A3G- induced 
mutations in the presence of Vif have negligible effects on viral evolution (245). As a result, there 
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are more studies that need to be done in this area to arrive at a consensus. However, our data at 
this time supports that as an individual enzyme A3F can contribute to HIV-1 evolution, but A3G 
is unlikely to contribute. 
Our knowledge of A3 enzyme structure and function is growing rapidly and research is on-
going to understand how A3 enzymes interact with nucleic acids and Vif and to develop novel 
therapies. However, more studies are still needed to fill in some of the gaps. Based on our data and 
given the fact that primary cells harbour multiple A3 proteins that are coordinately coexpressed, 
more research should examine whether heterologous A3-A3 interactions do influence anti-HIV 
function in primary cells, and if this will influence development of novel therapies relying on A3 
activity.  
In chapter 5, using cell lines, we investigated whether coexpressed A3F and A3G have an 
independent, additive, or synergistic effect on anti-HIV function and what the mechanisms were 
for this cooperation. We focused our study on A3F and A3G since these enzymes are most 
commonly expressed together in the human population (31, 32). First, using co-IP, size exclusion 
chromatography (SEC), and rotational anisotropy, we determined that A3F and A3G hetero-
oligomerize in the absence of RNA. We became interested in determining how the formation of 
A3F/G hetero-oligomeric species will affect anti-HIV function. Previous A3F/G coexpression 
models used either an equimolar (2) or non-equimolar (220) ratio of A3F and A3G containing 
plasmids to transfect cells. In such transfection strategies that use multiple plasmids, equimolar 
co-expression is not possible, which may result in the generation of a heterogeneous population of 
cells expressing A3F and A3G in various molar ratios on a single cell basis. Thus, transfection 
using separate plasmids will produce a mosaic population of viruses with diverse combinations 
and levels of A3 proteins. To ensure equimolar expression of A3F and A3G on a single-cell basis 
and to circumvent the problem of a mosaic population of viruses, we applied a novel strategy that 
expressed A3F and A3G from the same plasmid but using separate promoters. This approach 
resulted in more uniform expression and virion coencapsidation of both A3F and A3G.  
Notably, single-cycle infectivity assays and proviral DNA sequencing revealed that the 
combined expression of A3F and A3G had a synergistic effect on hypermutation and resulted in 
4- to 6- fold greater restriction than either A3G or A3F alone. To gain further mechanistic insights 
into the synergism between A3F and A3G, we systematically conducted biochemical analyses. We 
demonstrated that A3F promotes A3G deamination activity by forming an A3F/G hetero-oligomer, 
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which is more efficient at deaminating cytosines. Further, A3F/G triggered the accumulation of 
shorter reverse transcripts due to interference with reverse transcriptase efficiency, which would 
keep single-stranded (-)DNA exposed for extended periods of time allowing more deamination 
events to occur. Although A3F and A3G are known to function along with each other, these data 
provide the evidence for an A3F/G hetero-oligomeric A3 species with unique properties when 
compared to each counterpart.  
A3F is quite distinct from A3G due to many reasons. First, it prefers 5’TC, whereas 5’CC 
is A3G’s hot motif. The nucleotide specificity box ‘YYFW’ located on loop 7 of A3F is rich in 
aromatic amino acids and provides a highly complementary environment for the hydrophobic 
thymidine nucleotide (388). In contrast, A3G has ‘YDDQ’ nucleotide specificity box on loop 7, 
which facilitates the glutamine or aspartate acceptors forming hydrogen bonds to the 4-amino 
group on the cytosine base (note that a cytosine base is 3-times more hydrophilic than thymine) 
(388). Second, A3F is less potent than A3G in HIV-1 restriction. Third, both DNA deaminase 
activity and Vif binding reside within the CTD domain of A3F, in contrast, NTD and CTD domains 
of A3G are responsible for Vif binding and DNA deaminase activity, respectively. Fourth, unlike 
A3G, A3F is a difficult protein to purify in soluble, stable and high quantity. Fifth, in the course 
of our studies for chapter 3, we found that A3F CTD was 5 fold more active than A3F full-length, 
unlike A3G CTD that was 1000-fold less active than full-length A3G (213, 247). Sixth, unlike 
A3F, A3G is more sensitive to HIV Vif induced ubiquitin ligase complex-mediated proteasomal 
degradation (213, 391). Seventh, the dimerization interface of A3G 126F-127W (247) is adjacent to 
the residue 128D that HIV Vif uses to interact with human A3G (305, 320, 392). In contrast, HIV 
Vif interacts with human A3F using different residues 289E (321) and 324E (322). Since the data 
presented in this thesis indicate that A3F and A3G forms a hetero-oligomeric A3 species it would 
be interesting to examine if Vif binding to the interface of A3F and/or A3G are concealed when 
A3F/G hetero-oligomers are formed and such overlapping might influence Vif induced ubiquitin 
ligase complex-mediated proteasomal degradation of A3F/G hetero-oligomers. 
In our study (chapter 3), we tried, but could not identify the oligomerization interface of 
A3F. In the case of A3G, amino acids 126F -127W form the dimerization interface (247). When we 
mutated equivalent residues in A3F (131Y-132W), we could not disrupt A3F’s oligomerization. This 
suggested that A3F might have different oligomerization interface. Moreover, we do not 
understand the A3F-A3G hetero-oligomerization interface. This knowledge is necessary to gain 
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greater insights into A3-A3 hetero-oligomerization and its anti-HIV role. Future studies are needed 
first to localize the A3F oligomerization interface, and second, to identify the oligomerization 
interface of the A3F/G hetero-oligomer. This knowledge will help in further characterizing the 
anti-HIV ability of hetero-oligomeric A3 species biochemically and in cell-based systems. 
Although there are numerous studies characterizing A3G oligomeric interfaces (246, 247, 349, 
350, 358, 393, 394), very little is known about the oligomerization interfaces of A3F (263, 388).  
The only A3F oligomerization interface data comes from A3F CTD crystal structures (263, 314, 
388). However, each structure has different interfaces suggesting these dimer interfaces are due to 
crystal packing and may not be accurate (387). As a result, further biochemical studies on A3F 
oligomerization are needed.  
A remarkable observation by Ping et al., 2016, provided in vivo evidence for an anti-HIV 
function of A3F in natural HIV infected cohorts (391). The authors reported that A3F I231V 
variant is resistant to Vif-induced ubiquitin-mediated proteasomal degradation from the HIV-1 
recombinant strains AE (recombinant of subtypes A and E) and BC (recombinant of subtypes B 
and C) (391). A3F I231V variant was associated with slow progression of AIDS in European 
American patients (391). These data suggest that the host-pathogen arms race between host factor 
A3F and HIV Vif is still on-going, similar to what has been found for A3H (272, 276). A3F and 
A3G differ with each other concerning their susceptibility to Vif. For example, Vif can better 
induce ubiquitin ligase complex-mediated proteasomal degradation of A3G than A3F (2)  and 
HIV-1 cannot easily evolve a Vif-independent mechanism to evade A3F, but HIV-1 evolves to 
overcome A3G restriction pressure (260). Moreover, humans have some A3F variants that are 
resistant to Vif-induced degradation (391). Based on these data one can speculate that HIV-1 
adapted to counter host factor A3G earlier than A3F. It is not clear if the distinct host-pathogen 
arms race (Vif susceptibility) as seen for A3F and A3G concerning HIV is the result of A3G being 
the predominant anti-HIV factor and A3F plays a supporting role or because A3F is a more recently 
evolved gene than A3G (207). The data presented in this thesis provide evidence in support of the 
first view by showing that A3F alone has less anti-HIV function compared to A3G alone and that 
A3F supports anti-HIV function of A3G by forming A3F/G hetero-oligomers. However, our data 
do not refute the possibility that A3F evolved more recently, as suggested by an 8-event model 
proposed by LaRue et al., 2008 for human A3 Z domain history (207). A3s have expanded and 
diverged throughout vertebrate evolution. This 8-event model took into account the present-day 
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human locus and identified the highly similar sequences within the A3 locus to find the footprints 
for recent recombination events. Based on the nearly homologous nucleotide sequences in the 
flanking regions of the present-day human A3 locus, the authors suggested that A3A, A3B, A3D 
and A3F originated following recent gene duplication events.  
Studies on integrated proviral genome sequences of HIV patients have shown that proviral 
DNA contains mutations at both 5’CC and 5’TC sequence contexts suggesting that multiple A3s 
can mutate the same genome (26, 366-372). Using shRNA-mediated knockdown of endogenous 
A3D or A3F or A3G in the CEM T-cell line, Refsland et al., 2012 provided the evidence for their 
anti-HIV role (19). Studies as this in primary CD4+ T-cells are lacking, partly due to the difficulty 
in reliably suppressing A3 expression using shRNA. However, recently a CRISPR/Cas9 
ribonucleoprotein technique has been developed for the knockout HIV-relevant molecules in 
human CD4+ T-cells (395). Future studies using this tool could examine the HIV restriction of 
A3G in the presence and absence of A3F to determine the extent to which the interaction we 
characterized in cell lines contributes to HIV restriction in primary cells. It would be interesting to 
use Cas9 ribonucleoprotein platform to target the desired A3 for investigating hetero-
oligomerization among other endogenous A3s in various combinations, including A3D/F, A3D/G, 
A3D/H, A3F/G, A3F/H, or A3G/H. In our preliminary study, we noted that unlike A3F, A3H did 
not bind with A3G when tested using rotational anisotropy (data not shown). In contrast, A3H 
could interact with A3F in the nanomolar range, similar to the strength of the A3F/G interaction 
(data not shown). Future studies with other A3s are needed to address these issues and to 
investigate whether such hetero-oligomerization confer any advantage in vivo.  
Further studies will enhance our knowledge on unique hetero-oligomeric A3 species and 
their role in HIV restriction. Studies such as this may reconcile previous literature that found less 
activity for A3F. It might be that A3F was not effective if sufficient levels of A3G were not present 
in the cell. The study presented in this thesis suggests new avenues of inquiry on different A3s 
hetero-oligomers relevant to HIV restriction.  
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CHAPTER 7: OVERALL CONCLUSIONS  
In summary, my research has furthered understanding of the mechanisms of A3F- and 
A3G- mediated HIV restriction, i.e., how these enzymes act within the HIV lifecycle, and how 
these enzymes interact with each other. We have systematically dissected the mechanisms by 
which A3F and A3G can collectively impact the various stages of HIV infection. We demonstrate 
that the processive DNA scanning mechanism and preferred deamination motif (A3F, 5'TTC; A3G 
5'CCC) are responsible for differential anti-HIV function of A3F and A3G. Further, we provide 
evidence that A3F and A3G in cells can form a hetero-oligomer in an RNA-independent manner 
generating an A3 species with unique properties from the individual enzymes. We hypothesize 
that other A3s may also hetero-oligomerize and cooperate to restrict HIV. All together our data 
identify hetero-oligomerization as a potential mechanism that may contribute to enhanced activity 
of A3s and predicts that we may still not fully realize all the antiviral mechanisms of endogenous 
A3 enzymes. 
 
 
 
 
 
 
 
 
 158 
 
REFERENCES  
1. E. Britan-Rosich, R. Nowarski, M. Kotler, Multifaceted counter-APOBEC3G mechanisms 
employed by HIV-1 Vif. J Mol Biol 410, 1065-1076. 
2. M. T. Liddament, W. L. Brown, A. J. Schumacher, R. S. Harris, APOBEC3F properties 
and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol 14, 1385-
1391 (2004). 
3. T. Ikeda et al., Creation of chimeric human/rabbit APOBEC1 with HIV-1 restriction and 
DNA mutation activities. Sci Rep 6, 19035 (2016). 
4. Y. Sato et al., Deficiency in APOBEC2 leads to a shift in muscle fiber type, diminished 
body mass, and myopathy. J Biol Chem 285, 7111-7118. 
5. L. Chelico, P. Pham, J. Petruska, M. F. Goodman, Biochemical basis of immunological 
and retroviral responses to DNA-targeted cytosine deamination by activation-induced 
cytidine deaminase and APOBEC3G. J Biol Chem 284, 27761-27765 (2009). 
6. A. M. Sheehy, N. C. Gaddis, J. D. Choi, M. H. Malim, Isolation of a human gene that 
inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646-650 
(2002). 
7. Y. L. Chiu, W. C. Greene, The APOBEC3 cytidine deaminases: an innate defensive 
network opposing exogenous retroviruses and endogenous retroelements. Annu Rev 
Immunol 26, 317-353 (2008). 
8. V. C. Vieira, M. A. Soares, The role of cytidine deaminases on innate immune responses 
against human viral infections. BioMed research international 2013, 683095 (2013). 
9. M. Monajemi, C. F. Woodworth, J. Benkaroun, M. Grant, M. Larijani, Emerging 
complexities of APOBEC3G action on immunity and viral fitness during HIV infection 
and treatment. Retrovirology 9, 35 (2012). 
10. M. Imahashi, M. Nakashima, Y. Iwatani, Antiviral Mechanism and Biochemical Basis of 
the Human APOBEC3 Family. Frontiers in microbiology 3, 250 (2012). 
 159 
 
11. G. Dranoff, Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4, 11-
22 (2004). 
12. B. A. Desimmie et al., Multiple APOBEC3 restriction factors for HIV-1 and one Vif to 
rule them all. J Mol Biol 426, 1220-1245 (2014). 
13. R. S. Harris, J. P. Dudley, APOBECs and virus restriction. Virology 479-480, 131-145 
(2015). 
14. R. S. Harris, B. D. Anderson, Evolutionary Paradigms from Ancient and Ongoing Conflicts 
between the Lentiviral Vif Protein and Mammalian APOBEC3 Enzymes. PLoS pathogens 
12, e1005958 (2016). 
15. A. M. Sheehy, N. C. Gaddis, M. H. Malim, The antiretroviral enzyme APOBEC3G is 
degraded by the proteasome in response to HIV-1 Vif. Nat Med 9, 1404-1407 (2003). 
16. M. Marin, K. M. Rose, S. L. Kozak, D. Kabat, HIV-1 Vif protein binds the editing enzyme 
APOBEC3G and induces its degradation. Nat Med 9, 1398-1403 (2003). 
17. M. J. Wichroski, G. B. Robb, T. M. Rana, Human retroviral host restriction factors 
APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS Pathog 2, e41 
(2006). 
18. E. W. Refsland et al., Quantitative profiling of the full APOBEC3 mRNA repertoire in 
lymphocytes and tissues: implications for HIV-1 restriction. Nucleic acids research 38, 
4274-4284 (2010). 
19. E. W. Refsland, J. F. Hultquist, R. S. Harris, Endogenous origins of HIV-1 G-to-A 
hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS pathogens 8, 
e1002800 (2012). 
20. A. Rathore et al., The local dinucleotide preference of APOBEC3G can be altered from 5'-
CC to 5'-TC by a single amino acid substitution. J Mol Biol 425, 4442-4454 (2013). 
21. K. N. Bishop et al., Cytidine deamination of retroviral DNA by diverse APOBEC proteins. 
Curr Biol 14, 1392-1396 (2004). 
 160 
 
22. V. Zennou, P. D. Bieniasz, Comparative analysis of the antiretroviral activity of 
APOBEC3G and APOBEC3F from primates. Virology 349, 31-40 (2006). 
23. Y. H. Zheng et al., Human APOBEC3F is another host factor that blocks human 
immunodeficiency virus type 1 replication. J Virol 78, 6073-6076 (2004). 
24. H. L. Wiegand, B. P. Doehle, H. P. Bogerd, B. R. Cullen, A second human antiretroviral 
factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J 23, 
2451-2458 (2004). 
25. A. M. Land et al., Human immunodeficiency virus (HIV) type 1 proviral hypermutation 
correlates with CD4 count in HIV-infected women from Kenya. J Virol 82, 8172-8182 
(2008). 
26. C. Pace et al., Population level analysis of human immunodeficiency virus type 1 
hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol 80, 
9259-9269 (2006). 
27. J. A. Vazquez-Perez, C. E. Ormsby, R. Hernandez-Juan, K. J. Torres, G. Reyes-Teran, 
APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected 
individuals decreases with removal of exposure and with disease progression. 
Retrovirology 6, 23 (2009). 
28. X. Jin et al., APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human 
immunodeficiency virus viremia. J Virol 79, 11513-11516 (2005). 
29. M. Biasin et al., Apolipoprotein B mRNA-Editing Enzyme, Catalytic Polypeptide-Like 
3G: A Possible Role in the Resistance to HIV of HIV-Exposed Seronegative Individuals. 
J Infect Dis 195, 960-964 (2007). 
30. N. K. Ulenga et al., Relationship between human immunodeficiency type 1 infection and 
expression of human APOBEC3G and APOBEC3F. J Infect Dis 198, 486-492 (2008). 
31. F. A. Koning et al., Defining APOBEC3 expression patterns in human tissues and 
hematopoietic cell subsets. Journal of virology 83, 9474-9485 (2009). 
 161 
 
32. E. W. Refsland et al., Quantitative profiling of the full APOBEC3 mRNA repertoire in 
lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res,  (2010). 
33. K. M. Bruner et al., Defective proviruses rapidly accumulate during acute HIV-1 infection. 
Nat Med 22, 1043-1049 (2016). 
34. J. F. Arias, T. Koyama, M. Kinomoto, K. Tokunaga, Retroelements versus APOBEC3 
family members: No great escape from the magnificent seven. Front Microbiol 3, 275 
(2012). 
35. R. Cordaux, M. A. Batzer, The impact of retrotransposons on human genome evolution. 
Nat Rev Genet 10, 691-703 (2009). 
36. P. L. Deininger, M. A. Batzer, Mammalian retroelements. Genome Res 12, 1455-1465 
(2002). 
37. E. M. Ostertag, J. L. Goodier, Y. Zhang, H. H. Kazazian, Jr., SVA elements are 
nonautonomous retrotransposons that cause disease in humans. Am J Hum Genet 73, 1444-
1451 (2003). 
38. D. Ribet, M. Dewannieux, T. Heidmann, An active murine transposon family pair: 
retrotransposition of "master" MusD copies and ETn trans-mobilization. Genome Res 14, 
2261-2267 (2004). 
39. M. Dewannieux, A. Dupressoir, F. Harper, G. Pierron, T. Heidmann, Identification of 
autonomous IAP LTR retrotransposons mobile in mammalian cells. Nat Genet 36, 534-
539 (2004). 
40. Y. N. Lee, P. D. Bieniasz, Reconstitution of an infectious human endogenous retrovirus. 
PLoS pathogens 3, e10 (2007). 
41. S. R. Ross, Mouse mammary tumor virus molecular biology and oncogenesis. Viruses 2, 
2000-2012 (2010). 
42. A. Rein, Murine leukemia viruses: objects and organisms. Adv Virol 2011, 403419 (2011). 
43. O. C. Straub, Maedi-Visna virus infection in sheep. History and present knowledge. Comp 
Immunol Microbiol Infect Dis 27, 1-5 (2004). 
 162 
 
44. V. M. Vogt, Retroviral virions and genomes. In:  Retroviruses, J.M. Coffin, S.H. Hughes 
and H.E. Varmus (Eds).  (Cold Spring Harbor Laboratory 
Press, 1997), pp. 27-70. 
45. F. H. Lin, H. Thormar, On visna virus: purification and nucleic acid content. Virology 42, 
1140-1143 (1970). 
46. A. T. Haase, The slow infection caused by visna virus. Curr Top Microbiol Immunol 72, 
101-156 (1975). 
47. P. M. Sharp, B. H. Hahn, Origins of HIV and the AIDS pandemic. Cold Spring Harb 
Perspect Med 1, a006841 (2011). 
48. C. Centers for Disease, Kaposi's sarcoma and Pneumocystis pneumonia among 
homosexual men--New York City and California. MMWR Morb Mortal Wkly Rep 30, 305-
308 (1981). 
49. W. C. Greene, A history of AIDS: looking back to see ahead. Eur J Immunol 37 Suppl 1, 
S94-102 (2007). 
50. L. Chakrabarti et al., Sequence of simian immunodeficiency virus from macaque and its 
relationship to other human and simian retroviruses. Nature 328, 543-547 (1987). 
51. M. Guyader et al., Genome organization and transactivation of the human 
immunodeficiency virus type 2. Nature 326, 662-669 (1987). 
52. F. Clavel et al., Isolation of a new human retrovirus from West African patients with AIDS. 
Science 233, 343-346 (1986). 
53. T. Huet, R. Cheynier, A. Meyerhans, G. Roelants, S. Wain-Hobson, Genetic organization 
of a chimpanzee lentivirus related to HIV-1. Nature 345, 356-359 (1990). 
54. V. M. Hirsch, R. A. Olmsted, M. Murphey-Corb, R. H. Purcell, P. R. Johnson, An African 
primate lentivirus (SIVsm) closely related to HIV-2. Nature 339, 389-392 (1989). 
55. B. H. Hahn, G. M. Shaw, K. M. De Cock, P. M. Sharp, AIDS as a zoonosis: scientific and 
public health implications. Science 287, 607-614 (2000). 
 163 
 
56. J. C. Plantier et al., A new human immunodeficiency virus derived from gorillas. Nat Med 
15, 871-872 (2009). 
57. F. Simon et al., Identification of a new human immunodeficiency virus type 1 distinct from 
group M and group O. Nat Med 4, 1032-1037 (1998). 
58. P. M. Sharp, B. H. Hahn, AIDS: prehistory of HIV-1. Nature 455, 605-606 (2008). 
59. M. Peeters et al., Geographical distribution of HIV-1 group O viruses in Africa. AIDS 11, 
493-498 (1997). 
60. A. Vallari et al., Four new HIV-1 group N isolates from Cameroon: Prevalence continues 
to be low. AIDS Res Hum Retroviruses 26, 109-115 (2010). 
61. A. Vallari et al., Confirmation of putative HIV-1 group P in Cameroon. Journal of virology 
85, 1403-1407 (2011). 
62. D. L. Robertson et al., HIV-1 nomenclature proposal. Science 288, 55-56 (2000). 
63. B. S. Taylor, S. M. Hammer, The challenge of HIV-1 subtype diversity. N Engl J Med 359, 
1965-1966 (2008). 
64. M. T. Gilbert et al., The emergence of HIV/AIDS in the Americas and beyond. Proc Natl 
Acad Sci U S A 104, 18566-18570 (2007). 
65. J. Hemelaar et al., Global trends in molecular epidemiology of HIV-1 during 2000-2007. 
AIDS 25, 679-689 (2011). 
66. O. T. Campbell-Yesufu, R. T. Gandhi, Update on human immunodeficiency virus (HIV)-
2 infection. Clin Infect Dis 52, 780-787 (2011). 
67. T. I. de Silva, M. Cotten, S. L. Rowland-Jones, HIV-2: the forgotten AIDS virus. Trends 
Microbiol 16, 588-595 (2008). 
68. R. Marlink et al., Reduced rate of disease development after HIV-2 infection as compared 
to HIV-1. Science 265, 1587-1590 (1994). 
69. S. J. Popper et al., Lower human immunodeficiency virus (HIV) type 2 viral load reflects 
the difference in pathogenicity of HIV-1 and HIV-2. J Infect Dis 180, 1116-1121 (1999). 
 164 
 
70. P. J. Kanki et al., Slower heterosexual spread of HIV-2 than HIV-1. Lancet 343, 943-946 
(1994). 
71. D. O'Donovan et al., Maternal plasma viral RNA levels determine marked differences in 
mother-to-child transmission rates of HIV-1 and HIV-2 in The Gambia. MRC/Gambia 
Government/University College London Medical School working group on mother-child 
transmission of HIV. AIDS 14, 441-448 (2000). 
72. S. Hallenberger et al., Inhibition of furin-mediated cleavage activation of HIV-1 
glycoprotein gp160. Nature 360, 358-361 (1992). 
73. L. Li, H. S. Li, C. D. Pauza, M. Bukrinsky, R. Y. Zhao, Roles of HIV-1 auxiliary proteins 
in viral pathogenesis and host-pathogen interactions. Cell Res 15, 923-934 (2005). 
74. J. M. Watts et al., Architecture and secondary structure of an entire HIV-1 RNA genome. 
Nature 460, 711-716 (2009). 
75. R. Amorim, S. M. Costa, N. P. Cavaleiro, E. E. da Silva, L. J. da Costa, HIV-1 transcripts 
use IRES-initiation under conditions where Cap-dependent translation is restricted by 
poliovirus 2A protease. PloS one 9, e88619 (2014). 
76. G. Li, E. De Clercq, HIV Genome-Wide Protein Associations: a Review of 30 Years of 
Research. Microbiol Mol Biol Rev 80, 679-731 (2016). 
77. R. Wyatt, J. Sodroski, The HIV-1 envelope glycoproteins: fusogens, antigens, and 
immunogens. Science 280, 1884-1888 (1998). 
78. E. Helseth, U. Olshevsky, C. Furman, J. Sodroski, Human immunodeficiency virus type 1 
gp120 envelope glycoprotein regions important for association with the gp41 
transmembrane glycoprotein. Journal of virology 65, 2119-2123 (1991). 
79. J. G. Levin, J. Guo, I. Rouzina, K. Musier-Forsyth, Nucleic acid chaperone activity of HIV-
1 nucleocapsid protein: critical role in reverse transcription and molecular mechanism. 
Prog Nucleic Acid Res Mol Biol 80, 217-286 (2005). 
 165 
 
80. X. J. Yao, G. Kobinger, S. Dandache, N. Rougeau, E. Cohen, HIV-1 Vpr-chloramphenicol 
acetyltransferase fusion proteins: sequence requirement for virion incorporation and 
analysis of antiviral effect. Gene Ther 6, 1590-1599 (1999). 
81. E. Chertova et al., Proteomic and biochemical analysis of purified human 
immunodeficiency virus type 1 produced from infected monocyte-derived macrophages. 
Journal of virology 80, 9039-9052 (2006). 
82. L. Kleiman, R. Halwani, H. Javanbakht, The selective packaging and annealing of primer 
tRNALys3 in HIV-1. Curr HIV Res 2, 163-175 (2004). 
83. D. E. Ott et al., Cytoskeletal proteins inside human immunodeficiency virus type 1 virions. 
Journal of virology 70, 7734-7743 (1996). 
84. S. J. Rulli, Jr. et al., Selective and nonselective packaging of cellular RNAs in retrovirus 
particles. Journal of virology 81, 6623-6631 (2007). 
85. X. Wang et al., Moloney leukemia virus 10 (MOV10) protein inhibits retrovirus 
replication. The Journal of biological chemistry 285, 14346-14355 (2010). 
86. A. Telesnitsky, S. L. Wolin, The Host RNAs in Retroviral Particles. Viruses 8,  (2016). 
87. E. O. Freed, HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 251, 1-
15 (1998). 
88. N. M. Bell, A. M. Lever, HIV Gag polyprotein: processing and early viral particle 
assembly. Trends Microbiol 21, 136-144 (2013). 
89. J. Bhattacharya, A. Repik, P. R. Clapham, Gag regulates association of human 
immunodeficiency virus type 1 envelope with detergent-resistant membranes. Journal of 
virology 80, 5292-5300 (2006). 
90. R. H. Ghanam, A. B. Samal, T. F. Fernandez, J. S. Saad, Role of the HIV-1 Matrix Protein 
in Gag Intracellular Trafficking and Targeting to the Plasma Membrane for Virus 
Assembly. Front Microbiol 3, 55 (2012). 
91. M. Bukrinsky, A hard way to the nucleus. Mol Med 10, 1-5 (2004). 
 166 
 
92. R. Peytavi et al., HEED, the product of the human homolog of the murine eed gene, binds 
to the matrix protein of HIV-1. The Journal of biological chemistry 274, 1635-1645 (1999). 
93. U. von Schwedler, R. S. Kornbluth, D. Trono, The nuclear localization signal of the matrix 
protein of human immunodeficiency virus type 1 allows the establishment of infection in 
macrophages and quiescent T lymphocytes. Proc Natl Acad Sci U S A 91, 6992-6996 
(1994). 
94. S. B. Kutluay et al., Global changes in the RNA binding specificity of HIV-1 gag regulate 
virion genesis. Cell 159, 1096-1109 (2014). 
95. J. L. Darlix, J. L. Garrido, N. Morellet, Y. Mely, H. de Rocquigny, Properties, functions, 
and drug targeting of the multifunctional nucleocapsid protein of the human 
immunodeficiency virus. Adv Pharmacol 55, 299-346 (2007). 
96. D. Muriaux, J. L. Darlix, Properties and functions of the nucleocapsid protein in virus 
assembly. RNA Biol 7, 744-753 (2010). 
97. J. S. Buckman, W. J. Bosche, R. J. Gorelick, Human immunodeficiency virus type 1 
nucleocapsid zn(2+) fingers are required for efficient reverse transcription, initial 
integration processes, and protection of newly synthesized viral DNA. Journal of virology 
77, 1469-1480 (2003). 
98. J. G. Levin, M. Mitra, A. Mascarenhas, K. Musier-Forsyth, Role of HIV-1 nucleocapsid 
protein in HIV-1 reverse transcription. RNA Biol 7, 754-774 (2010). 
99. Y. Usami et al., The ESCRT pathway and HIV-1 budding. Biochem Soc Trans 37, 181-
184 (2009). 
100. E. Kondo, F. Mammano, E. A. Cohen, H. G. Gottlinger, The p6gag domain of human 
immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous 
viral particles. Journal of virology 69, 2759-2764 (1995). 
101. X. J. Yao et al., Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of 
a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion 
incorporation. Journal of virology 69, 7032-7044 (1995). 
 167 
 
102. P. M. Colman, M. C. Lawrence, The structural biology of type I viral membrane fusion. 
Nat Rev Mol Cell Biol 4, 309-319 (2003). 
103. M. Hill, G. Tachedjian, J. Mak, The packaging and maturation of the HIV-1 Pol proteins. 
Curr HIV Res 3, 73-85 (2005). 
104. A. Jacobo-Molina, E. Arnold, HIV reverse transcriptase structure-function relationships. 
Biochemistry 30, 6351-6356 (1991). 
105. S. C. Pettit, J. N. Lindquist, A. H. Kaplan, R. Swanstrom, Processing sites in the human 
immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral 
protease at different rates. Retrovirology 2, 66 (2005). 
106. A. Brik, C. H. Wong, HIV-1 protease: mechanism and drug discovery. Org Biomol Chem 
1, 5-14 (2003). 
107. R. L. Shoeman, C. Huttermann, R. Hartig, P. Traub, Amino-terminal polypeptides of 
vimentin are responsible for the changes in nuclear architecture associated with human 
immunodeficiency virus type 1 protease activity in tissue culture cells. Mol Biol Cell 12, 
143-154 (2001). 
108. P. R. Strack et al., Apoptosis mediated by HIV protease is preceded by cleavage of Bcl-2. 
Proc Natl Acad Sci U S A 93, 9571-9576 (1996). 
109. S. P. Goff, Retroviral reverse transcriptase: synthesis, structure, and function. J Acquir 
Immune Defic Syndr 3, 817-831 (1990). 
110. S. G. Sarafianos et al., Structure and function of HIV-1 reverse transcriptase: molecular 
mechanisms of polymerization and inhibition. J Mol Biol 385, 693-713 (2009). 
111. V. R. Prasad, S. P. Goff, Structure-function studies of HIV reverse transcriptase. Ann N Y 
Acad Sci 616, 11-21 (1990). 
112. A. Herschhorn, A. Hizi, Retroviral reverse transcriptases. Cell Mol Life Sci 67, 2717-2747 
(2010). 
113. T. K. Chiu, D. R. Davies, Structure and function of HIV-1 integrase. Curr Top Med Chem 
4, 965-977 (2004). 
 168 
 
114. T. Masuda, Non-Enzymatic Functions of Retroviral Integrase: The Next Target for Novel 
Anti-HIV Drug Development. Front Microbiol 2, 210 (2011). 
115. T. Takahata et al., Critical Contribution of Tyr15 in the HIV-1 Integrase (IN) in Facilitating 
IN Assembly and Nonenzymatic Function through the IN Precursor Form with Reverse 
Transcriptase. Journal of virology 91,  (2017). 
116. A. Engelman, G. Englund, J. M. Orenstein, M. A. Martin, R. Craigie, Multiple effects of 
mutations in human immunodeficiency virus type 1 integrase on viral replication. Journal 
of virology 69, 2729-2736 (1995). 
117. A. W. Cochrane, A. Perkins, C. A. Rosen, Identification of sequences important in the 
nucleolar localization of human immunodeficiency virus Rev: relevance of nucleolar 
localization to function. Journal of virology 64, 881-885 (1990). 
118. M. Fornerod, M. Ohno, M. Yoshida, I. W. Mattaj, CRM1 is an export receptor for leucine-
rich nuclear export signals. Cell 90, 1051-1060 (1997). 
119. H. C. Groom, E. C. Anderson, A. M. Lever, Rev: beyond nuclear export. J Gen Virol 90, 
1303-1318 (2009). 
120. B. Grewe, K. Uberla, The human immunodeficiency virus type 1 Rev protein: menage a 
trois during the early phase of the lentiviral replication cycle. J Gen Virol 91, 1893-1897 
(2010). 
121. S. Roy, U. Delling, C. H. Chen, C. A. Rosen, N. Sonenberg, A bulge structure in HIV-1 
TAR RNA is required for Tat binding and Tat-mediated trans-activation. Genes Dev 4, 
1365-1373 (1990). 
122. R. C. Gallo, Tat as one key to HIV-induced immune pathogenesis and Tat (correction of 
Pat) toxoid as an important component of a vaccine. Proc Natl Acad Sci U S A 96, 8324-
8326 (1999). 
123. J. M. Sabatier et al., Evidence for neurotoxic activity of tat from human immunodeficiency 
virus type 1. Journal of virology 65, 961-967 (1991). 
 169 
 
124. S. Henriet, G. Mercenne, S. Bernacchi, J. C. Paillart, R. Marquet, Tumultuous relationship 
between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the 
human APOBEC-3G and APOBEC-3F restriction factors. Microbiol Mol Biol Rev 73, 211-
232 (2009). 
125. R. D. Sloan, D. A. Donahue, B. D. Kuhl, T. Bar-Magen, M. A. Wainberg, Expression of 
Nef from unintegrated HIV-1 DNA downregulates cell surface CXCR4 and CCR5 on T-
lymphocytes. Retrovirology 7, 44 (2010). 
126. N. Michel, I. Allespach, S. Venzke, O. T. Fackler, O. T. Keppler, The Nef protein of human 
immunodeficiency virus establishes superinfection immunity by a dual strategy to 
downregulate cell-surface CCR5 and CD4. Curr Biol 15, 714-723 (2005). 
127. S. Venzke, N. Michel, I. Allespach, O. T. Fackler, O. T. Keppler, Expression of Nef 
downregulates CXCR4, the major coreceptor of human immunodeficiency virus, from the 
surfaces of target cells and thereby enhances resistance to superinfection. Journal of 
virology 80, 11141-11152 (2006). 
128. O. O. Yang et al., Nef-mediated resistance of human immunodeficiency virus type 1 to 
antiviral cytotoxic T lymphocytes. Journal of virology 76, 1626-1631 (2002). 
129. A. Rosa et al., HIV-1 Nef promotes infection by excluding SERINC5 from virion 
incorporation. Nature 526, 212-217 (2015). 
130. Y. Usami, Y. Wu, H. G. Gottlinger, SERINC3 and SERINC5 restrict HIV-1 infectivity and 
are counteracted by Nef. Nature 526, 218-223 (2015). 
131. W. B. Dyer et al., Lymphoproliferative immune function in the Sydney Blood Bank 
Cohort, infected with natural nef/long terminal repeat mutants, and in other long-term 
survivors of transfusion-acquired HIV-1 infection. AIDS 11, 1565-1574 (1997). 
132. M. Mikhail, B. Wang, N. K. Saksena, Mechanisms involved in non-progressive HIV 
disease. AIDS Rev 5, 230-244 (2003). 
133. K. Levesque, Y. S. Zhao, E. A. Cohen, Vpu exerts a positive effect on HIV-1 infectivity 
by down-modulating CD4 receptor molecules at the surface of HIV-1-producing cells. The 
Journal of biological chemistry 278, 28346-28353 (2003). 
 170 
 
134. F. Margottin et al., A novel human WD protein, h-beta TrCp, that interacts with HIV-1 
Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell 1, 
565-574 (1998). 
135. M. Tanaka et al., Downregulation of CD4 is required for maintenance of viral infectivity 
of HIV-1. Virology 311, 316-325 (2003). 
136. S. J. Neil, S. W. Eastman, N. Jouvenet, P. D. Bieniasz, HIV-1 Vpu promotes release and 
prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS 
Pathog 2, e39 (2006). 
137. J. L. Douglas et al., Vpu directs the degradation of the human immunodeficiency virus 
restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism. Journal of 
virology 83, 7931-7947 (2009). 
138. P. Di Marzio, S. Choe, M. Ebright, R. Knoblauch, N. R. Landau, Mutational analysis of 
cell cycle arrest, nuclear localization and virion packaging of human immunodeficiency 
virus type 1 Vpr. Journal of virology 69, 7909-7916 (1995). 
139. N. Morellet, S. Bouaziz, P. Petitjean, B. P. Roques, NMR structure of the HIV-1 regulatory 
protein VPR. J Mol Biol 327, 215-227 (2003). 
140. K. D. Jayappa, Z. Ao, X. Yao, The HIV-1 passage from cytoplasm to nucleus: the process 
involving a complex exchange between the components of HIV-1 and cellular machinery 
to access nucleus and successful integration. Int J Biochem Mol Biol 3, 70-85 (2012). 
141. M. Kamata, Y. Nitahara-Kasahara, Y. Miyamoto, Y. Yoneda, Y. Aida, Importin-alpha 
promotes passage through the nuclear pore complex of human immunodeficiency virus 
type 1 Vpr. J Virol 79, 3557-3564 (2005). 
142. Y. Nitahara-Kasahara et al., Novel nuclear import of Vpr promoted by importin alpha is 
crucial for human immunodeficiency virus type 1 replication in macrophages. J Virol 81, 
5284-5293 (2007). 
143. Y. Jenkins, M. McEntee, K. Weis, W. C. Greene, Characterization of HIV-1 vpr nuclear 
import: analysis of signals and pathways. J Cell Biol 143, 875-885 (1998). 
 171 
 
144. S. Mahalingam, V. Ayyavoo, M. Patel, T. Kieber-Emmons, D. B. Weiner, Nuclear import, 
virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional 
domains of human immunodeficiency virus type 1 Vpr. J Virol 71, 6339-6347 (1997). 
145. K. Muthumani et al., HIV-1 Vpr induces apoptosis through caspase 9 in T cells and 
peripheral blood mononuclear cells. J Biol Chem 277, 37820-37831 (2002). 
146. B. Trinite, C. N. Chan, C. S. Lee, D. N. Levy, HIV-1 Vpr- and Reverse Transcription-
Induced Apoptosis in Resting Peripheral Blood CD4 T Cells and Protection by Common 
Gamma-Chain Cytokines. J Virol 90, 904-916 (2015). 
147. R. Vanitharani et al., HIV-1 Vpr transactivates LTR-directed expression through 
sequences present within -278 to -176 and increases virus replication in vitro. Virology 
289, 334-342 (2001). 
148. L. K. Felzien et al., HIV transcriptional activation by the accessory protein, VPR, is 
mediated by the p300 co-activator. Proc Natl Acad Sci U S A 95, 5281-5286 (1998). 
149. J. P. Moore, R. W. Doms, The entry of entry inhibitors: a fusion of science and medicine. 
Proc Natl Acad Sci U S A 100, 10598-10602 (2003). 
150. C. B. Wilen, J. C. Tilton, R. W. Doms, HIV: cell binding and entry. Cold Spring Harb 
Perspect Med 2,  (2012). 
151. D. A. Jacques et al., HIV-1 uses dynamic capsid pores to import nucleotides and fuel 
encapsidated DNA synthesis. Nature 536, 349-353 (2016). 
152. C. Aiken, Viral and cellular factors that regulate HIV-1 uncoating. Curr Opin HIV AIDS 
1, 194-199 (2006). 
153. N. Arhel, Revisiting HIV-1 uncoating. Retrovirology 7, 96 (2010). 
154. R. S. Harris, J. F. Hultquist, D. T. Evans, The restriction factors of human 
immunodeficiency virus. J Biol Chem 287, 40875-40883 (2012). 
155. Y. Ma et al., Real-Time Imaging of Single HIV-1 Disassembly with Multicolor Viral 
Particles. ACS Nano 10, 6273-6282 (2016). 
 172 
 
156. S. F. Le Grice, Human immunodeficiency virus reverse transcriptase: 25 years of research, 
drug discovery, and promise. The Journal of biological chemistry 287, 40850-40857 
(2012). 
157. W. S. Hu, S. H. Hughes, HIV-1 reverse transcription. Cold Spring Harb Perspect Med 2,  
(2012). 
158. J. A. Thomas, R. J. Gorelick, Nucleocapsid protein function in early infection processes. 
Virus Res 134, 39-63 (2008). 
159. Y. Suzuki, R. Craigie, The road to chromatin - nuclear entry of retroviruses. Nat Rev 
Microbiol 5, 187-196 (2007). 
160. M. J. Roth, P. L. Schwartzberg, S. P. Goff, Structure of the termini of DNA intermediates 
in the integration of retroviral DNA: dependence on IN function and terminal DNA 
sequence. Cell 58, 47-54 (1989). 
161. P. O. Brown, B. Bowerman, H. E. Varmus, J. M. Bishop, Retroviral integration: structure 
of the initial covalent product and its precursor, and a role for the viral IN protein. Proc 
Natl Acad Sci U S A 86, 2525-2529 (1989). 
162. L. Krishnan, A. Engelman, Retroviral integrase proteins and HIV-1 DNA integration. J 
Biol Chem 287, 40858-40866 (2012). 
163. R. Craigie, F. D. Bushman, HIV DNA integration. Cold Spring Harb Perspect Med 2, 
a006890 (2012). 
164. B. Van Maele, Z. Debyser, HIV-1 integration: an interplay between HIV-1 integrase, 
cellular and viral proteins. AIDS Rev 7, 26-43 (2005). 
165. O. Jegede et al., HIV type 1 integrase inhibitors: from basic research to clinical 
implications. AIDS Rev 10, 172-189 (2008). 
166. M. Ott, M. Geyer, Q. Zhou, The control of HIV transcription: keeping RNA polymerase II 
on track. Cell Host Microbe 10, 426-435 (2011). 
167. J. Karn, C. M. Stoltzfus, Transcriptional and posttranscriptional regulation of HIV-1 gene 
expression. Cold Spring Harb Perspect Med 2, a006916 (2012). 
 173 
 
168. B. G. Turner, M. F. Summers, Structural biology of HIV. J Mol Biol 285, 1-32 (1999). 
169. B. K. Ganser-Pornillos, M. Yeager, W. I. Sundquist, The structural biology of HIV 
assembly. Curr Opin Struct Biol 18, 203-217 (2008). 
170. N. Jouvenet et al., Plasma membrane is the site of productive HIV-1 particle assembly. 
PLoS Biol 4, e435 (2006). 
171. W. Muranyi, S. Malkusch, B. Muller, M. Heilemann, H. G. Krausslich, Super-resolution 
microscopy reveals specific recruitment of HIV-1 envelope proteins to viral assembly sites 
dependent on the envelope C-terminal tail. PLoS pathogens 9, e1003198 (2013). 
172. N. K. Duggal, M. Emerman, Evolutionary conflicts between viruses and restriction factors 
shape immunity. Nat Rev Immunol 12, 687-695 (2012). 
173. D. Blanco-Melo, S. Venkatesh, P. D. Bieniasz, Intrinsic cellular defenses against human 
immunodeficiency viruses. Immunity 37, 399-411 (2012). 
174. W. E. Johnson, S. L. Sawyer, Molecular evolution of the antiretroviral TRIM5 gene. 
Immunogenetics 61, 163-176 (2009). 
175. D. Wolf, S. P. Goff, Host restriction factors blocking retroviral replication. Annu Rev Genet 
42, 143-163 (2008). 
176. H. Lahouassa et al., SAMHD1 restricts the replication of human immunodeficiency virus 
type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol 
13, 223-228 (2012). 
177. C. J. Spragg, M. Emerman, Antagonism of SAMHD1 is actively maintained in natural 
infections of simian immunodeficiency virus. Proc Natl Acad Sci U S A 110, 21136-21141 
(2013). 
178. J. S. Albin, R. S. Harris, Interactions of host APOBEC3 restriction factors with HIV-1 in 
vivo: implications for therapeutics. Expert Rev Mol Med 12, e4 (2010). 
179. B. D. Anderson, R. S. Harris, Transcriptional regulation of APOBEC3 antiviral immunity 
through the CBF-beta/RUNX axis. Sci Adv 1, e1500296 (2015). 
 174 
 
180. G. Berger et al., APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection 
in myeloid cells. PLoS pathogens 7, e1002221 (2011). 
181. B. K. Thielen et al., Innate immune signaling induces high levels of TC-specific deaminase 
activity in primary monocyte-derived cells through expression of APOBEC3A isoforms. 
The Journal of biological chemistry 285, 27753-27766 (2010). 
182. M. H. Malim, M. Emerman, HIV-1 accessory proteins--ensuring viral survival in a hostile 
environment. Cell Host Microbe 3, 388-398 (2008). 
183. M. Stremlau et al., The cytoplasmic body component TRIM5alpha restricts HIV-1 
infection in Old World monkeys. Nature 427, 848-853 (2004). 
184. M. Stremlau et al., Specific recognition and accelerated uncoating of retroviral capsids by 
the TRIM5alpha restriction factor. Proc Natl Acad Sci U S A 103, 5514-5519 (2006). 
185. T. Pertel et al., TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 
472, 361-365 (2011). 
186. M. H. Malim, P. D. Bieniasz, HIV Restriction Factors and Mechanisms of Evasion. Cold 
Spring Harb Perspect Med 2, a006940 (2012). 
187. C. E. Jones, A. McKnight, Retroviral restriction: nature's own solution. Curr Opin Infect 
Dis 29, 609-614 (2016). 
188. Y. H. Zheng, K. T. Jeang, K. Tokunaga, Host restriction factors in retroviral infection: 
promises in virus-host interaction. Retrovirology 9, 112 (2012). 
189. T. E. White et al., Contribution of SAM and HD domains to retroviral restriction mediated 
by human SAMHD1. Virology 436, 81-90 (2013). 
190. D. C. Goldstone et al., HIV-1 restriction factor SAMHD1 is a deoxynucleoside 
triphosphate triphosphohydrolase. Nature 480, 379-382 (2011). 
191. N. Laguette et al., SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction 
factor counteracted by Vpx. Nature 474, 654-657 (2011). 
192. K. Hrecka et al., Vpx relieves inhibition of HIV-1 infection of macrophages mediated by 
the SAMHD1 protein. Nature 474, 658-661 (2011). 
 175 
 
193. S. J. Neil, T. Zang, P. D. Bieniasz, Tetherin inhibits retrovirus release and is antagonized 
by HIV-1 Vpu. Nature 451, 425-430 (2008). 
194. N. Van Damme et al., The interferon-induced protein BST-2 restricts HIV-1 release and is 
downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3, 245-
252 (2008). 
195. K. Fitzpatrick et al., Direct restriction of virus release and incorporation of the interferon-
induced protein BST-2 into HIV-1 particles. PLoS pathogens 6, e1000701 (2010). 
196. F. Kirchhoff, Immune evasion and counteraction of restriction factors by HIV-1 and other 
primate lentiviruses. Cell Host Microbe 8, 55-67 (2010). 
197. F. Zhang et al., SIV Nef proteins recruit the AP-2 complex to antagonize Tetherin and 
facilitate virion release. PLoS pathogens 7, e1002039 (2011). 
198. A. Le Tortorec, S. J. Neil, Antagonism to and intracellular sequestration of human tetherin 
by the human immunodeficiency virus type 2 envelope glycoprotein. Journal of virology 
83, 11966-11978 (2009). 
199. D. H. Gabuzda et al., Role of vif in replication of human immunodeficiency virus type 1 
in CD4+ T lymphocytes. Journal of virology 66, 6489-6495 (1992). 
200. U. von Schwedler, J. Song, C. Aiken, D. Trono, Vif is crucial for human immunodeficiency 
virus type 1 proviral DNA synthesis in infected cells. Journal of virology 67, 4945-4955 
(1993). 
201. A. Jarmuz et al., An anthropoid-specific locus of orphan C to U RNA-editing enzymes on 
chromosome 22. Genomics 79, 285-296 (2002). 
202. R. S. Harris, S. K. Petersen-Mahrt, M. S. Neuberger, RNA editing enzyme APOBEC1 and 
some of its homologs can act as DNA mutators. Mol Cell 10, 1247-1253 (2002). 
203. M. B. Adolph et al., Cytidine deaminase efficiency of the lentiviral viral restriction factor 
APOBEC3C correlates with dimerization. Nucleic acids research,  (2017). 
204. H. Xu et al., Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions. Virology 
360, 247-256 (2007). 
 176 
 
205. R. Nowarski, E. Britan-Rosich, T. Shiloach, M. Kotler, Hypermutation by intersegmental 
transfer of APOBEC3G cytidine deaminase. Nat Struct Mol Biol 15, 1059-1066 (2008). 
206. F. A. Koning, C. Goujon, H. Bauby, M. H. Malim, Target cell-mediated editing of HIV-1 
cDNA by APOBEC3 proteins in human macrophages. Journal of virology 85, 13448-
13452 (2011). 
207. R. S. LaRue et al., The artiodactyl APOBEC3 innate immune repertoire shows evidence 
for a multi-functional domain organization that existed in the ancestor of placental 
mammals. BMC Mol Biol 9, 104 (2008). 
208. M. S. Neuberger, R. S. Harris, J. Di Noia, S. K. Petersen-Mahrt, Immunity through DNA 
deamination. Trends Biochem Sci 28, 305-312 (2003). 
209. R. S. Harris, M. T. Liddament, Retroviral restriction by APOBEC proteins. Nat Rev 
Immunol 4, 868-877 (2004). 
210. R. S. LaRue et al., Guidelines for naming nonprimate APOBEC3 genes and proteins. 
Journal of virology 83, 494-497 (2009). 
211. G. Hache, M. T. Liddament, R. S. Harris, The retroviral hypermutation specificity of 
APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase 
domain. The Journal of biological chemistry 280, 10920-10924 (2005). 
212. F. Navarro et al., Complementary function of the two catalytic domains of APOBEC3G. 
Virology 333, 374-386 (2005). 
213. Y. Feng, T. T. Baig, R. P. Love, L. Chelico, Suppression of APOBEC3-mediated restriction 
of HIV-1 by Vif. Front Microbiol 5, 450 (2014). 
214. R. M. Kohli et al., A portable hot spot recognition loop transfers sequence preferences from 
APOBEC family members to activation-induced cytidine deaminase. J Biol Chem 284, 
22898-22904 (2009). 
215. B. A. Desimmie et al., APOBEC3 proteins can copackage and comutate HIV-1 genomes. 
Nucleic Acids Res 44, 7848-7865 (2016). 
 177 
 
216. Q. Yu et al., Single-strand specificity of APOBEC3G accounts for minus-strand 
deamination of the HIV genome. Nat Struct Mol Biol 11, 435-442 (2004). 
217. R. S. Harris et al., DNA deamination mediates innate immunity to retroviral infection. Cell 
113, 803-809 (2003). 
218. Y. Dang, X. Wang, W. J. Esselman, Y. H. Zheng, Identification of APOBEC3DE as 
another antiretroviral factor from the human APOBEC family. Journal of virology 80, 
10522-10533 (2006). 
219. A. Harari, M. Ooms, L. C. Mulder, V. Simon, Polymorphisms and splice variants influence 
the antiretroviral activity of human APOBEC3H. J Virol 83, 295-303 (2009). 
220. B. A. Desimmie et al., APOBEC3 proteins can copackage and comutate HIV-1 genomes. 
Nucleic acids research,  (2016). 
221. L. Apolonia et al., Promiscuous RNA binding ensures effective encapsidation of 
APOBEC3 proteins by HIV-1. PLoS Pathog 11, e1004609 (2015). 
222. N. Jouvenet, S. M. Simon, P. D. Bieniasz, Imaging the interaction of HIV-1 genomes and 
Gag during assembly of individual viral particles. Proc Natl Acad Sci U S A 106, 19114-
19119 (2009). 
223. J. F. Hultquist et al., Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and 
APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J Virol 85, 
11220-11234 (2011). 
224. Y. L. Chiu et al., High-molecular-mass APOBEC3G complexes restrict Alu 
retrotransposition. Proc Natl Acad Sci U S A 103, 15588-15593 (2006). 
225. S. Gallois-Montbrun et al., Comparison of cellular ribonucleoprotein complexes associated 
with the APOBEC3F and APOBEC3G antiviral proteins. Journal of virology 82, 5636-
5642 (2008). 
226. A. Ara, R. P. Love, L. Chelico, Different mutagenic potential of HIV-1 restriction factors 
APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning 
mechanisms. PLoS pathogens 10, e1004024 (2014). 
 178 
 
227. L. Chelico, P. Pham, P. Calabrese, M. F. Goodman, APOBEC3G DNA deaminase acts 
processively 3' --> 5' on single-stranded DNA. Nat Struct Mol Biol 13, 392-399 (2006). 
228. R. A. Russell, M. D. Moore, W. S. Hu, V. K. Pathak, APOBEC3G induces a hypermutation 
gradient: purifying selection at multiple steps during HIV-1 replication results in levels of 
G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in 
virion RNA. Retrovirology 6, 16 (2009). 
229. K. N. Bishop, M. Verma, E. Y. Kim, S. M. Wolinsky, M. H. Malim, APOBEC3G inhibits 
elongation of HIV-1 reverse transcripts. PLoS Pathog 4, e1000231 (2008). 
230. S. M. Kaiser, M. Emerman, Uracil DNA glycosylase is dispensable for human 
immunodeficiency virus type 1 replication and does not contribute to the antiviral effects 
of the cytidine deaminase Apobec3G. Journal of virology 80, 875-882 (2006). 
231. H. Aydin, M. W. Taylor, J. E. Lee, Structure-guided analysis of the human APOBEC3-
HIV restrictome. Structure 22, 668-684 (2014). 
232. B. Yang, K. Chen, C. Zhang, S. Huang, H. Zhang, Virion-associated uracil DNA 
glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of 
APOBEC3G-edited nascent HIV-1 DNA. The Journal of biological chemistry 282, 11667-
11675 (2007). 
233. D. Lecossier, F. Bouchonnet, F. Clavel, A. J. Hance, Hypermutation of HIV-1 DNA in the 
absence of the Vif protein. Science 300, 1112 (2003). 
234. R. Nowarski et al., APOBEC3G inhibits HIV-1 RNA elongation by inactivating the viral 
trans-activation response element. J Mol Biol 426, 2840-2853 (2014). 
235. P. Jern, R. A. Russell, V. K. Pathak, J. M. Coffin, Likely role of APOBEC3G-mediated G-
to-A mutations in HIV-1 evolution and drug resistance. PLoS pathogens 5, e1000367 
(2009). 
236. H. A. Sadler, M. D. Stenglein, R. S. Harris, L. M. Mansky, APOBEC3G contributes to 
HIV-1 variation through sublethal mutagenesis. Journal of virology 84, 7396-7404 (2010). 
 179 
 
237. U. Neogi et al., Human APOBEC3G-mediated hypermutation is associated with 
antiretroviral therapy failure in HIV-1 subtype C-infected individuals. J Int AIDS Soc 16, 
18472 (2013). 
238. M. McCallum et al., Basis for early and preferential selection of the E138K mutation in 
HIV-1 reverse transcriptase. Antimicrob Agents Chemother 57, 4681-4688 (2013). 
239. E. Y. Kim et al., Human APOBEC3G-mediated editing can promote HIV-1 sequence 
diversification and accelerate adaptation to selective pressure. J Virol 84, 10402-10405 
(2010). 
240. L. C. Mulder, A. Harari, V. Simon, Cytidine deamination induced HIV-1 drug resistance. 
Proc Natl Acad Sci U S A 105, 5501-5506 (2008). 
241. A. E. Armitage et al., APOBEC3G-induced hypermutation of human immunodeficiency 
virus type-1 is typically a discrete "all or nothing" phenomenon. PLoS Genet 8, e1002550 
(2012). 
242. N. Wood et al., HIV evolution in early infection: selection pressures, patterns of insertion 
and deletion, and the impact of APOBEC. PLoS Pathog 5, e1000414 (2009). 
243. D. Ebrahimi, F. Anwar, M. P. Davenport, APOBEC3 has not left an evolutionary footprint 
on the HIV-1 genome. J Virol 85, 9139-9146 (2011). 
244. G. Hache, L. M. Mansky, R. S. Harris, Human APOBEC3 proteins, retrovirus restriction, 
and HIV drug resistance. AIDS Rev 8, 148-157 (2006). 
245. K. A. Delviks-Frankenberry et al., Minimal Contribution of APOBEC3-Induced G-to-A 
Hypermutation to HIV-1 Recombination and Genetic Variation. PLoS pathogens 12, 
e1005646 (2016). 
246. H. Huthoff, F. Autore, S. Gallois-Montbrun, F. Fraternali, M. H. Malim, RNA-dependent 
oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog 5, 
e1000330 (2009). 
 180 
 
247. L. Chelico, C. Prochnow, D. A. Erie, X. S. Chen, M. F. Goodman, Structural model for 
deoxycytidine deamination mechanisms of the HIV-1 inactivation enzyme APOBEC3G. J 
Biol Chem 285, 16195-16205 (2010). 
248. O. G. Berg, R. B. Winter, P. H. von Hippel, Diffusion-driven mechanisms of protein 
translocation on nucleic acids. 1. Models and theory. Biochemistry 20, 6929-6948 (1981). 
249. P. H. von Hippel, O. G. Berg, Facilitated target location in biological systems. The Journal 
of biological chemistry 264, 675-678 (1989). 
250. Y. Feng, L. Chelico, Intensity of deoxycytidine deamination of HIV-1 proviral DNA by 
the retroviral restriction factor APOBEC3G is mediated by the noncatalytic domain. J Biol 
Chem 286, 11415-11426 (2011). 
251. M. B. Adolph et al., Cytidine deaminase efficiency of the lentiviral viral restriction factor 
APOBEC3C correlates with dimerization. Nucleic acids research 45, 3378-3394 (2017). 
252. L. Chelico, E. J. Sacho, D. A. Erie, M. F. Goodman, A model for oligomeric regulation of 
APOBEC3G cytosine deaminase-dependent restriction of HIV. The Journal of biological 
chemistry 283, 13780-13791 (2008). 
253. G. Senavirathne et al., Single-stranded DNA scanning and deamination by APOBEC3G 
cytidine deaminase at single molecule resolution. The Journal of biological chemistry 287, 
15826-15835 (2012). 
254. E. P. Browne, C. Allers, N. R. Landau, Restriction of HIV-1 by APOBEC3G is cytidine 
deaminase-dependent. Virology 387, 313-321 (2009). 
255. R. K. Holmes, F. A. Koning, K. N. Bishop, M. H. Malim, APOBEC3F can inhibit the 
accumulation of HIV-1 reverse transcription products in the absence of hypermutation. 
Comparisons with APOBEC3G. The Journal of biological chemistry 282, 2587-2595 
(2007). 
256. C. A. Virgen, T. Hatziioannou, Antiretroviral activity and Vif sensitivity of rhesus macaque 
APOBEC3 proteins. Journal of virology 81, 13932-13937 (2007). 
 181 
 
257. C. Song, L. Sutton, M. E. Johnson, R. T. D'Aquila, J. P. Donahue, Signals in APOBEC3F 
N-terminal and C-terminal deaminase domains each contribute to encapsidation in HIV-1 
virions and are both required for HIV-1 restriction. The Journal of biological chemistry 
287, 16965-16974 (2012). 
258. E. Miyagi et al., Stably expressed APOBEC3F has negligible antiviral activity. J Virol 84, 
11067-11075 (2010). 
259. J. S. Albin, G. Hache, J. F. Hultquist, W. L. Brown, R. S. Harris, Long-term restriction by 
APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif 
function. Journal of virology 84, 10209-10219 (2010). 
260. G. Hache, K. Shindo, J. S. Albin, R. S. Harris, Evolution of HIV-1 isolates that use a novel 
Vif-independent mechanism to resist restriction by human APOBEC3G. Curr Biol 18, 819-
824 (2008). 
261. R. A. Russell, J. Smith, R. Barr, D. Bhattacharyya, V. K. Pathak, Distinct domains within 
APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency 
virus type 1 Vif. Journal of virology 83, 1992-2003 (2009). 
262. T. Kouno et al., Structure of the Vif-binding domain of the antiviral enzyme APOBEC3G. 
Nat Struct Mol Biol 22, 485-491 (2015). 
263. M. F. Bohn et al., Crystal structure of the DNA cytosine deaminase APOBEC3F: the 
catalytically active and HIV-1 Vif-binding domain. Structure 21, 1042-1050 (2013). 
264. A. M. Land et al., APOBEC3F determinants of HIV-1 Vif sensitivity. Journal of virology 
88, 12923-12927 (2014). 
265. Y. Dang et al., Identification of a single amino acid required for APOBEC3 antiretroviral 
cytidine deaminase activity. J Virol 85, 5691-5695 (2011). 
266. C. Chaipan, J. L. Smith, W. S. Hu, V. K. Pathak, APOBEC3G restricts HIV-1 to a greater 
extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and 
macrophages. Journal of virology 87, 444-453 (2013). 
 182 
 
267. J. Li et al., APOBEC3 multimerization correlates with HIV-1 packaging and restriction 
activity in living cells. J Mol Biol 426, 1296-1307 (2014). 
268. M. OhAinle, J. A. Kerns, H. S. Malik, M. Emerman, Adaptive evolution and antiviral 
activity of the conserved mammalian cytidine deaminase APOBEC3H. Journal of virology 
80, 3853-3862 (2006). 
269. M. Ooms, S. Majdak, C. W. Seibert, A. Harari, V. Simon, The localization of APOBEC3H 
variants in HIV-1 virions determines their antiviral activity. Journal of virology 84, 7961-
7969 (2010). 
270. X. Wang et al., Analysis of human APOBEC3H haplotypes and anti-human 
immunodeficiency virus type 1 activity. Journal of virology 85, 3142-3152 (2011). 
271. Y. Dang et al., Human cytidine deaminase APOBEC3H restricts HIV-1 replication. The 
Journal of biological chemistry 283, 11606-11614 (2008). 
272. E. W. Refsland et al., Natural polymorphisms in human APOBEC3H and HIV-1 Vif 
combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity. 
PLoS Genet 10, e1004761 (2014). 
273. M. M. Li, M. Emerman, Polymorphism in human APOBEC3H affects a phenotype 
dominant for subcellular localization and antiviral activity. Journal of virology 85, 8197-
8207 (2011). 
274. A. Zhen, J. Du, X. Zhou, Y. Xiong, X. F. Yu, Reduced APOBEC3H variant anti-viral 
activities are associated with altered RNA binding activities. PloS one 7, e38771 (2012). 
275. T. T. Baig, Y. Feng, L. Chelico, Determinants of efficient degradation of APOBEC3 
restriction factors by HIV-1 Vif. J Virol 88, 14380-14395 (2014). 
276. M. Ooms et al., HIV-1 Vif adaptation to human APOBEC3H haplotypes. Cell Host 
Microbe 14, 411-421 (2013). 
277. M. OhAinle, J. A. Kerns, M. M. Li, H. S. Malik, M. Emerman, Antiretroelement activity 
of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe 4, 249-259 
(2008). 
 183 
 
278. D. Sakurai et al., APOBEC3H polymorphisms associated with the susceptibility to HIV-1 
infection and AIDS progression in Japanese. Immunogenetics 67, 253-257 (2015). 
279. K. Zhao et al., Evolutionarily conserved pressure for the existence of distinct G2/M cell 
cycle arrest and A3H inactivation functions in HIV-1 Vif. Cell Cycle 14, 838-847 (2015). 
280. Y. Feng et al., Natural Polymorphisms and Oligomerization of Human APOBEC3H 
Contribute to Single-stranded DNA Scanning Ability. The Journal of biological chemistry 
290, 27188-27203 (2015). 
281. E. N. Newman et al., Antiviral function of APOBEC3G can be dissociated from cytidine 
deaminase activity. Curr Biol 15, 166-170 (2005). 
282. X. Wang et al., The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse 
transcriptase and inhibits its function during viral replication. Journal of virology 86, 3777-
3786 (2012). 
283. M. B. Adolph, J. Webb, L. Chelico, Retroviral restriction factor APOBEC3G delays the 
initiation of DNA synthesis by HIV-1 reverse transcriptase. PloS one 8, e64196 (2013). 
284. K. Belanger, M. Savoie, M. C. Rosales Gerpe, J. F. Couture, M. A. Langlois, Binding of 
RNA by APOBEC3G controls deamination-independent restriction of retroviruses. 
Nucleic Acids Res 41, 7438-7452 (2013). 
285. F. Guo, S. Cen, M. Niu, J. Saadatmand, L. Kleiman, Inhibition of tRNA(3)(Lys)-primed 
reverse transcription by human APOBEC3G during human immunodeficiency virus type 
1 replication. Journal of virology 80, 11710-11722 (2006). 
286. F. Guo et al., The interaction of APOBEC3G with human immunodeficiency virus type 1 
nucleocapsid inhibits tRNA3Lys annealing to viral RNA. J Virol 81, 11322-11331 (2007). 
287. K. Gillick et al., Suppression of HIV-1 infection by APOBEC3 proteins in primary human 
CD4(+) T cells is associated with inhibition of processive reverse transcription as well as 
excessive cytidine deamination. Journal of virology 87, 1508-1517 (2013). 
288. Y. Iwatani et al., Deaminase-independent inhibition of HIV-1 reverse transcription by 
APOBEC3G. Nucleic Acids Res 35, 7096-7108 (2007). 
 184 
 
289. K. Luo et al., Cytidine deaminases APOBEC3G and APOBEC3F interact with human 
immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J Virol 81, 
7238-7248 (2007). 
290. J. L. Anderson, T. J. Hope, APOBEC3G restricts early HIV-1 replication in the cytoplasm 
of target cells. Virology 375, 1-12 (2008). 
291. J. L. Mbisa et al., Human immunodeficiency virus type 1 cDNAs produced in the presence 
of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol 81, 
7099-7110 (2007). 
292. E. Miyagi et al., Enzymatically active APOBEC3G is required for efficient inhibition of 
human immunodeficiency virus type 1. J Virol 81, 13346-13353 (2007). 
293. A. J. Schumacher, G. Hache, D. A. Macduff, W. L. Brown, R. S. Harris, The DNA 
deaminase activity of human APOBEC3G is required for Ty1, MusD, and human 
immunodeficiency virus type 1 restriction. J Virol 82, 2652-2660 (2008). 
294. K. R. Chaurasiya et al., Oligomerization transforms human APOBEC3G from an efficient 
enzyme to a slowly dissociating nucleic acid-binding protein. Nat Chem 6, 28-33 (2014). 
295. A. Ara et al., Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine 
Deaminases APOBEC3F and APOBEC3G. Journal of virology 91,  (2017). 
296. K. N. Bishop, R. K. Holmes, M. H. Malim, Antiviral potency of APOBEC proteins does 
not correlate with cytidine deamination. Journal of virology 80, 8450-8458 (2006). 
297. T. Kobayashi et al., Quantification of deaminase activity-dependent and -independent 
restriction of HIV-1 replication mediated by APOBEC3F and APOBEC3G through 
experimental-mathematical investigation. Journal of virology 88, 5881-5887 (2014). 
298. J. S. Albin, W. L. Brown, R. S. Harris, Catalytic activity of APOBEC3F is required for 
efficient restriction of Vif-deficient human immunodeficiency virus. Virology 450-451, 49-
54 (2014). 
299. J. L. Mbisa, W. Bu, V. K. Pathak, APOBEC3F and APOBEC3G inhibit HIV-1 DNA 
integration by different mechanisms. J Virol 84, 5250-5259 (2010). 
 185 
 
300. Z. Xiao, E. Ehrlich, K. Luo, Y. Xiong, X. F. Yu, Zinc chelation inhibits HIV Vif activity 
and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J 21, 217-
222 (2007). 
301. B. J. Stanley et al., Structural insight into the human immunodeficiency virus Vif SOCS 
box and its role in human E3 ubiquitin ligase assembly. J Virol 82, 8656-8663 (2008). 
302. J. R. Bergeron et al., The SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-
folding to recruit its Cul5-containing ubiquitin ligase complex. PLoS pathogens 6, 
e1000925 (2010). 
303. X. Wang et al., Interactions between HIV-1 Vif and human ElonginB-ElonginC are 
important for CBF-beta binding to Vif. Retrovirology 10, 94 (2013). 
304. Y. Guo et al., Structural basis for hijacking CBF-beta and CUL5 E3 ligase complex by 
HIV-1 Vif. Nature 505, 229-233 (2014). 
305. H. P. Bogerd, B. P. Doehle, H. L. Wiegand, B. R. Cullen, A single amino acid difference 
in the host APOBEC3G protein controls the primate species specificity of HIV type 1 
virion infectivity factor. Proc Natl Acad Sci U S A 101, 3770-3774 (2004). 
306. M. Letko et al., Vif proteins from diverse primate lentiviral lineages use the same binding 
site in APOBEC3G. Journal of virology 87, 11861-11871 (2013). 
307. L. Etienne, B. H. Hahn, P. M. Sharp, F. A. Matsen, M. Emerman, Gene loss and adaptation 
to hominids underlie the ancient origin of HIV-1. Cell Host Microbe 14, 85-92 (2013). 
308. Y. Dang, X. Wang, T. Zhou, I. A. York, Y. H. Zheng, Identification of a novel WxSLVK 
motif in the N terminus of human immunodeficiency virus and simian immunodeficiency 
virus Vif that is critical for APOBEC3G and APOBEC3F neutralization. Journal of 
virology 83, 8544-8552 (2009). 
309. G. Chen, Z. He, T. Wang, R. Xu, X. F. Yu, A patch of positively charged amino acids 
surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences 
its interaction with APOBEC3G. Journal of virology 83, 8674-8682 (2009). 
 186 
 
310. M. Letko, T. Booiman, N. Kootstra, V. Simon, M. Ooms, Identification of the HIV-1 Vif 
and Human APOBEC3G Protein Interface. Cell Rep 13, 1789-1799 (2015). 
311. R. A. Russell, V. K. Pathak, Identification of two distinct human immunodeficiency virus 
type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. 
Journal of virology 81, 8201-8210 (2007). 
312. T. Yamashita, K. Kamada, K. Hatcho, A. Adachi, M. Nomaguchi, Identification of amino 
acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F. Microbes 
Infect 10, 1142-1149 (2008). 
313. C. Richards et al., The Binding Interface between Human APOBEC3F and HIV-1 Vif 
Elucidated by Genetic and Computational Approaches. Cell Rep 13, 1781-1788 (2015). 
314. M. Nakashima et al., Structural Insights into HIV-1 Vif-APOBEC3F Interaction. J Virol 
90, 1034-1047 (2015). 
315. E. Pery, K. S. Rajendran, A. J. Brazier, D. Gabuzda, Regulation of APOBEC3 proteins by 
a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian 
immunodeficiency virus SIVagm Vif. Journal of virology 83, 2374-2381 (2009). 
316. S. Kitamura, H. Ode, Y. Iwatani, Structural Features of Antiviral APOBEC3 Proteins are 
Linked to Their Functional Activities. Front Microbiol 2, 258 (2011). 
317. S. Kitamura et al., The APOBEC3C crystal structure and the interface for HIV-1 Vif 
binding. Nat Struct Mol Biol 19, 1005-1010 (2012). 
318. M. Ooms, M. Letko, V. Simon, The Structural Interface between HIV-1 Vif and Human 
APOBEC3H. J Virol 91,  (2017). 
319. M. Binka, M. Ooms, M. Steward, V. Simon, The activity spectrum of Vif from multiple 
HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H. J Virol 86, 49-59 
(2012). 
320. B. Schrofelbauer, D. Chen, N. R. Landau, A single amino acid of APOBEC3G controls its 
species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci U S A 
101, 3927-3932 (2004). 
 187 
 
321. J. L. Smith, V. K. Pathak, Identification of specific determinants of human APOBEC3F, 
APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with 
HIV-1 Vif. Journal of virology 84, 12599-12608 (2010). 
322. J. S. Albin et al., A single amino acid in human APOBEC3F alters susceptibility to HIV-1 
Vif. The Journal of biological chemistry 285, 40785-40792 (2010). 
323. G. Mercenne et al., HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation. 
Nucleic acids research 38, 633-646 (2010). 
324. S. Guerrero et al., Translational regulation of APOBEC3G mRNA by Vif requires its 
5'UTR and contributes to restoring HIV-1 infectivity. Sci Rep 6, 39507 (2016). 
325. V. B. Soros, W. Yonemoto, W. C. Greene, Newly synthesized APOBEC3G is incorporated 
into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS 
pathogens 3, e15 (2007). 
326. Y. Feng, R. P. Love, L. Chelico, HIV-1 viral infectivity factor (Vif) alters processive 
single-stranded DNA scanning of the retroviral restriction factor APOBEC3G. The Journal 
of biological chemistry 288, 6083-6094 (2013). 
327. E. Britan-Rosich, R. Nowarski, M. Kotler, Multifaceted counter-APOBEC3G mechanisms 
employed by HIV-1 Vif. J Mol Biol 410, 1065-1076 (2011). 
328. W. C. Greene et al., Novel targets for HIV therapy. Antiviral Res 80, 251-265 (2008). 
329. L. S. Shlyakhtenko et al., Nanoscale structure and dynamics of ABOBEC3G complexes 
with single-stranded DNA. Biochemistry 51, 6432-6440 (2012). 
330. L. C. Mulder et al., Moderate influence of human APOBEC3F on HIV-1 replication in 
primary lymphocytes. Journal of virology 84, 9613-9617 (2010). 
331. M. A. Langlois, R. C. Beale, S. G. Conticello, M. S. Neuberger, Mutational comparison of 
the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral 
cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids 
Res 33, 1913-1923 (2005). 
 188 
 
332. S. G. Conticello, R. S. Harris, M. S. Neuberger, The Vif protein of HIV triggers degradation 
of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol 13, 2009-2013 (2003). 
333. S. Kao et al., The human immunodeficiency virus type 1 Vif protein reduces intracellular 
expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus 
infectivity. J Virol 77, 11398-11407 (2003). 
334. K. Stopak, C. de Noronha, W. Yonemoto, W. C. Greene, HIV-1 Vif blocks the antiviral 
activity of APOBEC3G by impairing both its translation and intracellular stability. Mol 
Cell 12, 591-601 (2003). 
335. X. Yu et al., Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-
Cul5-SCF complex. Science 302, 1056-1060 (2003). 
336. R. Suspene et al., APOBEC3G is a single-stranded DNA cytidine deaminase and functions 
independently of HIV reverse transcriptase. Nucleic Acids Res 32, 2421-2429 (2004). 
337. T. Wang et al., Distinct viral determinants for the packaging of human cytidine deaminases 
APOBEC3G and APOBEC3C. Virology 377, 71-79 (2008). 
338. C. J. Wittkopp, M. B. Adolph, L. I. Wu, L. Chelico, M. Emerman, A Single Nucleotide 
Polymorphism in Human APOBEC3C Enhances Restriction of Lentiviruses. PLoS 
pathogens 12, e1005865 (2016). 
339. V. Pak, G. Heidecker, V. K. Pathak, D. Derse, The role of amino-terminal sequences in 
cellular localization and antiviral activity of APOBEC3B. J Virol 85, 8538-8547 (2011). 
340. S. E. Halford, J. F. Marko, How do site-specific DNA-binding proteins find their targets? 
Nucleic Acids Res 32, 3040-3052 (2004). 
341. R. P. Love, H. Xu, L. Chelico, Biochemical analysis of hypermutation by the deoxycytidine 
deaminase APOBEC3A. J Biol Chem 287, 30812-30822 (2012). 
342. S. F. Le Grice, F. Gruninger-Leitch, Rapid purification of homodimer and heterodimer 
HIV-1 reverse transcriptase by metal chelate affinity chromatography. Eur J Biochem 187, 
307-314 (1990). 
 189 
 
343. F. Gao et al., The heterosexual human immunodeficiency virus type 1 epidemic in Thailand 
is caused by an intersubtype (A/E) recombinant of African origin. Journal of virology 70, 
7013-7029 (1996). 
344. S. Creighton, L. B. Bloom, M. F. Goodman, Gel fidelity assay measuring nucleotide 
misinsertion, exonucleolytic proofreading, and lesion bypass efficiencies. Methods 
Enzymol 262, 232-256 (1995). 
345. U. O'Doherty, W. J. Swiggard, M. H. Malim, Human immunodeficiency virus type 1 
spinoculation enhances infection through virus binding. J Virol 74, 10074-10080 (2000). 
346. L. S. Shlyakhtenko et al., Atomic force microscopy studies provide direct evidence for 
dimerization of the HIV restriction factor APOBEC3G. J Biol Chem 286, 3387-3395 
(2011). 
347. L. S. Shlyakhtenko et al., Atomic force microscopy studies of APOBEC3G 
oligomerization and dynamics. J Struct Biol,  (2013). 
348. X. Wang, P. T. Dolan, Y. Dang, Y. H. Zheng, Biochemical differentiation of APOBEC3F 
and APOBEC3G proteins associated with HIV-1 life cycle. J Biol Chem 282, 1585-1594 
(2007). 
349. L. G. Holden et al., Crystal structure of the anti-viral APOBEC3G catalytic domain and 
functional implications. Nature 456, 121-124 (2008). 
350. K. M. Chen et al., Structure of the DNA deaminase domain of the HIV-1 restriction factor 
APOBEC3G. Nature 452, 116-119 (2008). 
351. N. P. Stanford, M. D. Szczelkun, J. F. Marko, S. E. Halford, One- and three-dimensional 
pathways for proteins to reach specific DNA sites. EMBO J 19, 6546-6557 (2000). 
352. B. A. Lieberman, S. K. Nordeen, DNA intersegment transfer, how steroid receptors search 
for a target site. J Biol Chem 272, 1061-1068 (1997). 
353. A. Furukawa et al., Structure and real-time monitoring of the enzymatic reaction of 
APOBEC3G which is involved in anti-HIV activity. Nucleic Acids Symp Ser (Oxf), 87-88 
(2009). 
 190 
 
354. D. D. Loeb et al., Complete mutagenesis of the HIV-1 protease. Nature 340, 397-400 
(1989). 
355. R. Suspene, C. Rusniok, J. P. Vartanian, S. Wain-Hobson, Twin gradients in APOBEC3 
edited HIV-1 DNA reflect the dynamics of lentiviral replication. Nucleic Acids Res 34, 
4677-4684 (2006). 
356. Y. Yang, F. Guo, S. Cen, L. Kleiman, Inhibition of initiation of reverse transcription in 
HIV-1 by human APOBEC3F. Virology 365, 92-100 (2007). 
357. R. Bransteitter, C. Prochnow, X. S. Chen, The current structural and functional 
understanding of APOBEC deaminases. Cell Mol Life Sci 66, 3137-3147 (2009). 
358. E. Harjes et al., An extended structure of the APOBEC3G catalytic domain suggests a 
unique holoenzyme model. J Mol Biol 389, 819-832 (2009). 
359. K. Belanger, M. A. Langlois, Comparative analysis of the gene-inactivating potential of 
retroviral restriction factors APOBEC3F and APOBEC3G. J Gen Virol 96, 2878-2887 
(2015). 
360. J. F. Krisko, N. Begum, C. E. Baker, J. L. Foster, J. V. Garcia, APOBEC3G and 
APOBEC3F Act in Concert To Extinguish HIV-1 Replication. J Virol 90, 4681-4695 
(2016). 
361. B. Mangeat et al., Broad antiretroviral defence by human APOBEC3G through lethal 
editing of nascent reverse transcripts. Nature 424, 99-103 (2003). 
362. Y. S. Zhang, Z. X. Ning, S. Z. Yang, H. Wu, Antioxidation properties and mechanism of 
action of dihydromyricetin from Ampelopsis grossedentata. Yao Xue Xue Bao 38, 241-244 
(2003). 
363. A. M. Sheehy, N. C. Gaddis, J. D. Choi, M. H. Malim, Isolation of a human gene that 
inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646-650 
(2002). 
364. R. Mariani et al., Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. 
Cell 114, 21-31 (2003). 
 191 
 
365. S. Jager et al., Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection. 
Nature 481, 371-375 (2012). 
366. M. Janini, M. Rogers, D. R. Birx, F. E. McCutchan, Human immunodeficiency virus type 
1 DNA sequences genetically damaged by hypermutation are often abundant in patient 
peripheral blood mononuclear cells and may be generated during near-simultaneous 
infection and activation of CD4(+) T cells. J Virol 75, 7973-7986 (2001). 
367. J. P. Vartanian, M. Henry, S. Wain-Hobson, Sustained G-->A hypermutation during 
reverse transcription of an entire human immunodeficiency virus type 1 strain Vau group 
O genome. J. Gen. Virol. 83, 801-805 (2002). 
368. J. P. Vartanian, A. Meyerhans, B. Asjo, S. Wain-Hobson, Selection, recombination, and 
G----A hypermutation of human immunodeficiency virus type 1 genomes. J. Virol. 65, 
1779-1788. (1991). 
369. J. P. Vartanian, A. Meyerhans, M. Sala, S. Wain-Hobson, G-->A hypermutation of the 
human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during 
reverse transcription. Proc Natl Acad Sci U S A 91, 3092-3096 (1994). 
370. V. K. Pathak, H. M. Temin, Broad spectrum of in vivo forward mutations, hypermutations, 
and mutational hotspots in a retroviral shuttle vector after a single replication cycle: 
substitutions, frameshifts, and hypermutations. Proc Natl Acad Sci U S A 87, 6019-6023 
(1990). 
371. T. L. Kieffer et al., G-->A hypermutation in protease and reverse transcriptase regions of 
human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol 79, 
1975-1980 (2005). 
372. A. Piantadosi, D. Humes, B. Chohan, R. S. McClelland, J. Overbaugh, Analysis of the 
percentage of human immunodeficiency virus type 1 sequences that are hypermutated and 
markers of disease progression in a longitudinal cohort, including one individual with a 
partially defective Vif. J Virol 83, 7805-7814 (2009). 
373. V. Simon et al., Natural variation in Vif: differential impact on APOBEC3G/3F and a 
potential role in HIV-1 diversification. PLoS Pathog 1, e6 (2005). 
 192 
 
374. B. Mangeat et al., Broad antiretroviral defence by human APOBEC3G through lethal 
editing of nascent reverse transcripts. Nature 424, 99-103 (2003). 
375. A. York, S. B. Kutluay, M. Errando, P. D. Bieniasz, The RNA Binding Specificity of 
Human APOBEC3 Proteins Resembles That of HIV-1 Nucleocapsid. PLoS Pathog 12, 
e1005833 (2016). 
376. D. Ebrahimi, F. Anwar, M. P. Davenport, APOBEC3G and APOBEC3F rarely co-mutate 
the same HIV genome. Retrovirology 9, 113 (2012). 
377. H. Zhang et al., Novel single-cell-level phenotypic assay for residual drug susceptibility 
and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. 
Journal of virology 78, 1718-1729 (2004). 
378. L. Naldini et al., In vivo gene delivery and stable transduction of nondividing cells by a 
lentiviral vector. Science 272, 263-267 (1996). 
379. K. A. Ahmed, L. Wang, P. Griebel, D. D. Mousseau, J. Xiang, Differential expression of 
mannose-6-phosphate receptor regulates T cell contraction. J Leukoc Biol 98, 313-318 
(2015). 
380. P. P. Rose, B. T. Korber, Detecting hypermutations in viral sequences with an emphasis 
on G --> A hypermutation. Bioinformatics 16, 400-401 (2000). 
381. R. P. Bennett, J. D. Salter, X. Liu, J. E. Wedekind, H. C. Smith, APOBEC3G subunits self-
associate via the C-terminal deaminase domain. The Journal of biological chemistry 283, 
33329-33336 (2008). 
382. S. Wurtzer et al., Functional central polypurine tract provides downstream protection of 
the human immunodeficiency virus type 1 genome from editing by APOBEC3G and 
APOBEC3B. J Virol 80, 3679-3683 (2006). 
383. C. Hu et al., The HIV-1 central polypurine tract functions as a second line of defense 
against APOBEC3G/F. J Virol,  (2010). 
384. J. L. Mbisa, W. Bu, V. K. Pathak, APOBEC3F and APOBEC3G Inhibit HIV-1 DNA 
Integration by Different Mechanisms. J Virol,  (2010). 
 193 
 
385. K. Shindo et al., The enzymatic activity of CEM15/Apobec-3G is essential for the 
regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral 
activity. J Biol Chem 278, 44412-44416 (2003). 
386. X. Xiao, S. X. Li, H. Yang, X. S. Chen, Crystal structures of APOBEC3G N-domain alone 
and its complex with DNA. Nat Commun 7, 12193 (2016). 
387. N. M. Shaban, K. Shi, M. Li, H. Aihara, R. S. Harris, 1.92 Angstrom Zinc-Free 
APOBEC3F Catalytic Domain Crystal Structure. J Mol Biol 428, 2307-2316 (2016). 
388. K. K. Siu, A. Sultana, F. C. Azimi, J. E. Lee, Structural determinants of HIV-1 Vif 
susceptibility and DNA binding in APOBEC3F. Nat Commun 4, 2593 (2013). 
389. J. A. Briggs et al., The stoichiometry of Gag protein in HIV-1. Nat Struct Mol Biol 11, 
672-675 (2004). 
390. K. Sato et al., Remarkable lethal G-to-A mutations in vif-proficient HIV-1 provirus by 
individual APOBEC3 proteins in humanized mice. J Virol 84, 9546-9556 (2010). 
391. P. An et al., Role of APOBEC3F Gene Variation in HIV-1 Disease Progression and 
Pneumocystis Pneumonia. PLoS Genet 12, e1005921 (2016). 
392. B. Mangeat, P. Turelli, S. Liao, D. Trono, A single amino acid determinant governs the 
species-specific sensitivity of APOBEC3G to Vif action. J Biol Chem 279, 14481-14483 
(2004). 
393. A. Furukawa et al., Structure, interaction and real-time monitoring of the enzymatic 
reaction of wild-type APOBEC3G. EMBO J 28, 440-451 (2009). 
394. S. M. Shandilya et al., Crystal structure of the APOBEC3G catalytic domain reveals 
potential oligomerization interfaces. Structure 18, 28-38 (2010). 
395. J. F. Hultquist et al., A Cas9 Ribonucleoprotein Platform for Functional Genetic Studies 
of HIV-Host Interactions in Primary Human T Cells. Cell Rep 17, 1438-1452 (2016). 
 
